COMBINED IMMUNOGENIC COMPOSITIONS

专利摘要:
Combined immunogenic compositions capable of providing protection against infection and disease caused by both RSV and B. pertussis. More specifically, this invention relates to compositions which comprise a recombinant analogue of RSV F protein, with cell-free (Pa) or whole cell (Pw) pertussis antigens and their use, in particular in neonatal immunization. and kindergarten. Vaccine schemes, methods, as well as uses, and kits, immunogenic compositions are also described for protecting the infant against disease caused by RSV and B. pertussis by maternal immunization.
公开号:BE1022008B1
申请号:E2014/0597
申请日:2014-08-04
公开日:2016-02-03
发明作者:Ann-Muriel Steff；Stéphane T. Temmerman；Jean-François Toussaint
申请人:Glaxosmithkline Biologicals S.A.；
IPC主号:

专利说明:

COMBINED IMMUNOGENIC COMPOSITIONS CONTEXT
This invention relates to the field of immunology. More particularly, this invention relates to compositions and methods capable of eliciting specific immune responses of respiratory syncytial virus (RSV) and Bordetella pertussis.
Respiratory syncytial virus (RSV) is the world's most common cause of lower respiratory tract infection (LRII) in infants under 6 months of age and preterm infants born at or below 35 weeks of gestation. The spectrum of RSV disease includes a broad array of respiratory symptoms ranging from rhinitis and otitis to pneumonia and bronchiolitis, the latter two diseases being associated with considerable morbidity and mortality. Man is the only known reservoir of the VRS. The spread of the virus from infected nasal secretions occurs through large respiratory droplets, so close contact with an infected person or contaminated surface is required for transmission. RSV can persist for hours on toys or other objects, which explains the high rate of nosocomial RSV infections, especially in pediatric services.
Annual global figures for RSV infections and deaths are estimated at 64 million and 160,000 respectively. In the United States alone it is estimated that the RSV is responsible for 18,000 to 75,000 hospitalizations and 90 to 1,900 deaths per year. In temperate climates, RSV is documented as a cause of annual, acute IVRI winter epidemics, including bronchiolitis and pneumonia. In the United States, virtually all children have been infected with RSV by the age of 2. The incidence rate of RSV-associated IVRI in otherwise healthy children was calculated to be 37 per 1000 child-years in their first two years of life (45 per 1000 children-year in infants less than 6 months) and the risk of hospitalization as 6 per 1000 child-years. The incidence is higher in children with cardiopulmonary disease and premature infants, who account for almost half of RSV-related hospitalizations in the United States. Children with more severe IVRI caused by RSV later have an increased incidence of childhood asthma. These studies demonstrate the widespread need for RSV vaccines and their use in industrialized countries, where the costs of treating patients with severe IVRI and their sequelae are substantial. RSV · 4 'is also increasingly recognized as a major cause of morbidity from influenza-like illness in the elderly.
Bordetella pertussis is the causative agent of whooping cough, a respiratory disease that can be severe in infants and young children. WHO estimates suggest that in 2008, about 16 million cases of pertussis occurred worldwide, and that 195,000 children died of the disease. Vaccines have been available for decades, and it is estimated (WHO) that vaccination averted about 687,000 deaths in 2008. The clinical course of the disease is characterized by rapid coughing followed by inspiratory effort. , often associated with a characteristic "cock song". In severe cases, oxygen deprivation can lead to brain damage; however, the most common complication is secondary pneumonia. Although antibiotic therapy is available, before the disease is diagnosed, bacterial toxins have often caused serious damage. Prevention of the disease is therefore very important, and progress in the area of immunization is therefore of significant interest. The first generation B. pertussis vaccines were whole cell vaccines consisting of whole bacteria that were killed by heat treatment, formalin or other means. They were introduced in many countries in the 1950s and 1960s and successfully reduced the incidence of whooping cough.
The problem with whole cell vaccines against B. pertussis is the high level of reactogenicity associated with them. This problem has been solved by the development of acellular pertussis vaccines containing highly purified B. pertussis proteins - usually at least pertussis toxoid (PT, pertussis toxoid treated chemically or genetically modified to eliminate its toxicity). and a filamentous haemagglutinin (FHA), often with the 69 kD pertactin protein (PRN) and in some cases, additionally, type 2 and 3 fimbriae (FIM 2 and 3). These acellular vaccines are generally much less reactogenic than whole cell vaccines, and have been adopted for vaccination programs in many countries. However, an increasing global trend in whooping cough cases reported in the United States since the early 1980s (with a resurgence of cases reported in 2012 greater than any year since 1955), and high-profile epidemics in many countries in recent years have led to the speculation that the protection afforded by acellular vaccines is less sustainable than that provided by whole cell vaccines. This decline in immunity after childhood immunizations means that adolescents and adults are potential reservoirs of this highly contagious disease. This puts neonates at particular risk during the first months of life, before the occurrence of pediatric vaccination at 2-3 months.
Strategies to protect vulnerable newborns include "cocooning", ie vaccination of adolescents and adults (including women who have just given birth) who may be in contact with newborns, while Vaccination of pregnant women (maternal immunization) is now recommended in several countries, so that anti-pertussis antibodies are transmitted placentially and provide protection until the newborn can be vaccinated directly. Vaccination at birth of newborns has also been evaluated in clinical trials.
Although pertussis vaccination is well established, despite attempts to produce a safe and effective RSV vaccine that can elicit long-lasting and protective immune responses in healthy and at-risk populations, none of the candidates evaluated to date have has been shown to be safe and effective in preventing RSV infection and / or reducing or preventing diseases caused by RSV. As a result, there remains an unmet need for a combination vaccine that provides protection against both RSV and B. pertussis and other related diseases that pose a risk to newborns and young children.
SHORT SUMMARY
This invention relates to combination immunogenic compositions, such as vaccines, capable of providing protection against infection and / or disease caused by both RSV and B. pertussis (sometimes referred to as pertussis herein). More specifically, this invention relates to compositions which comprise a recombinant analog of RSV F protein, with pertussis antigens of acellular (Pa) or whole cell (Pw) type and their use, particularly in the context of immunization. neonatal and maternal. Vaccine schemes, methods and uses of the immunogenic compositions are further disclosed to protect the infant from RSV and B. pertussis disease by administering to a pregnant woman a recombinant RSV F protein analog and a pertussis antigen in at least one immunogenic composition, the protection of newborns from birth being provided by the transplacental transfer of protective maternal antibodies against RSV and whooping cough. Said at least one immunogenic composition may be a combined VRS-B composition. pertussis as described in this application. Useful kits for this maternal immunization are also described.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. IA is a schematic representation highlighting the structural features of the RSV F protein.
FIG. IB is a schematic representation of examples of VRS prefusion F (PreF) antigens.
FIG. 2 shows the design of the study for an experiment on guinea pigs performed in Example 1.
FIG. 3 shows the results of Example 1 after virulent challenge in the offspring of guinea pigs with RSV.
FIG. 4 shows the chronology of the neutralizing antibody response in the guinea pig model of Example 1.
FIGs. 5A and 5B are graphs showing neutralizing titers and protection against RSV infection after immunization with combined RSV + pertussis vaccine (Example 2).
FIGs. 6A and 6B are graphs showing serum antibody titers and protection against infection caused by Bordetella pertussis after immunization with combined RSV + pertussis vaccine (Example 3).
FIGs. 7A and 7B are graphs showing the neutralizing titers in guinea-pig mothers and their offspring after maternal immunization of RSV first-inoculated mothers with combined RSV + pertussis vaccine (Example 4).
FIG. Figure 8 shows the protection against RSV infection of pups of guinea pig pups after maternal immunization of RSV-primed mothers with combined RSV + pertussis vaccine (Example 4).
DETAILED DESCRIPTION
INTRODUCTION
The development of vaccines to prevent RSV infection has been complicated by the fact that the immune responses of the host appear to play a role in the pathogenesis of the disease. Early studies dating back to the 1960s showed that children vaccinated with formalin-inactivated RSV vaccine had an aggravated form of the disease during subsequent exposure to the virus compared to unvaccinated control subjects. These early trials resulted in the hospitalization of 80% of the vaccinated and two deaths. The worsening of the disease has been replicated in animal models and appears to result from inadequate levels of serum neutralizing antibodies, lack of local immunity, and excessive induction of an immune response in T-helper cells. type 2 (Th2) with pulmonary eosinophilia and increased production of IL-4 and IL-5 interleukins. In contrast, a successful vaccine that protects against RSV infection induces a Th1-directed immune response, characterized by the production of IL-2 and interferon-γ (IFN).
Although pertussis immunization is well established, in the absence of an acceptable RSV vaccine, the desirability of studying a combination vaccine capable of providing protection against RSV and B infection and / or disease. . pertussis did not show up. As these infectious agents represent a very significant risk for the newborn and the young infant (which in the case of B. pertussis still have to be built up a complete protection stimulated by the pediatric vaccination scheme) and that they also present both a danger for the elderly, a combined immunogenic composition allowing the administration of both vaccines both in a single injection would be advantageous in terms of comfort for the recipient, observation of the vaccine regimen, cost-effectiveness , and free space in the immunization schedule for other vaccines.
The present invention describes combined immunogenic compositions (eg vaccines) that protect against infection, or the associated disease, by both RSV and B. pertussis, and methods of using them, particularly to protect newborns and infants, populations with the highest incidence and severity, in terms of morbidity and mortality, associated with these pathogens. Protecting this demographics presents challenges. Infants, especially premature infants, may have an immature immune system. There is also the possibility of interference of maternal antibodies with vaccination In very young children In the past there has been a problem of worsening RSV-related disease with vaccination of very young children against RSV. as well as the challenges posed by the decline of immunity caused by natural infection and immunization. Maternal immunization with pertussis-containing vaccines has been shown to increase anti-pertussis antibody titres in neonates (compared to neonates whose mothers have not been subjected to maternal immunization) (For example, Gall et al (2011), Am J Obstet Gynecol, 204: 334.el-5, incorporated herein by reference), and this maternal immunization is now recommended in some countries. In addition to disclosing the immunization methods using the combined compositions described herein, the present invention further describes the vaccine schemes, methods and uses of said immunogenic compositions for protecting infants and infants by immunizing pregnant women with combinations of of RSV and B. pertussis antigens, including by use of the combined RSV-B immunogenic compositions. pertussis described herein. The antigens advantageously elicit the production of antibodies that are transferred to the infant by the placenta and has the effect of providing passive immunological protection to the child after birth and which lasts throughout the critical period of time. infection and severe form of the disease caused by RSV and B. pertussis.
One aspect of this invention relates to a composition. combined immunogen comprising at least one RSV antigen and at least one B. pertussis antigen, wherein said at least one B. pertussis antigen comprises at least one acellular pertussis antigen (Pa) or comprises a whole cell antigen (Pw).
In particular, the invention relates to a combined immunogenic composition wherein said at least one RSV antigen is a recombinant soluble analogue of the F protein. F analogues stabilized in the postfusion conformation ("PostF"), or which are labile to the conformation, can be used. Advantageously, the F protein analog is a F or "PréF" prefusion antigen which comprises at least one modification that stabilizes the F protein preforming conformation.
In a particular embodiment, said at least one B. pertussis antigen of the combined immunogenic composition comprises at least one Pa antigen selected from the group consisting of: pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin (PRN), type 2 fimbriae (FIM2), type 3 fimbriae (FIM3). These Pa vaccines are well known in the art.
In another embodiment, said at least one B. pertussis antigen comprises a Pw antigen, wherein the Pw vaccines are well known in the art. As used herein, the term "whole cell antigen (Pw)" refers to an inactivated B. pertussis germ (which naturally contains many different antigens strictly), and is therefore equivalent to a Pw vaccine.
In some embodiments, the disclosed combined immunogenic composition comprises a pharmaceutically acceptable carrier or excipient, such as a buffer. In addition or alternatively, the immunogenic composition may comprise an adjuvant, for example, an adjuvant which comprises 3D-MPL, QS21 (eg, in a detoxified form), an oil-in-water emulsion (e.g. or without immunostimulatory molecules, such as α-tocopherol, inorganic salts such as aluminum salts (including alum, aluminum phosphate, aluminum hydroxide) and calcium phosphate. , or their combinations.
In some embodiments, the disclosed combined immunogenic compositions further comprise at least one antigen from at least one pathogenic organism other than RSV and B. pertussis. In particular, said at least one pathogenic organism may be chosen from the group consisting of: Corynebacterium diphtheriae; Clostridium tetani; hepatitis B virus; the polio virus; Haemophilus influenzae Type b; N. meningitidis Type C; N. meningitidis Type Y; N. meningitidis Type A, N. meningitidis Type W; and N. meningitidis Type B.
In another aspect, this invention relates to the use of the immunogenic compositions described for preventing and / or treating RSV / B. pertussis infection / disease. Therefore, a method for eliciting an immune response against RSV and B. pertussis comprising administering to an individual an immunologically effective amount of said combined immunogenic composition is described.
In another aspect, this invention relates to the combined immunogenic compositions described herein for use in medicine, particularly for preventing or treating in a subject an infection caused by RSV and B. pertussis, or a disease associated therewith.
In another aspect, this invention relates to a vaccine regimen for protecting an infant against infection or disease caused by RSV and B. pertussis, the vaccine regimen comprising: administering to a pregnant woman carrying a pregnant child at least one immunogenic composition capable of stimulating a specific humoral immune response of both RSV and B. pertussis, said at least one immunogenic composition comprising a recombinant RSV antigen comprising an F protein analog and at least one B antigen pertussis, wherein at least a subset of RSV-specific antibodies and at least a subset of antibodies specific for B. pertussis the production of which has been elicited or increased in the pregnant woman by said at least one immunogenic composition are transferred via the placenta to the unborn child to protect against infection or illness caused by RSV and B. pertussis.
In one aspect, a method for protecting an infant against infection or disease caused by RSV and B. pertussis is also disclosed, said method comprising: administering to a pregnant woman carrying a pregnant child at least one immunogenic composition capable of stimulating a humoral immune response specific to both RSV and B. pertussis, said at least one immunogenic composition comprising a recombinant RSV antigen comprising an F protein analog and at least one B. pertussis antigen, wherein least a subset of RSV-specific antibodies and at least a subset of B. pertussis-specific antibodies whose production has been elicited or increased in the pregnant woman by said at least one immunogenic composition are transferred via placenta to the unborn child to protect against infection or disease caused by RSV and B. pertussis.
Another aspect according to the present invention relates to an immunogenic composition or a plurality of compositions
immunogens comprising a recombinant RSV antigen comprising an F protein analog and at least one B. pertussis antigen that can be used to protect an infant from infection or disease caused by RSV and B. pertussis, wherein Immunogenic compositions are formulated for administration to a pregnant woman and wherein the immunogenic composition (s) is / are capable of stimulating a specific humoral immune response to both RSV and B wherein at least one subset of RSV-specific antibodies and at least one subset of B. pertussis specific antibodies whose production has been stimulated in the pregnant woman by the immunogenic composition (s) are transferred through the placenta to the unborn child, thereby protecting it from infection or disease caused by RSV and B. pertussis.
In another aspect, a kit comprising a plurality of immunogenic compositions formulated for administration to a pregnant woman is disclosed, the kit comprising: (a) a first immunogenic composition comprising a protein F analog capable of inducing, elicit or stimulate a specific humoral immune response to RSV; and (b) a second immunogenic composition comprising at least one B. pertussis antigen capable of inducing, eliciting or stimulating a specific humoral immune response of B. pertussis, wherein after administration to a. pregnant woman, the first and second immunogenic compositions induce, elicit or stimulate at least a subset of RSV-specific antibodies and at least a subset of antibodies specific for B. pertussis, said antibodies being transferred via placenta to the pregnant child, protecting it from infection or disease caused by RSV and B. pertussis.
TERMS
In order to facilitate the review of the various embodiments of the present invention, explanations are provided for the following terms. Additional terms and explanations may be provided within the scope of this invention.
Unless otherwise indicated, all technical and scientific terms used herein have the meanings normally known to those skilled in the art to which the invention relates. Definitions of common terms in molecular biology can be found in Benjamin Lewin, Gen. V, published by Oxford University Press, 1994 (ISBN 0-19-854287 ^ 9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: A Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
Unless otherwise indicated, the singular terms "a", "an", and "the", "the" include plural referents. Similarly, and unless otherwise indicated, the term "or" is intended to include "and". The term "plurality" refers to two or more. It will be further understood that all base sizes or amino acid sizes, and all molecular weight or molecular weight values, indicated for the nucleic acids or polypeptides are approximate, and are indicated for descriptive purposes. In addition, the numerical limits indicated with respect to the concentrations or levels of a substance, such as an antigen, are intended to be approximate. Thus, when it is stated that a concentration is at least (for example) 200 μg, it will be understood that the concentration is at least approximately (or "about" or 200 μg.
Although methods and materials similar or equivalent to those described herein may be used in the practice or testing of the present invention, suitable methods and materials are described below. The term "includes" means "includes". Thus, unless otherwise indicated, it will be understood that the term "includes", and its variants such as "include / understand", and "include" imply the inclusion of the indicated compound or composition (eg, nucleic acid, polypeptide, antigen) or a step, or a group of compounds or steps, but not to the exclusion of any other compound, composition, step, or group thereof. The abbreviation "e.g." is derived from the Latin exempli gratia, and serves herein to indicate a non-limiting example. Therefore, the abbreviation "e.g." is synonymous with the term "for example".
The term "F protein" or "fusion protein" or "F protein polypeptide" or "fusion protein polypeptide" refers to a polypeptide or protein having all or. part of an amino acid sequence of a RSV fusion protein polypeptide. Many RSV fusion proteins have been described and are known to those skilled in the art. WO2008 / 114149 gives examples of F protein variants (e.g., natural variants).
An "F protein analog" refers to an F protein that comprises a modification that alters its structure or function but retains its immunological properties such that an immune response generated against an F protein analog recognizes the native F protein. WO2010 / 149745, hereby incorporated in its entirety by reference, gives examples of F-protein analogs. WO2011 / 008974, hereby incorporated by reference in its entirety, also gives examples of F-protein analogs. Protein F analogs include, for example, PreF antigens that include at least one modification that stabilizes the F protein conformation conformation and that are generally soluble, ie, non-membrane bound. F-protein analogs also include post-fusion F (postF) antigens which are in the post-fusion conformation of RSV F protein, advantageously stabilized in this conformation. F analogs further include F protein in an intermediate conformation, advantageously stabilized in this conformation. In general, these alternatives are also soluble.
A "variant", with reference to a nucleic acid or polypeptide (eg, a nucleic acid or polypeptide of the RSV F or G protein, or a nucleic acid or polypeptide of an F analog) is a nucleic acid or a polypeptide that differs from a reference nucleic acid or polypeptide. Generally, the difference (s) between the variant and the reference nucleic acid or polypeptide is (are) of a proportionally small number of differences compared to the reference.
A "domain" of polypeptide or protein is a structurally defined element within the polypeptide or protein. For example, a "trimerization domain" is an amino acid sequence within a polypeptide that promotes assembly of the polypeptide into trimers. For example, a trimerization domain may promote assembly into trimers by associations with other trimerization domains (other polypeptides having the same or different amino acid sequence). The term also serves to designate a polynucleotide that encodes a peptide or polypeptide.
The terms "native / native" and "natural / natural" refer to an element, such as a protein, a polypeptide or a nucleic acid that is present in the same state as in nature. That is, the element has not been artificially modified. It will be understood that, in the context of the present invention, there are many native / natural variants of RSV proteins or polypeptides, e.g., obtained from natural strains or from different isolates of RSV. WO2008 / 114149, incorporated herein by reference in its entirety, contains examples of RSV strains, proteins and polypeptides, see for example Figure 4.
The term "polypeptide" refers to a polymer in which the monomers are amino acid residues which are joined to each other by amide linkages. The terms "polypeptide" or "protein" as used herein are intended to include any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" is specifically intended to encompass natural proteins, as well as those that are produced by recombination or synthesis. The term "fragment", with reference to a polypeptide, refers to a portion (i.e., a subsequence) of a polypeptide. The term "immunogenic fragment" refers to all fragments of a polypeptide that retain at least one immunodominant epitope of the entire reference protein or polypeptide. The orientation within a polypeptide is generally indicated in the N-terminal to C-terminal direction, said sense being defined by the orientation of the amino and carboxy moieties of the individual amino acids. The polypeptides are translated from the N- or amino-terminal end to the C- or carboxy-terminal end.
A "signal peptide" is a short amino acid sequence (e.g., about 18-25 amino acids long) that directs the newly synthesized secretory or membrane proteins to and through the membranes, e.g., into the endoplasmic reticulum. Signal peptides are frequently but not always located at the N-terminus of a polypeptide, and are frequently cleaved by signal peptidases after the protein has passed the membrane. Signal sequences typically contain three characteristics. Common structural structures: a basic polar N-terminal region (n-region), a hydrophobic central region, and a hydrophilic C-terminal region (c-region).
The terms "polynucleotide" and "nucleic acid sequence" denote a polymeric form of nucleotides having a length of at least 10 bases. The nucleotides may be ribonucleotides, deoxyribonucleotides, or modified forms of either of these nucleotides. The term includes both single and double stranded forms of DNA. By "isolated polynucleotide" is meant a polynucleotide which is not immediately contiguous to the two coding sequences to which it is immediately contiguous (one on the 5 'end and one on the 3' end) in the natural genome of the organism from which it is derived. In one embodiment, a polynucleotide encodes a polypeptide. The 5 'and 3' sense of a nucleic acid is defined with reference to the connectivity of the individual nucleotide units, and is referred to as the carbon positions of the sugar deoxyribose (or ribose) cycle. The information content (coding) of a polynucleotide sequence is read in the 5 'to 3' direction.
A "recombinant" nucleic acid is a nucleic acid whose sequence is not natural or whose sequence consists of the artificial combination of two normally separated sequence segments. This artificial combination can be achieved by chemical synthesis or, more commonly, by the artificial manipulation of isolated nucleic acid segments, e.g., by genetic engineering techniques. A "recombinant" protein is a protein that is encoded by a heterologous (e.g., recombinant) nucleic acid that has been introduced into a host cell, such as a bacterial or eukaryotic cell. The nucleic acid can be introduced into an expression vector containing signals capable of expressing the protein encoded by the introduced nucleic acid or the nucleic acid can be integrated into the chromosome of the host cell.
The term "heterologous", when applied to a nucleic acid, polypeptide or other cellular component, indicates that the component is found where it is not normally found in nature and / or is derived from a source or a different species.
The term "purification" (e.g., applied to a pathogen or pathogen-containing composition) refers to the process of removing certain components of a composition, the presence of which is not desired. Purification is a relative term, and does not require that all traces of the undesirable component be removed from the composition. In vaccine production, purification includes methods such as centrifugation, dialysis, ion exchange chromatography, and exclusion chromatography, affinity purification or precipitation. Thus, the term "purified" does not require absolute purity; rather, it is considered a relative term. Thus, for example, a nucleic acid or purified protein preparation is a preparation in which the specified nucleic acid or protein is more enriched than the nucleic acid or protein in its generating environment, for example within a cell or in a biochemical reaction chamber. A substantially pure nucleic acid or protein preparation may be purified such that the desired nucleic acid accounts for at least 50% of the total nucleic acid content of the preparation. In some embodiments, a substantially pure nucleic acid or protein will be at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95% or more of the content. nucleic acid or total protein of the preparation.
An "isolated" biological component (such as a nucleic acid molecule, a protein or an organelle) has been essentially separated or separated by purification from the other biological components in the body cell in which the component is naturally present, such as other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles. Nucleic acids and "isolated" proteins include nucleic acids and proteins purified by standard purification methods. The term also encompasses nucleic acids and proteins prepared by recombinant expression in a host cell as well as nucleic acids and chemically synthesized proteins.
An "antigen" is a compound, a composition, or a substance that can stimulate the production of antibodies and / or a T-cell response in a subject, including compositions that are injected, absorbed, or otherwise administered to the subject . The term "antigen" includes all related antigenic epitopes. The term "epitope" or "antigenic determinant" refers to a site on an antigen to which B and / or T cells respond. "Dominant antigenic epitopes" or "dominant epitope" are those epitopes to which a functionally significant host immune response, e.g., an antibody response or a T cell response, is provided. Thus, in the case of a protective immune response against a pathogen, the dominant antigenic epitopes are the antigenic fragments which, when recognized by the host's immune system, have the effect of protecting against the disease caused by the pathogen. . The term "T epitope" refers to an epitope that, when it binds to a suitable MHC molecule, is specifically attached by a T cell (via a T cell receptor). An "epitope B" is an epitope that is specifically bound by an antibody (or a B cell receptor molecule).
An "adjuvant" is an agent that enhances the production of an immune response in a non-specific manner to the antigen. Common adjuvants include the suspensions of minerals (alum, aluminum hydroxide, aluminum phosphate) on which the antigen is adsorbed; emulsions, including water-in-oil and oil-in-water emulsions (and variants thereof, including double emulsions and reversible emulsions), liposaccharides, lipopolysaccharides, immunostimulatory nucleic acids (such as oligonucleotides CpG), liposomes, Toll-like receptor agonists (in particular, TLR2, TLR4, TLR7 / 8 and TLR9 agonists), and various combinations of these components.
An "antibody" or "immunoglobulin" is a plasma protein consisting of four polypeptides that specifically binds to an antigen. An antibody molecule consists of two heavy chain polypeptides and two light chain polypeptides (or multiples thereof) held together by disulfide bonds. In humans, antibodies are defined in five isotypes or classes: IgG, IgM, IgA, IgD, and IgE. IgG antibodies can be further subdivided into four subclasses (IgG1, IgG2, IgG3 and IgG4). A "neutralizing" antibody is an antibody that is capable of inhibiting the infectivity of a virus. For example, RSV-specific neutralizing antibodies are capable of inhibiting or reducing RSV infectivity.
An "immunogenic composition" is a composition of matter that can be administered to a human or animal subject (eg, in an experimental or clinical setting) that is capable of eliciting a specific immune response, eg, against a pathogen, such as the VRS or B. pertussis. As such, an immunogenic composition comprises one or more antigens (e.g., polypeptide antigens) or antigenic epitopes. An immunogenic composition may also include one or more additional components capable of eliciting or enhancing an immune response, such as an excipient, a vehicle, and / or an adjuvant. In some instances, the immunogenic compositions are administered to elicit an immune response that protects the subject against pathogen-induced symptoms or conditions. In some cases, pathogen-induced symptoms or disease are prevented (or reduced or improved) by inhibiting replication of the pathogen (e.g., RSV or B. pertussis) following exposure of the subject to the pathogen. In the context of the present invention, it will be understood that the term "immunogenic composition" encompasses compositions which are intended to be administered to a subject or population of subjects in order to elicit a protective or palliative immunogenic response against RSV and / or B. pertussis (ie, vaccine compositions or vaccines). The term "combined immunogenic composition" is used herein as a reference to specifically refer to the immunogenic compositions described herein which include both RSV and B. pertussis antigens (as opposed to immunogenic compositions comprising RSV antigens but not B. pertussis, or vice versa).
An "immune response" is the response of an immune system cell, such as a B cell, a T cell, or a monocyte, to a stimulus, such as a pathogen or antigen (eg, formulated as an immunogenic composition or a vaccine). An immune response may be a B-cell response, resulting in the production of specific antibodies, such as neutralizing antibodies specific for the antigen. An immune response may also be a T cell response, such as a CD4 + response or a CD8 + response. B-cell and T-cell responses are aspects of a "cellular" immune response. An immune response can also be a "humoral" immune response, mediated by antibodies. In some cases, the response is specific for a particular antigen (ie, "antigen specific response"). If the antigen is derived from a pathogen, the specific response of the antigen is a "pathogen specific response". A "protective immune response" is an immune response that inhibits the harmful function or activity of a pathogen, reduces infection with a pathogen, or decreases the symptoms (including death) that result from infection with a pathogen. pathogenic. A protective immune response can be measured, for example, by inhibition of viral replication or plaque formation in a plaque reduction assay or neutralization assay by ELISA, or by measurement of resistance to challenge virulent by an in vivo pathogen. Exposing a subject to a pathogenic stimulus, such as a pathogen or an antigen (eg, formulated as an immunogenic composition or a vaccine), elicits a stimulus-specific primary immune response, i.e. , the exposure "primes" the immune response. Subsequent exposure, e.g., by immunization, to the stimulus may increase or "stimulate" the amplitude (or duration, or both) of the specific immune response. Therefore, "stimulating" a pre-existing immune response by administering an immunogenic composition increases the magnitude of a specific antigen (or pathogen) response, (eg, by increasing the antibody titer and / or affinity, by increasing the frequency of antigen-specific B or T cells, by induction of an effector function of maturation, or any of their combinations).
A "Th1" oriented immune response is characterized by the presence of CD4 + helper T helper cells producing IL-2 and IFN-γ, and therefore by the secretion or presence of IL-2 and IFN-γ. γ. In contrast, a "Th2" oriented immune response is characterized by a preponderance of CD4 + cells producing IL-4, IL-5, and IL-13.
An "immunologically effective amount" is the amount of composition (typically, immunogenic composition) used to elicit an immune response in a subject to the composition or antigen contained in the composition. Generally, the desired result is the production of a specific immune response of the antigen (e.g., the pathogen) that is capable of protecting or helping to protect the subject against the pathogen. However, obtaining a protective immune response against a pathogen may require multiple administrations of the immunogenic composition. Therefore, in the context of the present invention, the term "immunologically effective amount" encompasses a fractional dose which contributes in combination with prior and subsequent administrations to obtain a protective immune response. The adjective "pharmaceutically acceptable" indicates that the referent is amenable to administration to a subject (e.g., a human or animal subject). Remington's Pharmaceutical Sciences, by EW Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), discloses compositions and formulations (including diluents) suitable for the pharmaceutical administration of therapeutic and / or prophylactic compositions, comprising immunogenic compositions.
The term "modulate" with reference to a response, such as an immune response, means "alter," or "vary," the occurrence, magnitude, duration, or characteristics of the response. An agent that modulates an immune response at least alters the occurrence and / or the amplitude and / or the duration and / or the characteristics of the immune response after its administration, or at least alters its occurrence and / or its amplitude and / or its duration and / or characteristics, compared to a reference agent.
The term "reduced" is a relative term, in the sense that an agent reduces a response or condition if the response or condition is quantitatively decreased after administration of the agent, or if it is decreased after administration of the agent , compared to a reference agent. Similarly, the term "protect" does not necessarily mean that an agent completely eliminates the risk of infection or disease caused by the infection, but that at least one characteristic of the response or the The condition is substantially or significantly reduced or eliminated. Thus, an immunogenic composition that protects against or reduces an infection or disease, or a symptom thereof, may prevent or eliminate infection or disease but not necessarily in all subjects, provided that the incidence or severity of the infection or the incidence or severity of the disease is measurably reduced, for example, by at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the infection or disease in the absence of the agent, or compared to a reference agent.
A "subject" is a living multicellular vertebrate organism, such as a mammal. In the context of the present invention, the subject may be an experimental subject, such as a non-human animal, e.g., a mouse, a cotton rat, a guinea pig, a cow, or a non-human primate. Alternatively, the subject may be a human subject.
VRS PROTEIN F ANALOGUES
In a particular embodiment, the F protein analog is a prefusion antigen F or "PréF" which comprises at least one modification which stabilizes the F protein preforming conformation. Alternatively, stabilized F analogues in postfusion conformation ( "PostF"), or which are labile to the conformation can be used. Generally, the F protein analog antigen (eg, PreF, PostF, etc.) lacks a transmembrane domain, and is soluble, ie, not bound to the membrane (e.g., to facilitate expression and purification of the F protein analog).
Details regarding the structure of the RSV F protein are provided herein with reference to terminology and designations widely accepted in the art, and are shown schematically in FIG. IA. A schematic representation of examples of PreF antigens is illustrated in FIG. IB.
In exemplary embodiments, the F protein analog comprises in the N-terminus to C-terminus direction: at least a portion or substantially all of the F2 domain and the F domain of a F protein polypeptide of VRS, optionally with a heterologous trimerization domain. In one embodiment, there is no furine cleavage site between domain F2 and domain Fi. In certain exemplary embodiments, the F2 domain comprises at least a portion of a RSV F protein polypeptide corresponding to amino acids 26-105 of the reference F protein precursor polypeptide (Fo) of SEQ ID NO: 2 and / or the Fi domain comprises at least a portion of a RSV F protein polypeptide corresponding to amino acids 137-516 of the precursor polypeptide of the reference F protein (Fo) of SEQ ID NO: 2.
For example, in specific embodiments, the F protein analog is selected from the group consisting of: (a) a polypeptide comprising a polypeptide selected from the group of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22;
(b) a polypeptide encoded by a polynucleotide selected from the group of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 17, SEQ ID NO: 19 and SEQ ID NO: 21, or a polynucleotide sequence that hybridizes under substantially stringent stringent conditions to a polynucleotide selected from the group of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 17, SEQ ID NO: 19 and SEQ ID NO: 21, said polypeptide comprising an amino acid sequence corresponding at least in part to a natural strain of RSV; (c) a polypeptide having a sequence identity of at least 95% with a polypeptide selected from the group of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 18, SEQ ID No: 20 and SEQ ID NO: 22, said polypeptide comprising an amino acid sequence that does not correspond to a natural strain of RSV.
Optionally, the F protein analog further comprises a signal peptide. Optionally, the F protein analog may further comprise a "tag" or sequence to facilitate purification, e.g., a multi-histidine sequence.
In embodiments comprising a heterologous trimerization domain, this domain may comprise a super-helix domain, such as an isoleucine barrier, or it may comprise an alternating trimerization domain, derived for example from fibrinin ("foldon"). ") bacteriophage T4 or HA influenza.
In some exemplary embodiments, the F protein analog comprises at least one modification selected from: (i) a modification that alters glycosylation; (ii) a modification that removes at least one non-furine cleavage site; (iii) a modification that deletes one or more amino acids from the pep27 domain; and (iv) a hydrophilic amino acid substitution or substitution modification in a hydrophobic domain of the extracellular domain of the F protein.
In some embodiments, the F protein analog comprises a multimer of polypeptides, for example, a polypeptide trimer.
As mentioned above, in a particular embodiment the RSV recombinant antigen of the described combined immunogenic composition comprises a Fusion protein (F) analog which contains a soluble protein F polypeptide, which has been modified to stabilize the F-protein pre-fusion conformation, that is, the conformation of the mature assembled F protein prior to its fusion to the host cell membrane. These F protein analogs are designated "PreF" or "PreF antigens" for reasons of clarity and simplicity. These antigens, described and exemplified in WO2010 / 149745, exhibit improved immunogenic characteristics, and are safe and highly protective when administered to a subject in vivo. It will be understood by those skilled in the art that any RSV F protein can be modified to stabilize the prefusion conformation according to the teachings of the present application. Therefore, to facilitate understanding of the principles governing the production of PreF antigens, the individual structural components will be indicated with reference to an exemplary F protein whose polynucleotide and amino acid sequences are provided in SEQ ID Nos: 1 and 2, respectively. Similarly, if applicable, the G protein antigens are described with reference to an exemplary G protein whose polynucleotide and amino acid sequences are provided in SEQ ID Nos: 3 and 4, respectively.
With reference to the primary amino acid sequence of the F protein polypeptide (FIG IA), the following terms are used to describe the structural features of the PreF antigens.
The term Fo designates a precursor of whole protein F after translation. The Fo polypeptide may be subdivided into a F2 domain and a Fi domain separated by an intermediate peptide, designated pep27. During maturation, the Fo polypeptide undergoes proteolytic cleavage at the two furin sites located between F2 and Fi and flanking pep27. For the following discussion, domain F2 comprises at least a portion, and up to all amino acids 1-109, and the soluble portion of domain F1 comprises at least a portion, and up to all amino acids 137- As indicated above, these amino acid positions (and all subsequent amino acid positions indicated in the present application) are given with reference to the precursor polypeptide of the exemplary F protein (Fo) of SEQ ID NO: 2. The F (or "PreF") pre-fusion antigen is a soluble (i.e., non-membrane bound) analog of F protein that comprises at least one modification that stabilizes the conformation of the pre-fusion protein. F, so that the RSV antigen retains at least one immunodominant epitope of the F protein conformation conformation. The soluble analog of the F protein comprises the F2 domain and the domain
Fi of the RSV F protein (but does not include the transmembrane domain of the RSV F protein). In exemplary embodiments, the F2 domain comprises amino acids. 26-105 and the Fi domain includes the amino acids 137-516 of an F protein. However, smaller portions can also be used, as long as the three-dimensional conformation of the stabilized PreF antigen is retained. Similarly, polypeptides that include additional structural components (eg, fusion polypeptides) can also be used in place of the exemplary F2 and F1 domains, as long as the additional components do not alter the three-dimensional conformation, or do not affect otherwise. negatively impact stability, production or maturation, or do not decrease, the immunogenicity of the antigen. The F2 and F1 domains are positioned in an N-terminus to C-terminus orientation designed to replicate the folding and assembly of the F-protein analog into a mature prefusion conformation. To improve production, the F2 domain may be preceded by a secretory signal peptide, such as a signal peptide native to the F protein or a heterologous signal peptide selected to enhance production and secretion in host cells in which the Recombinant PreF antigen must be expressed.
The PreF antigens are stabilized (in their trimer prefusion conformation) by introduction of one or more modifications, such as addition, deletion or substitution, of one or more amino acids. One of these stabilizing modifications is the addition of an amino acid sequence comprising a heterologous stabilizing domain. In exemplary embodiments, the heterologous stabilizing domain is a protein multimerization domain. A particularly advantageous example of this protein multimerization domain is a coiled-coil domain such as an isoleucine zipper domain which promotes the trimerization of multiple polypeptides having this domain. An exemplary isoleucine slide domain is shown in SEQ ID NO: 11. Typically, the heterologous stabilizing domain is on the C-terminal end with respect to the Fi domain.
Optionally, the multimerization domain is linked to the Fi domain by a short amino acid linker sequence, such as the GG sequence. The linker may also have a longer sequence (eg, containing the GG sequence, such as the amino acid sequence: GGSGGSGGS; SEQ ID
No: 14). Many conformationally neutral linkers known in the art can be used in this context without altering the conformation of the PreF antigen.
Another stabilizing modification is the elimination of a furin recognition and cleavage site located between the F2 and F1 domains in the native Fo protein. One or both of the furin recognition sites, located at positions 105-109 and positions 133-136, can be removed by deletion or substitution of one or more amino acids from the furin recognition sites, so that the protease is incapable. to cleave the PréF polypeptide into its constituent domains. Optionally, the pep27 intermediate peptide may also be removed or substituted, e.g., by a linker peptide. In addition, or optionally, a non-furine cleavage site (e.g., metalloproteinase site at positions 112-113) in the vicinity of the fusion peptide may be removed or substituted.
Another example of a stabilizing mutation is the addition or substitution of hydrophilic amino acid type in a hydrophobic domain of the F protein. Typically, a charged amino acid, such as lysine, will be added to or substitute for a neutral residue, such as as leucine, in the hydrophobic region. For example, a hydrophilic amino acid can be added. or to substitute for a hydrophobic or neutral amino acid in the HRB superhelical domain of the extracellular domain of the F protein. For example, a charged amino acid residue, such as lysine, may be substituted for the leucine present at the 512 position of the F protein. Alternatively, or in addition, a hydrophilic amino acid may be added to, or substituted for, a hydrophobic or neutral amino acid in the HRA domain of the F protein. For example, one or more charged amino acids, such as lysine, can be inserted at or near positions 105-106 (eg, following the amino acid corresponding to residue 105 of SEQ ID No. 2, for example, between amino acids 105 and 106) of the PreF antigen. Optionally, hydrophilic amino acids may be added or substituted in both the HRA and HRB domains. Alternatively, one or more hydrophobic residues may be deleted, as long as the overall conformation of the PreF antigen is not adversely affected.
In addition or alternatively, one or more modifications that alter the glycosylation state of the PreF antigen may be introduced. For example, one or more amino acids in a glycosylation site present in a native RSV F protein, eg, at or around amino acid residue 500 (compared to SEQ ID No: 2) may be deleted or substituted (or amino acid may be added for the glycosylation site to be altered) to increase or decrease the glycosylation state of the PreF antigen. For example, amino acids corresponding to positions 500-502 of SEQ ID NO: 2 may be selected from: NGS; NKS; NGT; and NKT. Thus, in some embodiments, the PreF antigens comprise a soluble analog of the F protein consisting of a F2 domain (eg, corresponding to amino acids 26-105 of SEQ ID No: 2) and a Fi domain (eg , corresponding to amino acids 137-516 of SEQ ID NO: 2) of a RSV F protein polypeptide, wherein at least one alteration that alters glycosylation has been introduced. The RSV PreF antigen typically includes an intact fusion peptide between the F2 domain and the F1 domain. Optionally, the PreF antigen includes a signal peptide.
As described above, these F protein analogs may comprise at least one modification selected from: (i) adding an amino acid sequence comprising a trimerization domain.heterologist (such as a isoleucine); (ii) deletion of at least one furin cleavage site; (iii) deletion of at least one non-furine cleavage site; (iv) the deletion of one or more amino acids from the pep27 domain; and (v) at least one hydrophilic amino acid substitution or addition in a hydrophobic domain of the extracellular domain of the F protein.
As described above, these modified VSR PreF antigens in terms of glycosylation assemble into multimers, e.g., trimers.
In exemplary embodiments, the modified PreF antigens in terms of glycosylation are selected from the following group: a) a polypeptide comprising or consisting of SEQ ID NO: 22; b) a polypeptide encoded by SEQ ID NO: 21 or a polynucleotide sequence which hybridizes under stringent conditions over substantially all of its length. length at SEQ ID NO: 21; c) a polypeptide having a sequence identity of at least 95% with SEQ ID No: 22. Any one and / or all such stabilizing modifications may be used individually and / or in combination with any of the other stabilizing modifications described herein to obtain a PreF antigen. In exemplary embodiments, the PreF protein comprises a polypeptide comprising a F2 domain and a Fi domain without an intermediate furin cleavage site between the F2 domain and the Fi domain, with a heterologous stabilizing domain (eg, trimerization domain) positioned on the end side. C-terminal with respect to the domain Fi. In some embodiments, the PreF antigen also comprises one or more hydrophilic residue additions and / or substitutions in a hydrophobic HRA and / or HRB domain. Optionally, the PreF antigen carries a modification of at least one non-furine cleavage site, such as a metalloproteinase site.
PreF antigen may optionally include an additional polypeptide component which comprises at least one immunogenic portion of the RSV G protein. Namely, in some embodiments, the PreF antigen is a chimeric protein that comprises both a protein F and protein G component. The protein component F can be any of the preF antigens described above, and the component selected G protein is an immunologically active portion of RSV G protein (up to and / or comprising an entire G protein). In exemplary embodiments, the G protein polypeptide comprises amino acids 149-229 of a G protein (amino acid positions are indicated with reference to the G protein sequence shown in SEQ ID NO: 4). It will be understood by those skilled in the art that a smaller portion or fragment of protein G may be used, as long as the selected portion retains the dominant immunological characteristics of the larger G protein fragment. The immunologically dominant epitope roughly enters amino acid positions 184-198 (eg, amino acids 180-200), and is long enough to fold and assemble in a stable conformation that exhibits the immunodominant epitope. Longer fragments may also be used, eg, ranging from amino acid 128 to about amino acid 229, to the entire G protein, as long as the selected fragment folds to a stable conformation within of the chimeric protein, and does not interfere with production, molecular processing, or stability when recombinantly produced in host cells. Optionally, the protein G component is bound to the F protein component by a short amino acid linker sequence, such as the GG sequence. The linker may also have a longer sequence (such as the amino acid sequence: GGSGGSGGS: SEQ ID NO: 14). Many conformationally neutral linkers known in the art can be used in this context without altering the conformation of the PreF antigen.
Optionally, the protein G component may comprise one or more amino acid substitutions that reduce or prevent the worsening of the viral disease in an animal model of the RSV-caused disease. Namely, the G protein may include an amino acid substitution such that when an immunogenic composition comprising the PreF-G chimeric antigen is administered to a subject selected from an accepted animal model (eg, murine model of RSV), the subject has reduced symptoms, if any, of viral disease exacerbated by the vaccine (eg, eosinophilia, neutrophilia) compared to a control animal receiving a vaccine that contains unmodified G protein. The reduction and / or prevention of viral disease exacerbated by the vaccine may be apparent when the immunogenic compositions are administered in the absence of adjuvant (but not, for example, when the antigens are administered in the presence of an adjuvant inducing a strong Thl response). In addition, amino acid substitution can reduce or prevent the viral disease exacerbated by the vaccine when administered to a human subject. An example of suitable amino acid substitution is the replacement of asparagine at position 191 with an alanine (Asn → Ala at amino acid position 191: N191A).
Optionally, any PreF antigen described above may include an additional sequence as a purification aid. An example is a polyhistidine tag. This label can be removed from the final product if desired.
When expressed, the PreF antigens undergo intramolecular folding and assemble into a mature protein that comprises a multimer of polypeptides. Favorably, the preF antigen polypeptides assemble into a trimer that resembles the prefusion conformation of mature RSV F protein.
In some embodiments, the immunogenic composition comprises a PreF antigen (such as the exemplary embodiment represented by SEQ ID NO: 6) and a second polypeptide that comprises a protein component G. The protein G component typically comprises at least amino acids 149-229 of a G protein. Although smaller portions of protein G can be used, the fragments should comprise, at a minimum, the immunodominant epitope of amino acids 184-198. Alternatively, the protein G component may comprise a larger portion of the G protein, such as amino acids 128-229 or 130-230, optionally as an element of a larger protein, such as protein G whole, or a chimeric polypeptide.
In other embodiments, the immunogenic composition comprises a PreF antigen that is a chimeric protein that also comprises a G protein component (such as the exemplary embodiments represented by SEQ ID Nos: 8 and 10). The protein G component of this chimeric PreF (or PreF-G) antigen typically comprises at least the amino acids 149-229 of a G protein. As noted above, smaller or larger fragments (such as amino 129-229 · or 130-230) of the G protein can also be used, as long as the immunodominant epitopes are conserved, and the conformation of the PreF-G antigen is not adversely affected. Further details regarding the PreF antigens, and methods for using them, are set forth below, and in the Examples.
The RSV recombinant antigens described herein are F-protein analogs derived from and, corresponding immunologically in whole or in part, to the RSV F protein. They may include one or more modifications that alter the structure or function of the F protein but retain its immunological properties such that an immune response generated against an F protein analog recognizes the native F protein and therefore recognizes RSV. The above-described F protein analogs are useful as immunogens.
In nature, RSV F protein is expressed as a single polypeptide precursor of 574 amino acids long, designated Fo. In vivo, Fo is oligomerized in the endoplasmic reticulum and proteolytically treated with a furin protease at two retained furin consensus sequences (furin cleavage sites), RARR109 (SEQ ID No: 15) and RKRR136 (SEQ ID NO: 16) to generate an oligomer consisting of two disulfide bonded moieties. The smallest of these fragments is called F2 and comes from the N-terminal part of the Fo precursor. The largest C-terminal fragment, Fi, anchors the F protein in the membrane via a hydrophobic amino acid sequence, which is adjacent to a cytoplasmic tail of 24 amino acids. Three F2-F1 dimers associate to form a mature F protein, which adopts a metastable pre-fused conformation ("pre-fusion") that upon initiation undergoes a conformational change upon contact with a target cell membrane. This conformational change exposes a hydrophobic sequence, known as a fusion peptide, that associates with the host cell membrane and promotes fusion of the virus membrane, or an infected cell, with the target cell membrane.
The Fi fragment contains at least two heptad repeat domains, designated HRA and HRB, which are located in the vicinity of the fusion peptide and the transmembrane anchor domains, respectively. In the prefusion conformation, the F2-F1 dimer forms a globular head and stem-type structure, in which the HRA domains are in a segmented (extended) conformation in the globular head. In contrast, the HRB domains form a three-stranded super-helix rod extending from the head region. During the transition from the pre-fusion to post-fusion conformations, the HRA domains collapse and are brought near the HRB domains to form an anti-parallel six-helix beam. In the post-fusion state, the fusion peptide and the transmembrane domains are juxtaposed to facilitate fusion to the membrane.
Although the conformational description provided above is based on the molecular model of crystallographic data, the distinctions between pre-fusion and post-fusion conformations can be monitored without resorting to crystallography. For example, electron micrograph can be used to distinguish between pre-fusion and post-fusion conformations (also referred to as prefusogenic and fusogenic), as demonstrated by Calder et al., Virology, 271: 122-131 (2000) and Morton et al. al., Virology, 311: 275-288, which are incorporated herein by reference for their technological teachings. The pre-fusion conformation can also be distinguished from the fusogenic (post-fusion) conformation by liposome association assays as described by Connolly et al., Proc. Natl. Acad. Sci. USA, 103: 17903-17908 (2006), which is also incorporated herein by reference for its technological teachings. In addition, the pre-fusion and fusogenic conformations can be distinguished using antibodies that specifically recognize the conformational epitopes present on one of the pre-fusion or fusogenic forms of the RSV F protein, but not on the other. These conformational epitopes may be due to the preferential exposure of an antigenic determinant to the surface of the molecule. Alternatively, the conformational epitopes can come from the juxtaposition of amino acids that are non-contiguous in the linear polypeptide.
Typically, F-protein analogs (PreF, PostF, etc.) lack a transmembrane domain and a cytoplasmic tail, and may also be referred to as "F protein ectodomain" or "F protein soluble ectodomain".
F protein analogs include a F protein polypeptide, which has been modified to stabilize the pre-fusion conformation of the F protein, that is, the conformation of the assembled mature F protein prior to its fusion with the host cell membrane. These F-protein analogs are referred to as "PreF analogs", "PreF" or "PreF antigens" for the sake of clarity and simplicity, and are generally soluble. The above-described PreF analogs are explained by the finding that soluble F-protein analogs that have been modified by incorporation of a heterologous trimerization domain exhibit improved immunogenic characteristics, and are safe and highly protective when they are administered to a subject in vivo. Pre-exemplary antigens are described in WO2010 / 149745, incorporated herein by reference in its entirety for its description of examples of PreF antigens.
F protein analogs also include a F protein polypeptide having the conformation of a post-fusion F protein and which may be referred to as "PostF antigen" or "post-fusion antigen". PostF analogs are described in WO2011 / 008974, incorporated herein by reference. The PostF antigen contains at least one modification to alter the structure or function of the native post-fusion F protein.
The above-described PreF 'analogs are designed to stabilize and preserve the pre-fusion conformation of the RSV F protein, so that in a population of expressed protein, a substantial portion of the expressed protein population is in the prefusogenic conformation (pre-fusion). (eg, as predicted by structural and / or thermodynamic modeling or as evaluated by one or more of the methods described above). The stabilizing modifications are introduced into a native (or synthetic) F protein, such as the exemplary F protein of SEQ ID NO: 2, so that the major immunogenic epitopes of the pre-fusion conformation of the F protein are retained after introduction of the PréF analogue in a cellular or extracellular environment (e.g., in vivo, eg, after administration to a subject).
First, a heterologous stabilizing domain can be placed at the C-terminus of the construct to replace the membrane anchoring domain of the Fo polypeptide. This stabilizing domain should compensate for HRB instability, help stabilize the preform melting. In exemplary embodiments, the heterologous stabilizing domain is a protein multimerization domain. A particularly favorable example of this field of protein multimerization is a trimerization domain. The exemplary trimerization domains fold into a super-helix which favors the assembly into trimers of multiple polypeptides possessing these domains in a super-helix. As examples of trimerization domains, there are the trimerization domains derived from influenza hemagglutinin, the SARS spiculate, the HIV gp41, the modified GCN4, the bacteriophage T4 fibritin. and ATCase. A favorable example of a trimerization domain is an isoleucine barrier. An illustrative isoleucine slide domain is the revamped GCN4 isoleucine variant described by Harbury et al. Science 262: 1401-1407 (1993). The sequence of a suitable isoleucine zipper domain is represented by SEQ ID NO: 11, although variants of this sequence that retain its ability to form a super-helix stabilizing domain are also suitable. Other stabilizing super-helix trimerization domains include: TRAF2 (GENBANK® accession number Q12933 [gi: 23503103]; amino acids 299-348); thrombospondin 1 (Accession No. P07996 [gi: 135717]; amino acids 291-314); matrilin-4 (Accession No. 095460 [gi: 14548117]; amino acids 594-618; CMP (matrilin-1) (Accession No. NP_002370 [gi: 4505111]; amino acids 463-496; HSF1 ( Accession No. AAX42211 [gi: 61362386], amino acids 165-191, and cubilin (Accession No. NP_001072 [gi: 4557503]; amino acids 104-138. A suitable trimerization domain should permit the assembly of a substantial portion of the protein expressed as trimers For example, at least 50% of a recombinant PreF polypeptide having a trimerization domain will assemble into a trimer (eg, as assessed by AFF-MALS). 60%, more favorably at least 70%, and most preferably at least about 75% or more of the expressed polypeptide is in the form of a trimer.
Another example of a stabilizing mutation is the addition or substitution of hydrophilic amino acid type in a hydrophobic domain of the F protein. Typically, a charged amino acid, such as lysine, will be added to or substitute for a neutral residue, such as as leucine, in the hydrophobic region. For example, a hydrophilic amino acid may be added, or substituted for a hydrophobic or neutral amino acid in the HRB superhelical domain of the extracellular domain of protein F. For example, a charged amino acid residue such as that lysine can substitute for the leucine present at the 512 position of the F protein (relative to the native Fo: L482K polypeptide in the exemplary analogous PréF polypeptide of SEQ ID NO: 6). Alternatively, or in addition, a hydrophilic amino acid may be added to, or substituted for, a hydrophobic or neutral amino acid in the HRA domain of the F protein. For example, one or more charged amino acids, such as lysine, can be inserted at or near positions 105-106 (eg, following the amino acid corresponding to residue 105 of SEQ ID NO: 2 reference, for example between amino acids 105 and 106) of analogous PreF. Optionally, hydrophilic amino acids can be added or introduced by substitution in both the HRA and HRB domains. Alternatively, one or more hydrophobic residues may be deleted, as long as the overall conformation of the PreF analog is not adversely affected.
Second, pep27 can be eliminated. Analysis of a structural model of pre-fusion RSV F protein suggests that pep27 creates a large unconstrained loop between Fi and F2 · This loop does not contribute to pre-fusion state stabilization , and is removed after cleavage of the native protein by furin. Therefore, pep27 can also be eliminated from embodiments that involve a conformational analog post-fusion (or other).
Third, one or both furin cleavage patterns (located between the F2 and F1 domains in the native Fo protein) can be deleted. One or both of the furin recognition sites located at positions 105-109 or 106-109 and at positions 133-136 may be removed by deletion or substitution of one or more amino acids from the furin recognition sites, for example deletion of one or more amino acids or substitution of one or more amino acids, or combinations of one or more substitutions or deletions, or modification such that the protease is unable to cleave the PréF polypeptide (or other analogue of the protein F) in its constituent domains. Optionally, the peptide pep27 intermediate may also be removed or substituted, e.g., by a linker peptide. In addition, or optionally, a non-furine cleavage site (e.g., metalloproteinase site at positions 112-113) in the vicinity of the fusion peptide may be removed or substituted.
Therefore, an analog of the F protein that can be used in the methods and uses of the present invention which is an uncleaved ectodomain having one or more altered furin cleavage sites can be obtained. These F-like polypeptides are produced by recombinant techniques in a host cell that secretes them in the uncleaved state at amino acid positions 101 to 161, eg in the uncleaved state at the cleavage sites. furine at positions 105-109 and 131-136. In particular embodiments, K131Q substitution, deletion of amino acids at positions 131-134, or substitutions K131Q or R133Q or R135Q or R136Q, are used to inhibit 136/137 cleavage.
In exemplary design, the fusion peptide is not separated from F2 by cleavage, which prevents the release of the pre-fusion conformer from the globular head and the accessibility to nearby membranes. The interaction between the fusion peptide and the membrane interface is considered a major point in the instability of the pre-fusion state. During the fusion process, the interaction between the fusion peptide and the target membrane results in exposure of the fusion peptide out of the globular head structure, increasing instability of the pre-fusion state and folding in the conformer. post-fusion. This conformational change allows the merging process to the membrane. The removal of one or both furin cleavage sites should deprive the N-terminal portion of the fusion peptide of membrane accessibility, stabilizing the pre-fusion state. Thus, in the exemplary embodiments described above, removal of the furin cleavage units results in a PreF analog which comprises an intact fusion peptide, which is not cleaved by furin during or after maturation and assembly. .
Optionally, at least one non-furine cleavage site may also be removed, for example by substitution of one or more amino acids. For example, experimental findings suggest that under conditions leading to cleavage by some metalloproteinases, the F protein analog may be cleaved near amino acids 110-118 (for example, with cleavage occurring between amino acids 112 and 113 of the F protein analog between leucine at position 142 and glycine at position 143 of the reference F protein polypeptide of SEQ ID NO: 2). Therefore, modification of one or more amino acids in this region may reduce cleavage of the F analog. For example, leucine at position 112 may be substituted with a different amino acid, such as isoleucine, glutamine or tryptophan (as illustrated in the exemplary embodiment of SEQ ID NO: 20). Alternatively or additionally, glycine at position 113 may be substituted with serine or alanine. In other embodiments, the F-protein analogs further contain altered trypsin cleavage sites, and the F-protein analogs are not cleaved by trypsin at a site between amino acid 101. and 161.
Optionally, an F protein analog may include one or more modifications that alter the glycosylation pattern or state (eg, by increasing or reducing the proportion of glycosylated molecules on one or more of the glycosylation sites present in a polypeptide native F protein). For example, the native F protein polypeptide of SEQ ID NO: 2 should be glycosylated at amino acid positions 27, 70 and 500 (corresponding to positions 27, 70 and 470 of the representative PreF analog of SEQ ID No: 6). In one embodiment, a modification is introduced in the vicinity of the glycosylation site at amino acid position 500 (designated N470). For example, the glycosylation site can be removed by substitution of an amino acid, glutamine (Q) type in place of asparagine at position 500 (of the reference sequence, which corresponds by alignment at position 470 of the exemplary PréF analogue). Advantageously, a modification that increases the efficiency of glycosylation at this glycosylation site is introduced. As examples of suitable modifications, there are at positions 500-502, the following amino acid sequences: NGS; NKS; NGT; NKT. Interestingly, it has been found that modifications of this glycosylation site that induce increased glycosylation also induce substantially increased PreF production. Therefore, in some embodiments, the PreF analogs have a modified glycosylation site at the position corresponding to amino acid 500 of the reference PreF sequence (SEQ ID No: 2), eg, at position 470 of the present invention. Analog PreF represented by SEQ ID No: 6. Suitably, the modifications include the sequences: NGS; NKS; NGT; Amino acid NKT corresponding to positions 500-502 of the polypeptide sequence of the reference F protein. The amino acid sequence of an exemplary embodiment which comprises an "NGT" modification is illustrated in SEQ ID No. 18. Those skilled in the art can readily determine similar modifications for the corresponding NGS, NKS, and NKT modifications. . These modifications favorably combine with any of the stabilizing mutations described herein (eg, a heterologous superhelix, such as an isoleucine zipper-like domain and / or a modification in a hydrophobic region, and / or the elimination of pep27, and / or the removal of a furine cleavage site, and / or the removal of a non-furine cleavage site). For example, in a specific embodiment, the F protein analog includes a substitution that eliminates a non-furin cleavage site and a modification that enhances glycosylation. An exemplary Pref F analog sequence is illustrated in SEQ ID No: 22 (said exemplary embodiment comprising an "NGT" modification and a glutamine substitution instead of leucine at position 112). For example, in certain exemplary embodiments, the glycosylation-modified PreF analogues are selected from the following group: a) a polypeptide comprising or consisting of SEQ ID NO: 22; b) a polypeptide encoded by SEQ ID NO: 21 or a polynucleotide sequence that hybridizes under stringent conditions substantially its entire length to SEQ ID NO: 21; c) a polypeptide having a sequence identity of at least 95% with SEQ ID No: 22.
More generally, any of the stabilizing modifications described herein, eg, the addition of a heterologous stabilizing domain, such as a superhelix (e.g., an isoleucine zipper-like domain), preferably located at the C-terminal end of the soluble analogue of the F protein; modifying a residue, such as leucine to lysine, in the hydrophobic HRB domain; elimination of pep27; removing one or both furin cleavage patterns; removing a non-furin cleavage site such as a trypsin cleavage site; and / or modification of a glycosylation site may be used in combination with the groin of one or more of the other stabilizing modifications (or all of them in any desired combination). For example, a heterologous superhelix (or other heterologous stabilizing domain) may be used alone or in any combination with: a modification in a hydrophobic region, and / or the removal of pep27, and / or the removal of a furin cleavage, and / or elimination of a non-furine cleavage site. In certain specific embodiments, the protein F protein analog, such as the PreF analog, comprises a C-terminal super-helix domain (isoleucine barrier), a stabilizing substitution in the hydrophobic HRB domain, and elimination of one or both furin cleavage sites. This embodiment comprises an intact fusion peptide that is not removed by furin cleavage. In a specific embodiment, the F protein analog also comprises a modified glycosylation site at amino acid position 500. The F protein analog for the compositions and methods described herein can be obtained by a method which comprises the use of a biological material containing the F protein analogue (eg, PreF analogue, PostF analogue or uncleaved ectodomain of F protein, etc.) and the purification of the monomers or multimers (eg, trimers ) polypeptides of the analog or a mixture thereof from the biological material. The protein F analog may be in the form of polypeptide monomers or trimers, or a mixture of monomers and trimers, which may exist at equilibrium. The presence of a single form can provide benefits such as a more predictable immune response or better stability.
Therefore, in one embodiment, the F protein analog usable according to the invention is a purified F protein analog, which may be in the form of monomers or trimers or a mixture of monomers and trimers , essentially free of lipids and lipoproteins.
The F protein polypeptide may be selected from any F protein of a VRS A or VRS B strain, or from variants thereof (as defined above). In certain exemplary embodiments, the F protein polypeptide is the F protein represented by SEQ ID NO: 2. For ease of understanding of the present invention, all amino acid residue positions, regardless of the strain, are indicated by relative to (i.e., the position of the amino acid residue corresponds to) the amino acid position of the exemplary F protein. The comparable amino acid positions of any other RSV strain A or B can be readily determined by those skilled in the art by aligning the amino acid sequences of the selected VRS strain with those of the exemplary sequence using Alignment algorithms easy to obtain and well known (such as BLAST, eg, using the default settings). Numerous other examples of F protein polypeptides from different strains of RSV are described in WO2008 / 114149 (which is hereby incorporated by reference for its description of additional examples of RSV F and G protein sequences). Additional variants may result from genetic drift, or may be artificially produced by targeted or random mutagenesis, or by recombination of two or more pre-existing variants. These additional variants are also suitable in the context of the F protein analogs used in the immunogenic compositions described herein.
In other alternative embodiments useful in the compositions and methods described herein, the RSV F protein is a protein F analog as described in WO2011 / 008974, hereby incorporated by reference for its description of protein analogs. For example, see F protein analogs in Figure 1 of WO2011 / 008974 and also described in Example 1 of WO2011 / 008974.
For the choice of the F2 and F1 domains of the F protein, those skilled in the art will know that it is not strictly necessary to include the entire F2 and / or Fi domain.
Typically, conformational considerations are important when selecting a subsequence (or fragment) of the F2 domain. Thus, the F2 domain typically comprises a portion of the F2 domain that facilitates assembly and stability of the polypeptide. In certain exemplary variants, the F2 domain comprises amino acids 26-105. However, variants with minor changes in length (by addition, or deletion of one or more amino acids) are also possible.
Typically, at least one sub-sequence (or fragment) of the Fi domain is chosen and designed to maintain a stable conformation that includes the immunodominant epitopes of the F-protein. For example, it is generally desirable to choose a subsequence of the domain. polypeptide Fi which includes epitopes recognized by neutralizing antibodies in the amino acid regions 262-275 (neutralization with palivizumab) and 423-436 (MAb chlOlF from Centocor). In addition, it may be desirable to include T epitopes, eg, in the amino acid region 328-355, more generally, a single contiguous portion of the sub-motif Fi (eg, covering amino acids 262-436) is used, the epitopes that can be retained in a synthetic sequence that includes these immunodominant epitopes in the form of discontinuous elements assembled in a stable conformation. For example, a domain FI polypeptide comprises at least amino acids 262-436 of a VRS F protein polypeptide. In a non-limiting example provided in the present application, the FI domain comprises amino acids 137 to 516 of a native F protein polypeptide. Those skilled in the art will understand that shorter additional subsequences may be used at the discretion of the practitioner.
For the choice of a sub-sequence of the F2 or F1 domain (eg, as discussed below for the G protein component of some PreF-G analogues), in addition to the conformational consideration, it may be desirable to select sequences (eg, variants, subsequences, and others) based on the inclusion of additional immunogenic epitopes. For example, additional T epitopes can be identified using anchor motifs or other methods, such as neural network determination or polynomial determination, known in the art, see, eg, RANKPEP (accessible through the Web at: mif.dfci.harvard.edu/Tools/rankpep.html); ProPredl (accessible via the Web at: imtech.res.in/raghava/propredl/index.html); Bimas (accessible via the Web at: www-bimas.dcrt.nih.gov/molbi/hla_bind/index.html); and SYFPEITH (accessible via the Web at: syfpeithi.bmi-heidelberg.com/scripts/MHCServer.dll/home.htm). For example, the algorithms are used to determine the "binding threshold" of the peptides, and choose those whose scores give them a high probability of binding to the MHC or the antibody at a certain affinity. The algorithms are based on either effects on MHC binding of a particular amino acid at a particular position, or on the effects on antibody binding of a particular amino acid at a particular position, or effects on the binding of a particular substitution in a peptide containing a motif. In the context of an immunogenic peptide, a "conserved residue" is a residue that appears at a significantly higher frequency than expected by random distribution at a particular position in a peptide. Anchor residues are conserved residues that provide a point of contact with the MHC molecule. The T epitopes identified by these predictive methods can be confirmed by measuring their binding to a specific MHC protein and by their ability to stimulate T cells when presented as part of the MHC protein.
Advantageously, an analogue of the F protein, for example the PreF analogs (including the PreF-G analogs discussed below), a PostF analog, or other conformational analog, comprises a signal peptide corresponding to the expression system, for example, a mammalian or viral signal peptide, such as a native RS signal sequence Fo (eg, amino acids 1-25 of SEQ ID No: 2 or amino acids 1-25 of SEQ ID No: 6). Typically, the signal peptide is selected to be compatible with cells selected for recombinant expression. For example, a signal peptide (such as a baculovirus signal peptide, or the signal peptide of melittin) may be substituted for expression in insect cells. Suitable plant signal peptides are known in the art, if a plant expression system is preferred. Many examples of signal peptides are known in the art, (see, e.g., Zhang & Henzel,
Protein Sci., 13: 2819-2824 (2004), which describes numerous human signal peptides) and is cataloged, eg, in the SPdb signal peptide database, which contains the signal sequences of Archae, prokaryotes and eukaryotes (http://proline.bic.nus.edu.sg/spdb/). Any of the foregoing antigens may optionally include an additional sequence or tag, such as a His tag, to facilitate purification.
Optionally, the F protein analog (eg, the PreF or PostF analog or the like) may include additional immunogenic components. In some particularly advantageous embodiments, the F protein analog includes an antigenic component of the RSV G protein. Exemplary chimeric proteins comprising a PreF and G component include PreF_V1 (represented by SEQ ID Nos: 7 and 8) and PreF_V2 (represented by SEQ ID Nos: 9 and 10).
In PreF-G analogs, an antigenic portion of protein G (e.g., truncated G protein, represented by amino acid residues 149-229) is added to the C-terminus of the construct. Typically, the protein component G is joined to the protein component F by a flexible linker sequence. For example, in the exemplary PreF_V1 motif, the G protein is joined to the PreF component by a -GGSGGSGGS- linker (SEQ ID No: 14). In the PreF_V2 pattern, the linker is shorter. Instead of the -GGSGGSGGS- (SEQ ID No: 14) linker, PreF_V2 includes 2 glycines (-GG-) as a linker.
When present, the polypeptide domain of the G protein may include all or part of a G protein selected from any VRS A or VRS B strain. In some exemplary embodiments, the G protein is (or has 95% identity to) the G protein represented by SEQ ID NO: 4. Additional examples of suitable G protein sequences are found in WO2008 / 114149 (which is incorporated herein by reference).
The polypeptide component of protein G is selected to include at least one subsequence (or fragment) of the G protein that conserves the immunodominant T-epitope (s), eg, in the region of amino acids 183-197, such as fragments of the G protein which comprise amino acids 151-229, 149-229, or 128-229 of a native G protein. In an exemplary embodiment, the G protein polypeptide is a subsequence (or fragment) of a native protein G polypeptide that comprises all or part of amino acid residues 149 to 229 of a native G protein polypeptide . Those skilled in the art will readily understand that longer or shorter portions of the G protein can also be used, as long as the selected portion does not destabilize the conformation or alter the expression, folding or maturation of the protein. the F protein analog. Optionally, the G protein domain includes an amino acid substitution at position 191, which has previously been shown to be involved in the reduction and / or prevention of aggravation of the disease characterized by eosinophilia associated with formalin-inactivated RSV vaccines. A full description of the attributes of natural and substituted G proteins (N191A) is shown, e.g., in U.S. Patent Publication No. 2005/0042230, which is incorporated herein by reference.
Alternatively, the F protein analog may be formulated into an immunogenic composition that also contains a second polypeptide that includes a protein G component. The protein G component typically comprises at least the amino acids 149-229 of a protein. G. Although smaller portions of the G protein may be used, these fragments must include, at a minimum, the immunodominant epitope consisting of amino acids 184-198. Alternatively, the G protein may comprise a larger portion of protein G, such as amino acids 128-229 or 130-230, optionally as a component of a larger protein, such as an entire G protein, or a chimeric polypeptide.
For example, with regard to the choice of sequences corresponding to naturally occurring strains, one or more of the domains may sequentially correspond to a strain of RSV A or B, such as routine laboratory isolates designated A2 or Long, or any other strain or natural isolate. Many strains of RSV have been isolated so far. Exemplary strains designated by their GenBank Access Number and / or EMBL appearing in WO2008 / 114149, hereby incorporated by reference for its description of the RSV nucleic acid and polypeptide protein F sequences that can be used in the F protein analogs herein. -décrits. Additional strains of RSV are likely to be isolated, and are included in the genus of RSV. Similarly, the genus of RSV includes variants resulting from natural (e.g., previously identified or later) strains obtained by genetic derivatives, and / or recombination.
In addition to these natural and isolated variants, the modified variants that. share sequence similarity with the aforementioned sequences may also be used in the context of F-protein analogs, including the analogs PreF, PostF or other analogs (including F-G). Those skilled in the art will understand that the similarity between the F protein analog polypeptide (and the polynucleotide sequences described below), and the polypeptide (and nucleotide sequences in general), can be expressed in terms similarity between sequences, also called sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity), the higher the percentage, and the more similar the primary structures of the two sequences. In general, the more similar the primary structures of the two amino acid (or polynucleotide) sequences, the higher order structures resulting from folding and assembly are similar. The polypeptide (and polynucleotide) sequences of F protein variants typically have a single or a small number of amino acid deletions, additions, or substitutions, but will, however, share a very high percentage of their amino acid sequence, and typically of polynucleotides. More importantly, the variants retain the structural and, therefore, conformational attributes of the reference sequences described herein.
Methods for determining sequence identity are well known in the art, and apply to polypeptides of F protein analogs, as well as to the nucleic acids that encode them (e.g., as described below). Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2: 482, 1981; Needleman and Wunsch, J. Mol. Biol. 48: 443, 1970; Higgins and Sharp, Gene 73: 237, 1988; Higgins and Sharp, CABIOS 5: 151, 1989; Corpet et al., Nucleic Acids Research 16: 10881, 1988; and Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85: 2444, 1988. Altschul et al., Nature Genet. 6: 119, 1994, present a detailed aspect of sequence alignment methods and homology calculations. NCBI's Basic Local Alignment Search Tool (Altschul et al., J. Mol Biol 215: 403, 1990) is available from several sources, including NCBI (National Center for Biotechnology Information,
Bethesda, MD) and the Internet, and can be used in conjunction with blastp, blastn, blastx, tblastn and tblastx sequence analysis programs. A description of how to determine the sequenced identity using these programs is available on the NCBI website.
In some instances, the F protein analog has one or more amino acid changes relative to the amino acid sequence of the naturally occurring strain from which it is derived (eg, in addition to the aforementioned stabilizing modifications) . These differences can be an addition, deletion or substitution of one or more amino acids. A variant typically differs by no more than about 1, or 2, or 5, or 10, or 15, or about 20% of the amino acid residues. For example, a F, eg, PreF or PostF protein analog variant, or other analogous polypeptide sequence may include 1, or 2, or up to 5, or up to about 10, or up to about 15. , or up to about 50, or up to about 100 amino acid differences, compared to the relevant portion of a standard F protein sequence (e.g., the polypeptide sequences of the PreF analogs of SEQ ID Nos: 6 , 8, 10, 18, 20 and / or 22). Therefore, a variant in the context of a RSV F or G protein, or protein F analog, typically shares a sequence identity of at least 80%, or 85%, more commonly, from at least about 90% or more, e.g. 95%, or even 98% or 99% with a reference protein, eg, in the case of a PreF analog: the reference sequences illustrated in SEQ ID NO: 2, 4, 6, 8, 10, 18, 20 and / or 22, or any other analog of the invention. Additional variants included as a feature of the present disclosure are the F-protein analogs that comprise all or part of a nucleotide or amino acid sequence selected from the natural variants described in WO2008 / 114149. Other variants may result from genetic drift, or may be artificially produced by targeted or random mutagenesis, or by recombination of two or more pre-existing variants. These additional variants are also suitable in the context of the F-like analogue antigens described above. For example, the modification may be a substitution of one or more amino acids (such as two amino acids, three amino acids, four amino acids, five amino acids, up to about ten amino acids, or more) which does not alter the conformation or immunogenic epitopes of the F protein analog obtained.
Alternatively or additionally, the modification may include a deletion of one or more amino acids and / or an addition of one or more amino acids. It goes without saying that, if desired, one or more of the polypeptide domains may be a synthetic polypeptide that does not correspond to any single strain, but includes sub-sequences from multiple strains, or even a consensus sequence deduced by multiple alignment. strains of VRS virus polypeptides. In some embodiments, one or more of the polypeptide domains are modified by adding an amino acid sequence that constitutes a tag, which facilitates subsequent maturation or purification. This label may be an antigenic or epitopic label, an enzymatic label or a polyhistidine label. Typically the tag is at either end of the protein, ie at the C-terminus or at the N-terminus of the antigen or fusion protein.
Analogues of the F protein (and also, if applicable, the G antigens) described herein may be produced using well-established procedures for the expression and purification of recombinant proteins.
Briefly, the recombinant nucleic acids that encode the F-protein analogs are introduced into host cells by any of a number of well-known procedures, such as electroporation, liposome-mediated transfection, phosphate precipitation. calcium, infection, transfection and other, depending on the choice of vectors and host cells. Preferred host cells include prokaryotic (ie, bacterial) host cells, such as E. coli, as well as many eukaryotic host cells, including fungal cells (eg, yeast, such as Saccharomyces cerevisiae and Picchia pastoris), insects, plant cells, and mammalian cells (such as 3T3, COS, CHO, BHK, HEK 293) or Bowes melanoma cells. After expression in a selected host cell, recombinant analogs of the F protein can be isolated and / or purified according to procedures known in the art. Exemplary expression methods, as well as nucleic acids that encode the PreF analogs (including the PreF-G analogs) are provided in WO2010 / 149745, which is incorporated herein for its description of suitable methods for expression and purification. of F protein analogs.
ANTIGENS OF B. PERTUSSIS
In a particular embodiment of the described combined immunogenic compositions, said at least one B. pertussis antigen comprises at least one Pa antigen selected from the group consisting of: pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin (PRN), type 2 fimbriae (FIM2), and type 3 fimbriae (FIM3). The antigens are partially or highly purified.
PT can be produced in various ways, for example by purifying toxoid from a B. pertussis culture followed by chemical detoxification (e.g. as described in WO91 / 12020, incorporated herein by reference), or variant by purifying a genetically detoxified PT analog (for example, as described in the following documents, incorporated herein by reference for their description of the contemplated genetic modifications of PT: EP306318, EP322533, EP396964, EP322115, EP275689). In a particular embodiment, PT is genetically detoxified. More particularly, the genetically detoxified PT has one or both of the following substitutions: R9K and E129G.
The combined immunogenic composition described may comprise any of 1, 2, 3, 4 or 5 acellular pertussis antigens PT, FHA, PRN, FIM2 and FIM3. More particularly, said composition may comprise the combinations: PT and FHA; PT, FHA and PRN; PT, FHA, PRN and FIM2; PT, FHA, PRN and FIM3; and PT, FHA, PRN, FIM2 and FIM3.
In a particular embodiment, PT is used in an amount of 2-50 μg (e.g. exactly or approximately 2.5 or 3.2 μg per dose), 5-40 μg (e.g. 8 μg per dose), or 10-30 μg (eg exactly or approximately 20 or 25 μg per dose).
In a particular embodiment, FHA is used in an amount of 2-50 μg (for example exactly or approximately 2.5 or 34.4 μg per dose), 5-40 μg (for example exactly or approximately 5 or 8 μg per dose) or 10-30 μg (eg exactly or approximately 20 or 25 μg per dose).
In a particular embodiment, the PRN is used in an amount of 0.5-20 μg, 0.8-15 μg (e.g. exactly or approximately 0.8 or 1.6 μg per dose) or 2-10 μg per dose. pg (for example exactly or approximately 2.5 or 3 μg or 8 μg per dose).
In a particular embodiment, the FIM2 and / or FIM3 are used in a total amount of 0.5-10 μg (e.g. exactly or approximately 0.8 or 5 μg per dose).
In a particular embodiment, the combined immunogenic composition comprises PT and FHA in equivalent amounts per dose, either exactly or approximately 8 or 20 or 25 μg. Alternatively, the combined immunogenic composition comprises PT and FHA at exactly or approximately 5 and 2.5 μg respectively, or exactly or approximately 3.2 and 34.4 μg. In another embodiment, the immunogenic composition comprises PT, FHA and PRN in exact or approximate amounts per dose of 25: 5: 8 μg; 8: 8: 2.5 μg; 20: 20: 3 μg; 2.5: 5: 3 μg; 5: 2.5: 2.5 μg; or 3.2: 34.4: 1.6 μg.
Alternatively, or in combination with any of the above-described Pa antigens, the described combined immunogenic composition may comprise an antigen derived from the B. pertussis "BrkA" protein (as described in WO2005 / 032584, and Marr et al. al (2008), Vaccine, 26 (34): 4306-4311, incorporated herein by reference).
In another embodiment, said at least one Pa antigen comprises an outer membrane vesicle (OMV) obtained from B. pertussis, as described in Roberts et al (2008), Vaccine, 26: 4639-4646, incorporated herein by reference. In particular, this OMV can be derived from a recombinant strain of B. pertussis expressing a lipid A-modifying enzyme, such as 3-O-deacylase, for example PagL (Asensio et al (2011), Vaccine, 29: 1649-1656, incorporated herein by reference).
In another alternative embodiment, said at least one B. pertussis antigen comprises a Pw antigen. Pw can be inactivated by several known methods, including mercury-free methods. These methods may include inactivation by heat (eg 55-65 ° C or 56-60 ° C, for 5-60 minutes or for 10-30 minutes, eg 60 ° C for 30 minutes), with formaldehyde (eg 0.1% at 31 °, 24 hours), with glutaraldehyde (eg 0.05% at room temperature, 10 minutes), with acetone-I (eg three treatments at room temperature) or acetone-II ( eg three treatments at room temperature and a fourth at 37 ° C) (see for example Gupta et al., 1987, J. Biol Stand 15:87, Gupta et al., 1986, Vaccine, 4: 185). Methods for preparing killed Pw antigens that can be used in the combined immunogenic composition are described in WO93 / 24148.
More particularly, the immunogenic combination comprises Pw in an amount per dose (in International Units of Opacity, "IOU") of: 5-50, 7-40, 9-35, 11-30, 13-25, 15-21. , or approximately or exactly 20.
In a particular embodiment of a combined immunogenic composition comprising a Pw antigen according to the invention, the Pw component of the composition elicits reduced reactogenicity. The reactogenicity (pain, fever, edema, etc.) of Pw vaccines is mainly caused by a lipo-oligosaccharide ("LOS", which is synonymous with lipopolysaccharide ("LPS") in, part of B. pertussis; "LOS" will be used here), which is the endotoxin from the outer membrane of the bacteria. The lipid A part of LOS is mainly responsible. In order to produce a vaccine containing a less reactive Pw antigen (compared to "conventional" Pw vaccines such as those produced by the inactivation procedures discussed above), the endotoxin may be genetically or chemically detoxified and / or extracted from the outer membrane. However, this must be done in a way that does not significantly alter the immunogenicity of the Pw antigen, since LOS is a potent adjuvant of the immune system.
In one embodiment, said at least one B. pertussis antigen of the described combined immunogenic composition comprises a "low reactogenicity" Pw antigen in which the LOS has been genetically or chemically detoxified and / or extracted. For example, the Pw antigen may be subjected to treatment with a mixture of an organic solvent, such as butanol, and water, as described in WO2006 / 002502 and Dias et al (2012), Human Vaccines & Immunotherapeutics, 9 (2): 339-348 which are hereby incorporated by reference for their description of the chemical extraction of LOS.
In an alternative embodiment, "low reactogenicity" is achieved by derivatizing the Pw antigen from a strain of B. genetically manipulated pertussis to produce a less toxic LOS. WO2006 / 065139 (hereby incorporated by reference) discloses the genetic O-deacylation and detoxification of B. pertussis LOS, to obtain strains comprising at least partially 3-O-deacylated LOS. The at least one B. pertussis antigen of the combined immunogenic composition can therefore be a Pw antigen derived from a B. pertussis strain that has been engineered to express a lipid A-modifying enzyme, such as de-O-acylase. . In particular, this strain can express PagL as described in WO2006 / 065139, as well as in Geurtsen et al (2006), Infection and Immunity, 74 (10): 5574-5585 and Geurtsen et al (2007), Microbes and Infection, 9 : 1096-1103, all incorporated herein by reference. Alternatively or additionally, the strain from which the Pw antigen is derived can naturally, or following manipulation: lose its ability to modify its lipid A-phosphate groups with a glucosamine; have a lipid A-diglucosamine backbone substituted at the C-3 'position by C10-OH or C12-OH; and / or expressing molecular LOS species lacking terminal heptose. This strain, 18-323, is described in Marr et al (2010), The Journal of Infectious Diseases, 202 (12): 1897-1906 (incorporated herein by reference).
IMMUNOGENIC COMPOSITION
The combined immunogenic compositions described herein typically contain a pharmaceutically acceptable carrier or excipients, and optionally contain additional antigens.
Pharmaceutically acceptable carriers and excipients are known and may be selected by those skilled in the art. For example, the vehicle or excipient may advantageously include a buffer. Optionally, the vehicle or excipient also contains at least one component that stabilizes solubility and / or compositions. Examples of solubilizing / stabilizing agents include detergents, for example, laurel sarcosine and / or Tween. Other solubilizing / stabilizing agents include arginine, and vitrifying polyols (such as sucrose, trehalose and the like). Many pharmaceutically acceptable carriers and / or pharmaceutically acceptable excipients are known in the art and are described, e.g., in Remington's Pharmaceutical Sciences, by E.W. Martin, Mack Publishing Co., Easton, PA, 5th Edition (975).
Therefore, suitable excipients and vehicles may be selected by those skilled in the art to provide a formulation amenable to administration to a subject by the chosen route of administration.
Suitable excipients include, but are not limited to, glycerol, polyethylene glycol (PEG), sorbitol, trehalose, N-lauroylsarcosine sodium salt, L-proline, non-detergent sulfobetaine, guanidine hydrochloride, and the like. urea, trimethylamine oxide, KC1, Ca2 +, Mg2 +, Mn2 +, Zn2 + and other divalent cation salts, dithiothreitol, dithioerytrol, and β-mercaptoethanol. Other excipients may be detergents (including: Tween80, Tween20, Triton X-00, NP-40, Empigen BB, octylglucoside, lauroylmaltoside, Zwittergent 3-08, Zwittergent 3-0, Zwittergent 3-2, Zwittergent 3-4, Zwittergent 3-6, CHAPS, sodium deoxychloate, sodium dodecyl sulfate, cetyltrimethylammonium bromide).
Optionally, the combined immunogenic composition described also contains an adjuvant, which adjuvant may also be used with the vaccine schemes, methods, uses and kit described. When the combined immunogenic composition is to be administered to a subject in a particular age group susceptible (or at increased risk) to RSV and / or B. pertussis infection, the adjuvant is selected for its safety and efficacy in the subject or population of subjects. Therefore, to formulate a combined immunogenic composition for administration to an elderly subject (such as a subject over 65 years of age), the adjuvant is selected for its safety and efficacy in the elderly. Similarly, when the combined immunogenic composition is to be administered to neonatal subjects or infants (such as subjects from birth to two years), the adjuvant is selected for its safety and efficacy in the new and the infant. In the case of an adjuvant selected for its safety and efficacy in the newborn and infant, a dose of adjuvant that is a dilution (eg, dose representing a fraction) of the dose typically administered to an adult subject may be to be chosen.
In addition, the adjuvant is typically selected to enhance the desired appearance of the immune response when administered by a route of administration, whereby the combined immunogenic composition is administered. For example, to formulate a combined immunogenic composition for nasal administration, the proteosome and protolline are beneficial adjuvants. In contrast, when the combined immunogenic composition is formulated for intramuscular administration, adjuvants comprising one or more of the following: 3D-MPL, squalene (e.g., QS21), liposomes, and / or oil and water emulsions are advantageously selected.
A suitable adjuvant that can be used in combination with RSV F-like type antigens is a nontoxic bacterial lipopolysaccharide derivative. An example of a suitable nontoxic derivative of lipid A is monophosphorylated lipid A or more particularly 3-deacylated monophosphoryl lipid A (3D-MPL). 3D-MPL is marketed as MPL by GlaxoSmithKline Biologicals N.A., and is referred to herein as MPL or 3D-MPL. See, for example, US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094. 3D-MPL primarily promotes CD4 + T cell responses having an IFN-γ (Th1) phenotype. It can be produced according to the methods described in GB2220211 A. Chemically it is a mixture of monophosphoryl lipid A 3 deacylated with 3, 4, 5 or 6 acylated chains. In the compositions according to the present disclosure, a small particle 3D-MPL may be used. The small particle 3D-MPL has a particle size such that it can be sterilized by 0.22 μg membrane filtration. These preparations are described in WO94 / 21292.
A lipopolysaccharide, such as 3D-MPL, can be used in amounts between 1 and 50 μg, per human dose of the immunogenic composition. This 3D-MPL can be used at a level of about 25 μg, for example between 20-30 μg, suitably between 21-29 μg or between 22 and 28 μg or between 23 and 27 μg or between 24 and 26 μg, or 25 pg. In another embodiment, the human dose of the immunogenic composition comprises 3D-MPL at about 10 μg, for example between 5-15 μg, suitably between 6-14 μg, for example between 7 and 13 μg. pg or between 8 and 12 pg or between 9 and 11 pg, or 10 pg. In another embodiment, the human dose of the immunogenic composition comprises 3D-MPL at about 5 μg, for example between 1-9 μg, or between 2-8 μg or conveniently between 3-7 μg. or 4-5 μg, or 5 μg.
In other embodiments, the lipopolysaccharide may be a disaccharide of β (1-6) -glucosamine, as described in US Patent No. 6,005,099 and EP Patent No. 0,729,473 B1. profession will easily produce various lipopolysaccharides, such as 3D-MPL, based on the teachings of these references. However, each of these references is incorporated herein by reference. In addition to the aforementioned immunostimulants (which have a structure similar to that of LPS or MPL or 3D-MPL), the acylated monosaccharide and disaccharide derivatives which represent a sub-part of the above structure of MPL are also suitable adjuvants. In other embodiments, the adjuvant is a synthetic derivative of lipid A, some of which are described as TLR-4 agonists, and include, but are not limited to: OM174 (2-deoxy-6-o- [2 2-deoxy-[(R) -3-dodecanoyl-oxytetadecanoylamino] -4-o-phosphon.opD-glucopyranosyl] -2 - [(R) -3-hydroxytetradecanoyl-amino] -α-D-glucopyranosyldihydrogenphosphate), (WO 95 / 14026); OM 294 (3S, 9R) -3 - [(R) -Dodecanoyloxytetradecanoylamino] -4-oxo-5-aza-9 (R) - [(R) -3-hydroxytetradecanoylamino] decan-1,10-diol, 1 10-bis (dihydrogenphosphate) (WO 99/64301 and WO 00/0462); and OM 197 MP-Ac DP (3S, 9R) -3 - [(R) -Dodecanoyl-oxytetadecanoyl-amino] -4-oxo-5-aza-9 - [(R) -3-hydroxytetradecanoyl-amino] decanon 1,10-diol, 1-dihydrogenphosphate 10- (6-aminohexanoate) (WO 01/46127). Other TLR4 ligands that can be used are the glucosaminide alkylphosphates (AGP) such as those described in WO 98/50399 or US Pat. No. 6,303,347 (processes for the preparation of AGPs are also described), such as Suitable RC527 or RC529 or the pharmaceutically acceptable salts of AGP as described in US Pat. No. 6,764,840. Some AGPs are TLR4 agonists, and others antagonists. Both should be useful as adjuvants. Other suitable TLR-4 ligands capable of eliciting a signaling response via TLR-4s (Sabroe et al., JI 2003 pl630-5) are, for example, lipopolysaccharide from Gram-negative bacteria and its derivatives, or fragments, in particular a non-toxic derivative of LPS (such as 3D-MPL). Other suitable TLR agonists are: heat shock protein (HSP) 10, 60, 65, 70, 75 or 90; Surfactant Protein A, hyaluronan oligosaccharides, heparan sulfate fragments, fibronectin fragments, fibrinogen peptides and b-defensin-2, and muramyl dipeptide (MDP). In one embodiment, the TLR agonist is HSP 60, 70 or 90. Other suitable TLR-4 ligands are those described in WO 2003/011223 and in WO 2003/099195, such as compound I, the compound II and the compound III described on pages 4-5 of WO2003 / 011223 or on pages 3-4 of WO2003 / 099195 and in particular the compounds described in WO2003 / 011223 such as ER803022, ER803058, ER803732, ER804053, ER804057, ER804058, ER804059, ER804442, ER804680, and ER804764. For example, a suitable TLR-4 ligand is ER804057. Other TLR agonists are also useful as adjuvants. The term "TLR agonist" refers to an agent that is capable of eliciting a signaling response through the TLR signaling pathway, either as a direct ligand or indirectly by generation of endogenous or exogenous ligands. . These natural or synthetic TLR agonists may be used as alternative or additional adjuvants. A brief review of the role of TLRs as adjuvant receptors is provided in Kaisho & Akira, Biochimica and Biophysica Acta 1589: 1-13, 2002. These potential adjuvants include, but are not limited to, TLR2, TLR3, TLR7, TLR8 and TLR9 agonists. Therefore, in one embodiment, the adjuvant and the combined immunogenic composition further comprise an adjuvant that is selected from the group consisting of: a TLR-1 agonist, a TLR-2 agonist, a TLR-agonist, and 3, a TLR-4 agonist, a TLR-5 agonist, a TLR-6 agonist, a TLR-7 agonist, a TLR-8 agonist, a TLR-9 agonist, or a combination thereof. this.
In one embodiment of the present invention, a TLR agonist that is capable of eliciting a signaling response through TLR-1 is used. Suitably, the TLR agonist capable of eliciting a TLR-1 signaling response is selected from: tri-acylated lipopeptides (LPs); phenol soluble modulin; LP of Mycobacterium tuberculosis; LP S- (2,3-bis (palmitoyloxy) - (2-RS) -propyl) -N-palmitoyl- (R) -Cys- (S) -Ser- (S) -Lys (4) -OH, trihydrochloride (Pam3Cys) which mimics the acetylated amino terminus of a bacterial lipoprotein and LP OspA from Borrelia burgdorferi.
In another embodiment, a TLR agonist that is capable of eliciting a signaling response through TLR-2 is used. Suitably, the TLR agonist capable of eliciting a TLR-2 signaling response is one or more of the following: a lipoprotein, a peptidoglycan, a bacterial lipopeptide derived from M. tuberculosis, B burgdorferi or T pallidum; peptidoglycans from species comprising Staphylococcus aureus; lipoteichoic acids, mannuronic acids, Neisseria porins, bacterial fimbriae, Yersinia virulence factors, CMV virions, measles haemagglutinin, and zymosan from yeast.
In another embodiment, a TLR agonist that is capable of eliciting a signaling response through TLR-3s is used. Suitably, the TLR agonist capable of eliciting a TLR-3 signaling response is double-stranded RNA (dsRNA), or polyinosinic-polycytidylic acid (Poly IC), a d molecular nucleic acid associated with the viral infection.
In another embodiment, a TLR agonist that is capable of eliciting a response of. Signaling type via TLR-5 is used. Suitably, the TLR agonist capable of eliciting a signaling response via TLR-5 is bacterial flagellin.
In another embodiment, a TLR agonist that is capable of eliciting a signaling response through TLR-6 is used. Suitably, the TLR agonist capable of eliciting a signaling response through TLR-6 is mycobacterial lipoprotein, di-acylated LP, and phenol-soluble modulin. Other TLR6 agonists are described in WO 2003/043572.
In another embodiment, a TLR agonist that is capable of eliciting a signaling response through TLR-7 is used. Suitably, the TLR agonist capable of eliciting a TLR-7 signaling response is a single-stranded RNA (ssRNA), loxoribine, a guanosine analog at positions N7 and C8, or a compound or derivative of imidazoquinoline. In one embodiment, the TLR agonist is imiquimod. Other TLR7 agonists are described in WO 2002/085905.
In another embodiment, a TLR agonist that is capable of eliciting a signaling response through TLR-8s is used. Suitably, the TLR agonist capable of eliciting a signaling response through TLR-8 is a single-stranded RNA (ssRNA), an imidazoquinoline molecule having antiviral activity, for example resiquimod ( R848); the resimimod can also be recognized by TLR-7. Other agonists. TLR8 that can be used include those described in WO 2004/071459.
In another embodiment, a TLR agonist that is capable of eliciting a signaling response through TLR-9 is used. In one embodiment, the TLR agonist capable of provoking a signaling response via TLR-9 is HSP90. Alternatively, the TLR agonist capable of eliciting a signaling response through TLR-9 is bacterial or viral DNA, DNA containing unmethylated CpG nucleotides, particularly sequence contexts known as than CpG patterns. Oligonucleotides containing CpG predominantly induce a Th1 response. These oligonucleotides are known and described, for example, in WO 96/02555, WO 99/33488 and U.S. 6,008,200 and 5,856,462. Suitably, these CpG nucleotides are CpG oligonucleotides. Suitable oligonucleotides for use in the combined immunogenic composition are CpG-containing oligonucleotides, which optionally comprise two or more CpG dinucleotide units separated by at least three, suitably at least six or more nucleotides. A CpG motif is a cytosine nucleotide followed by a guanine nucleotide. CpG oligonucleotides are typically deoxynucleotides. In a specific embodiment, the internucleotide in the oligonucleotide is a phosphoro-dithioate, or suitably a phosphorothioate linkage, although a phosphodiester and other internucleotide linkages are possible. Oligonucleotides with mixed internucleotide linkages are also possible. Methods of producing phosphorothioate or phosphorodithioate oligonucleotides are described in US Pat. 5,666,153, 5,278,302 and WO 95/26204. Other adjuvants which may be used in the described combined immunogenic composition, and with the described vaccine schemes, methods, uses and kits comprising an F protein analog, such as an analogue
PreF, e.g., alone or in combination with 3D-MPL, or other adjuvant herein, are saponins, such as QS21. These adjuvants are typically not used (but could be so desired) with a B. pertussis antigen.
Saponins are described in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins, Phytomedicine vol 2 pp. 363-386). Saponins are steroidal or triterpenic glycosides widely distributed in the vegetable kingdom and that of marine animals. Saponins are known to form colloidal solutions in water that foam after shaking, and to precipitate cholesterol. When saponins are close to cell membranes, they create porogenic structures in the membrane that cause them to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of some, but not all, saponins.
Saponins are known as adjuvants in vaccines for systemic administration. The adjuvant and hemolytic activity of individual saponins has been studied extensively in the art (Lacaille-Dubois and Wagner, supra). For example, Quil A (derived from the bark of the South American Quillaja Saponaria Molina tree), and fractions thereof, are described in US Pat. No. 5,057,540 and "Saponins as vaccine adjuvants", Kensil, CR, Crit Rev. Ther Drug Carrier Syst, 1996, 12 (1-2): 1-55; and EP 0 362 279 B1. Particle structures, termed immune stimulating complexes (ISCOM), comprising Quil A moieties are hemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 B1, WO 96 / 11711; WO 96/33739). The hemolytic saponins QS21 and · QS17 (HPLC purified Quil A fractions) have been described as potent systemic adjuvants, and their production method is described in US Patent No. 5,057,540 and EP 0 362 279 B1, which are incorporated herein by reference. incorporated herein by reference. Other saponins that have been used in systemic vaccination studies include those derived from other plant species such as Gypsophila and Saponaria (Bomford et al., Vaccine, 10 (9): 572-577, 1992). QS21 is a nontoxic fraction purified by Hplc derived from Quillaja Saponaria Molina bark. A process for producing QS21 is described in US Patent No. 5,057,540. Non-reactogenic adjuvant formulations containing QS21 are described in WO 96/33739. The aforementioned references are incorporated herein by reference. Immunologically active saponin, such as QS21, can be used in amounts between 1 and 50 μg, per human dose of the combined immunogenic composition. Advantageously, QS21 is used at a level of about 25 μg, for example between 20-30 μg, suitably between 21-29 μg or between 22-28 μg or between 23-27 μg or between 24-26 μg, or 25 pg. In another embodiment, the human dose of the combined immunogenic composition comprises QS21 at a level of about 10 μg, for example between 5-15 μg, suitably between 6-14 μg, for example between 7-13 μg or between 8-12 pg or between 9-11 pg, or 10 pg. In another embodiment, the human dose of the combined immunogenic composition comprises QS21 at about 5 μg, for example between 1-9 μg, or between 2-8 μg, or suitably between 3-7 μg or 4 μg. -6 μg, or 5 μg. Formulations comprising QS21 and cholesterol have been shown to be effective adjuvants when formulated with an antigen. Thus, for example, the RSV F protein analog polypeptides may be advantageously used in the combined immunogenic composition with an adjuvant comprising a combination of QS21 and cholesterol.
Optionally, the adjuvant may also include an inorganic salt such as aluminum salt, particularly aluminum hydroxide or aluminum phosphate, or calcium phosphate. For example, an adjuvant containing 3D-MPL in combination with an aluminum salt (eg, aluminum hydroxide or "alum") is suitable for formulation into a combined immunogenic composition containing an antigen of the VRS for administration to a human subject. Alternatively, these inorganic salt adjuvants may be used otherwise than in combination with adjuvants without an inorganic salt, ie the combined immunogenic composition may be adjuvanted only with one or more inorganic salt adjuvants such as aluminum hydroxide, aluminum phosphate and calcium phosphate.
Another class of suitable adjuvants which can be used with RSV F-like type antigens (and optionally, with pertussis antigens, such as purified acellular proteins of B. pertussis) is that of immunostimulatory compositions based on OMP. OMP immunostimulatory compositions are particularly suitable for mucosal adjuvants, e.g., for intranasal administration. OMP-based immunostimulatory compositions are a kind of outer membrane protein preparations (OMP, including certain porins) derived from Gram-negative bacteria, such as, but not limited to, Neisseria species (see, eg, Lowell et al., J. Exp Med 167: 658, 1988, Lowell et al., Science 240: 800, 1988, Lynch et al., Biophys J. 45: 104, 1984, Lowell, in "New Generation Vaccines "2nd ed., Marcel Dekker, Inc., New York, Basil, Hong
Kong, page 193, 1997; U.S. Patent No. 5,726,292; U.S. Patent No. 4,707,543), which is useful as a carrier or in immunogenic compositions, such as bacterial or viral antigens. Some OMP immunostimulatory compositions which are hydrophobic and safe for use in humans may be referred to as "proteosomes". Proteosomes have the ability to self-assemble into vesicular clusters or OMP of vesicular type from about 20 to about 800 nm, and to incorporate, coordinate, associate non-covalently (eg , electrostatically or hydrophobically), or otherwise cooperate with protein antigens (Ag), in particular antigens comprising a hydrophobic moiety. Any method of preparation which provides an outer membrane protein component in vesicular or vesicular form, comprising multi-molecular membranous structures or melt globular OMP compositions consisting of one or more OMPs, included in the definition of proteosome. Proteosomes can be prepared, for example, as described in the art (see, e.g., U.S. Patent No. 5,726,292 or U.S. Patent No. 5,985,284). The proteosomes may also contain an endogenous lipopolysaccharide or lipooligosaccharide (LPS or LOS, respectively) from the bacteria used to produce OMP porins (e.g., Neisseria species), which will generally represent less than 2% of the total OMP preparation.
Proteosomes are mainly composed of outer membrane proteins (OMPs) chemically extracted from Neisseria. menigitidis (mainly porins A and B as well as class 4 OMPs), maintained in detergent solution (Lowell GH, Proteosomes for Improved Nasal, Oral, Injectable Vaccines In: MM Levine, Woodrow GC, Kaper JB,
Cobon GS, eds, New Generation Vaccines. New York: Marcel Dekker, Inc. 1997; 193-206). The proteosomes can be formulated with various antigens such as purified or recombinant proteins derived from viral sources, including the RSV F protein polypeptides described herein, eg, by diafiltration or by conventional dialysis methods or with antigenic proteins. purified B. pertussis. The progressive removal of the detergent allows the formation of particulate hydrophobic complexes of about 100-200 nm in diameter (Lowell GH Proteosomes for Improved Nasal, Oral, Injectable Vaccines In: MM Levine, Woodrow GC, Kapér JB, Cobon GS , eds, New Generation Vaccines, New York: Marcel Dekker, Inc. 1997; 193-206). "Proteosome: LPS or Protolline" herein refers to mixed proteosomal preparations, e.g., by exogenous addition, with at least one type of lipopolysaccharide to provide OMP-LPS composition (which may serve as an immunostimulatory composition). Therefore, the OMP-LPS composition may consist of two of the basic components of protollin, which comprise (1) a proteosome preparation (eg, Projuvant) based on outer membrane proteins obtained from Gram-negative bacteria, such as Neisseria meningitidis, and (2) a preparation of one or more liposaccharides. The lipo-oligosaccharide may be endogenous (eg, naturally occurring in the preparation of OMP type proteosomes), it may be mixed with or combined with an OMP preparation in the form of an exogenously prepared lipo-oligosaccharide ( eg, prepared from a different culture or microorganism than that used for OMP preparation), or a combination of both. Exogenously added LPS may be from the same Gram-negative bacterium as that used to obtain OMP or a different gram-negative bacterium. It will also be understood that protollin may optionally include lipids, glycolipids, glycoproteins, small molecules, or the like, and combinations thereof. The protolline can be prepared, for example, as described in U.S. Patent Application Publication No. 2003/0044425.
Combinations of different adjuvants, such as those mentioned above, can also be used in compositions containing F-protein analogs such as PreF analogs (and optionally containing B. pertussis antigens also, if desired). For example, as already indicated, QS21 can be formulated with 3D-MPL. The QS21: 3D-MPL ratio will typically be in the range of 1:10 to 10: 1; such as 1: 5 to 5: 1, and often substantially 1: 1. Typically, the 3D-MPL: QS21 ratio is in the range of 2.5: 1 to 1: 1. Another formulation based on a combination of adjuvants includes 3D-MPL and an aluminum salt, such as aluminum hydroxide.
In some cases, the formulation of the adjuvant comprises an inorganic salt, such as an aluminum salt (alum), for example. an aluminum phosphate or an aluminum hydroxide, or a calcium phosphate. When alum is present, eg, in combination with 3D-MPL, its amount is typically between about 100 цд and 1 mg, such as about 100 цд, or about 200 цд at about 750 цд, as about 500 tons per dose.
In some embodiments, the adjuvant comprises an oil and water emulsion, e.g., an oil-in-water emulsion. An example of an oil-in-water emulsion includes a metabolizable oil, such as squalene, a tocol such as a tocopherol, eg, alpha-tocopherol, and a surfactant, such as sorbitan trioleate (Span 85 ™ ) or the monooleate. of polyoxyethylene sorbitan (Tween 80 ™) in an aqueous vehicle. In some embodiments, the oil-in-water emulsion does not contain any additional immunostimulant, (in particular it does not contain a non-toxic lipid A derivative, such as 3D-MPL, or saponin, such as QS21). The aqueous vehicle may be, for example, phosphate buffered saline. In addition, the oil-in-water emulsion may contain Span 85 and / or lecithin and / or tricapryline.
In another embodiment, the combined immunogenic composition comprises an oil-in-water emulsion and optionally one or more other immunostimulants, said oil-in-water emulsion comprising 0.5-10 mg of metabolizable oil (suitably, squalene), 0.5-11 mg of tocol (conveniently a tocopherol, such as alpha-tocopherol) and 0.4-4 mg of emulsifier.
In a specific embodiment, the adjuvant formulation comprises 3D-MPL prepared in the form of an emulsion, such as an oil-in-water emulsion. In some cases, the emulsion has a small particle size of less than 0.2 μιη in diameter, as described in WO 94/21292. For example, the 3D-MPL particles are small enough to be sterilized by filtration on a 0.22 micron membrane (as described in European Patent No. 0 689 454). Alternatively, 3D-MPL can be prepared in a liposomal formulation. Optionally, the adjuvant containing 3D-MPL (or a derivative thereof) also contains an additional immunostimulatory component. The adjuvant is chosen for its safety and effectiveness in the. population. to which the immunogenic composition is to be administered. For adult and elderly populations, the formulations typically comprise more adjuvant than in a typical infant formulation. In particular formulations using an oil-in-water emulsion, this emulsion may comprise additional components such as, for example, cholesterol, squalene, alpha-tocopherol, and / or detergent, such as Tween 80 or Span85. In exemplary formulations, these components may be present in the following amounts: about 1-50 mg cholesterol, 2-10% squalene, 2-10% alpha-tocopherol and 0.3-3% Tween 80. Typically, the ratio squalene: alpha-tocopherol is equal to or less than 1 to obtain a more stable emulsion. In some cases, the formulation may also contain a stabilizer.
When a combined immunogenic composition containing a RSV F protein polypeptide antigen is formulated for administration to an infant, the dosage of the adjuvant is determined to be effective and relatively non-reactogenic in an infant subject. Generally, the adjuvant dosage in an infant formulation is lower (e.g., the dose may be a fraction of that present in a formulation for administration to adults) than that used in formulations designed to be administered to infants. adults (eg, adults 65 years of age or older). For example, the amount of 3D-MPL is typically in the range of 1-200 цд, for example 10-100 цд, or 10-50 цд per dose. An infant dose is typically at the low end of this range, e.g., about 1 to about 50 hours, such as about 2 hours, or about 5 hours, or about 10 hours, about 25 hours, or about 50 hours. Typically, when QS21 is used in the formulation, the ranges are comparable (and consistent with the ratios shown above). In the case of an oil-and-water emulsion (e.g., an oil-in-water emulsion), the adjuvant dose administered to a child or infant may be a fraction of that administered to an adult subject. A demonstration of the efficacy of immunogenic compositions containing a PreF antigen in combination at various doses of an exemplary adjuvant in the form of an oil-in-water emulsion is disclosed in WO2010 / 149745.
In the compositions (comprising the described combined immunogenic composition) containing an RSV F-protein analogue and a B. pertussis antigen for maternal immunization, the composition is designed to induce a disease. strong neutralizing antibody response. Mothers have already been exposed to RSV and B. pertussis and will therefore produce an existing primary response, so that the purpose of providing protection to the future infant is to stimulate this primary response as effectively as possible and by respecting the sub- classes of antibodies such as IgGi that are able to cross the placenta at high efficiency and provide protection to the infant. Protection can be obtained without including adjuvant, or including an adjuvant that includes only inorganic salts, particularly aluminum hydroxide (alum), aluminum phosphate, or calcium phosphate. Alternatively, it can be obtained by a formulation containing an adjuvant in the form of an oil and water emulsion, or other adjuvant that enhances the production of antibodies of the IgG1 subclass. Therefore, the F protein analog for maternal immunization is advantageously formulated with an inorganic salt, advantageously alum, or with an adjuvant in the form of an oil and water emulsion.
In this context, the adjuvant is chosen for its safety and good tolerance in pregnant women. Optionally, the immunogenic compositions also comprise an adjuvant other than alum. For example, adjuvants comprising one or more 3D-MPL and / or squalene (eg, QS21) and / or liposomes, and / or oil and water emulsions are advantageously selected, provided that the final formulation improves the woman sensitized the production of antibodies specific for RSV and / or B. pertussis having the desired characteristics (eg, in terms of subclass and neutralization function).
It should be noted that regardless of the adjuvant chosen, its concentration in the final formulation is calculated for its safety and efficacy in the target population. For example, in the context of maternal immunization, regardless of the adjuvant chosen, its concentration in the final formulation is calculated to be safe and effective in the target population of pregnant women.
An immunogenic composition as hereinbefore described (ie combined), or for use in the vaccine schedules, methods, uses and kits described, typically contains an immunoprotective amount (or a dose corresponding to a fraction thereof) ) antigen and can be prepared by conventional techniques. In the case of maternal immunization, the amount required is that which allows the passive transfer of antibodies to be immunoprotective in infants of immunized pregnant women. The preparation of immunogenic compositions, including that for administration to human subjects, is generally described in Pharmaceutical Biotechnology, Vol.61 Vaccine Design-the Subunit and Adjuvant Approach, edited by Powell and Newman, Plenurri Press, 1995; New Trends and Developments in Vaccines, edited by Voiler et al., University Park Press, Baltimore, Maryland, U.S.A. 1978. Encapsulation in liposomes is described, for example, by Fullerton, U.S. The conjugation of proteins to macromolecules is described, for example, by Likhite, U.S. Patent 4,372,945 and Armor et al., U.S. 4,474,757.
Typically, the amount of antigen (e.g. protein) in each dose of the immunogenic composition is selected as an amount that induces an immunoprotective response without harmful side effects, significant in the typical subject. "Immunoprotective" in this context does not necessarily mean complete protection against infection; but protection against symptoms or disease, including serious disease associated with pathogens. The amount of antigen may vary depending on the specific immunogen that is used. Generally, each human dose should comprise 1-1000 t of each protein or antigen, such as, for example, about 1 to about 100 TDC, for example, about 1 to about 50, such as about 1 TDC, about 2 TDC, about 5 pg, about 10 цд, about 15 цд, about 20 цд, about 25 цд, about 30 цд, about 40 цд, or about 50 цд, or about 60 цд. Generally, a human dose will be in a volume of 0.5 ml. Thus the composition for the uses and methods described herein may for example be 10 or 30 or 60 tons in a human dose of 0.5 ml. The amount used in an immunogenic composition is chosen according to the target population (e.g., infant or elderly person or pregnant woman). The optimum amount for a particular composition may be determined by standard studies involving observation of antibody titers and other responses in the subject. After an initial vaccination, subjects may be recalled within 4-12 weeks (or, for maternal immunization, at any time before delivery, at least two or at least four weeks before scheduled for delivery). For example, for administration of an immunogenic composition to an infant, initial and subsequent inoculations may be practiced to coincide with other vaccines administered during this period.
Additional details of the formulations are provided in WO2010 / 149745, which is hereby incorporated by reference for its description of additional details relating to the formulation of immunogenic compositions comprising RSV F-like analogs such as PreF analogs.
In some embodiments, the disclosed combined immunogenic compositions further comprise at least one antigen from at least one pathogenic organism other than RSV and B. pertussis. More particularly, said at least one antigen may be selected from the group consisting of: diphtheria toxoid (D); tetanus toxoid (T); hepatitis B surface antigen (HBsAg); inactivated polio virus (IPV); capsular saccharide of H. influenzae type b (Hib) conjugated to a carrier protein; capsular saccharide of N. meningitidis type C conjugated to a carrier protein (MenC); capsular saccharide of N. meningitidis type Y conjugated to a carrier protein (MenY); capsular saccharide of N. meningitidis type A conjugated to a carrier protein (MenA); capsular saccharide of N. meningitidis type W conjugated to a carrier protein (MenW); and an antigen from N. meningitidis type B (MenB).
Combination vaccines containing B. pertussis antigens (Pa or Pw) with D and T and various combinations of other antigens selected from IPV, HBsAg, Hib and N. meningitidis conjugated capsular saccharides are known in the art, for example under the brand names Infanrix ™ (DTPa-IPV-HBsAg-Hib) and Boostrix ™ (dTpa). In this regard, WO93 / 024148, WO97 / 000697 and WO98 / 019702, are hereby incorporated by reference, as is W002 / 00249 which discloses a DTPw-HepB-MenAC-Hib composition. Suitable carrier proteins for capsular saccharide antigens are known in the art, and include T, D, and the CRM197 D derivative.
Particular combined immunogenic compositions include, in addition to at least one RSV antigen and at least one B. pertussis antigen: D and T; D, T and IPV; D, T and HBsAg; D, T and Hib; D, T, IPV and HBsAg; D, T, IPV and Hib; D, T, HBsAg and Hib; or D, T, IPV, HBsAg and Hib.
In a particular embodiment, D is used in an amount per dose of 1-10 International Units (IU) (for example exactly or approximately 2 IU) or 10-40 IU (for example exactly or approximately 20 or 30 IU) or of 1-10 Flocculation Limit Units (Lf) (e.g., exactly or approximately 2 or 2.5 or 9 Lf) or 10-30 Lf (e.g., exactly or approximately 15 or 25 Lf).
In a particular embodiment, T is used in an amount per dose of 10-30 IU (e.g. exactly or approximately 20 IU) or 30-50 IU (e.g. exactly or approximately 40 IU) or 1-15 LF ( for example exactly or approximately 5 or 10 Lf).
In exemplary embodiments, the combined immunogenic compositions comprise, in addition to the at least one RSV antigen and the at least one B. pertussis antigen, D and T in exact or approximate amounts per dose of: 30:40 IU, respectively; 25:10 Lf; 20:40 UI; 15: 5Lf; 2:20 IU; 2.5: 5 Lf; 2: 5 Lf; 25:10 Lf; 9: 5 Lf. For example, this composition may comprise (in addition to said at least one RSV antigen): (i) 20-30 μg, for example exactly or approximately 25 μg PT; (ii) 20-30 μg, for example exactly or approximately 25 μg of FHA; (iii) 1-10 μg, for example exactly or approximately 3 or 8 μg of PRN; (iv) 10-30 Lf, e.g. exactly or approximately 15 or 25 Lf of D; and (v) 1-15 Lf, for example exactly or approximately 5 or 10 Lf of T. As another example, this composition may comprise (in addition to said at least one RSV antigen): (i) 2-10 μg for example exactly or approximately 2.5 or 8 μg of PT; (ii) 2-10 μg, for example exactly or approximately 5 or 8 μg of FHA; (iii) 0.5-4 μg, for example 2-3 μg as exactly or approximately 2.5 or 3 μg of PRN; (iv) 1-10 Lf, for example exactly or approximately 2 or 2.5 or 9 Lf of D; and (v) 1-15 Lf, for example exactly or approximately 5 or 10 Lf of T.
The immunogenic composition may further comprise additional antigens, such as another RSV antigen (eg, a G protein antigen as described in WO2010 / 149745) or a human metapneumovirus antigen (hMPV), or an antigen of the influenza, or an antigen from Streptococcus or Pneumococcus. WO2010 / 149743 describes examples of hMPV antigens that can be combined with RSV antigens, and is hereby incorporated by reference for its description of examples of hMPV antigens.
The embodiment of the maternal immunization described herein is carried out by a suitable route for administering an anti-RSV and B. pertussis vaccine, including intramuscular, intranasal, or cutaneous administration. Advantageously, the maternal immunization described herein is performed cutaneously, which means that the antigen is introduced into the dermis and / or epidermis of the skin (e.g., intradermal route). In a particular embodiment, a recombinant RSV antigen comprising an F protein analog such as a PreF antigen or a PostF antigen and / or a B. pertussis antigen comprising B. pertussis or B. pertussis acellular proteins. as whole germs is administered to a pregnant woman dermally or intradermally. In a particular embodiment, the immunogenic composition is formulated with an adjuvant described herein, for example a saponin such as QS21, with or without 3D-MPL, for dermal or intradermal administration. In another embodiment, the immunogenic composition is formulated with an inorganic salt such as aluminum hydroxide or the like. aluminum phosphate or calcium phosphate, with or without immunostimulant such as QS21 or 3D-MPL, for dermal or intradermal administration. B. pertussis antigen is typically formulated in combination with an aluminum salt and may optionally be administered cutaneously or intradermally. Optionally, the F protein analog and the B. pertussis antigen are co-formulated in a combined immunogenic composition as described herein, eg, in the presence of an inorganic salt such as aluminum hydroxide. or aluminum phosphate or calcium phosphate, with or without immunostimulant such as QS21 or 3D-MPL, for dermal or intradermal administration. Dermal administration comprising the intradermal route may require or permit a lower dose of antigen than other routes such as intramuscular administration. Therefore, a combined immunogenic composition for dermal or intradermal administration is described, said composition comprising at least one RSV antigen and at least one B. pertussis antigen at a low dose, eg less than the normal intramuscular dose, eg at 50% or less of the normal intramuscular dose, for example 50 μg or less, or 20 μg or less, or 10 μg or less or 5 μg or less per human dose of an F protein analogue, and for example, between 1-10 μg PT, between 1-10 μg FHA, and between 0.5-4 μg PRN (with or without additional antigenic component). Optionally, the immunogenic composition for dermal or intradermal administration also includes an adjuvant, e.g., an aluminum salt or QS21 or 3D-MPL or a combination thereof.
Devices for dermal delivery include short needle devices (having a needle of about 1 to about 2 mm in length) as described in US 4,886,499, US 5,190,521, US 5,328,483, US 5,527 288, US 4,270,537, US 5,015,235, US 5,141,496, US 5,417,662 and EP1092444. Cutaneous vaccines may also be administered by devices which limit the effective penetration distance of the needle into the skin, such as those described in WO99 / 34850, incorporated herein by reference, and their functional equivalents. Jet injectors that administer liquid vaccines into the dermis via a liquid jet injector or a needle that pierces the stratum corneum and produces a jet that reaches the dermis are also suitable. Jet injection devices are described for example in US 5,480,381, US 5,599,302, US 5,334,144, US 5,993,412, US 5,649,912, US 5,569,189, US 5,704,911, US 5,383 851, US 5,893,397, US 5,466,220, US 5,339,163, US 5,312,335, US 5,503,627, US 5,064,413, US 5,520,639, US 4,596,556, US 4,790,824, US 4,941. 880, US 4,940,460, WO 97/37705 and WO 97/13537.
Devices for dermal delivery also include ballistic-type devices for administering powder / particles that utilize compressed gas to accelerate the powdered vaccine through the outer layers of the skin to the dermis. In addition, ordinary syringes can be used according to the conventional Mantoux dermal method. However, the use of conventional syringes requires very competent operators and therefore devices capable of precise administration without an ultra-skilled user are preferred. Other devices for dermal administration include patches containing the immunogenic compositions described herein. A patch for cutaneous administration comprises a solid substrate substrate (e.g., occlusive or non-occlusive surgical dressing). These patches administer the immunogenic composition to the dermis or epidermis via microprojections that pierce the stratum corneum. These microprojections generally measure between 10 Dm and 2 mm, for example 20 to 500 Dm, 30 Dm to 1 mm, 100 to 200, 200 to 300, 300 to 400, 400 to 500, 500 to 600, 600 to 700, 700. , 800, 800 to 900, 100 Dm at 400 Dm, in particular between about 200 and 300 Dm or between about 150 and 250 Dm. Patches for cutaneous administration generally comprise a plurality of microprojections, for example between 2 and 5000 micro-needles, for example between 1000 and 2000 microneedles. The microprojections can be of any form suitable for piercing the stratum corneum, the epidermis and / or the dermis. The microprojections can be shaped as described in WO02 / 074765 and WO02 / 074766 for example. They can have an aspect ratio (height to diameter at the base) of at least 3: 1, at least about 2: 1, or at least about 1: 1. A suitable form for these microprojections is that of a cone with a polygonal base, for example hexagonal or rhombic. Other forms of possible microprojections are described, for example, in the published U.S. patent application. 2004/0087992. In a particular embodiment, the microprojections have a shape that thickens towards the base. The number of microprotrusions in the matrix is typically at least about 100, at least about 500, at least about 1000, at least about 1400, at least about 1600, or at least about 2000. The density of microprotuberances, given their small size, may not be high, but for example the number of microprotuberances per cm 2 may be at least about 50, at least about 250, at least about 500, at least about 750, at least about 1000, or at least about 1500. In one embodiment of the invention, the combined immunogenic composition is administered to the subject within 5 hours of placement. patch on the skin of the host, for example, within 4 hours, 3 hours, 2 hours, 1 hour or 30 minutes. In a particular embodiment, the combined immunogenic composition is administered within 20 minutes after placement of the patch on the skin, for example, within 30 seconds, 1, 2, 3, 4, 5, 6, 7, 8 , 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 minutes thereafter.
Microprojections may be based on any suitable material known to those skilled in the art. In a particular embodiment, at least a portion of the microprojections are biodegradable, in particular their tip or outermost layer. In a particular embodiment, substantially all microprojection is biodegradable. The term "biodegradable" as used herein means "degradable under the intended conditions of in vivo use" (e.g., insertion into the skin), regardless of the mechanism of biodegradation. Exemplary biodegradation mechanisms include disintegration, dispersion, dissolution, erosion, hydrolysis, and enzymatic degradation.
Examples of microprojections containing antigens are described in WO2008 / 130587 and WO2009 / 048607. Processes for manufacturing metabolizable micro-needles are described in WO2008 / 130587 and WO2010 / 124255. The microprojections can be coated with antigen by any method known to those skilled in the art, for example by the methods described in WO06 / 055844, WO06 / 055799.
Suitable administration devices for dermal administration comprising intradermal administration, in the methods and uses described herein include the BD Soluvia ™ device which is a micro-needle device for intradermal administration, Corium MicroCor ™ Patch System, the Georgia Tech Micro Needle Vaccine Patch, the Nanopass Micro Needle Delivery Device, and the Debiotech Nanoject ™ Micro Needle Device. A dermal or transdermal delivery device containing a combined immunogenic composition as described herein, optionally formulated with an adjuvant such as an inorganic salt eg alum, or QS21, or 3D-MPL or a combination of those it is also described.
With regard to the method described for eliciting an immune response against RSV and B. pertussis, comprising administering to a subject an immunologically effective amount of the combined immunogenic composition, the immune response elicited against RSV and B. pertussis. advantageously comprises a protective immune response which reduces or prevents the incidence, or reduces the severity of RSV and B. pertussis infection and / or reduces or prevents the incidence, or reduces the severity of a pathological response after a infection with RSV and B. pertussis. Said immune response may be a response to stimulation. In addition, the combined immunogenic composition achieves this without aggravating the viral disease after contact with RSV.
The combined immunogenic composition can be administered by a variety of pathways, some of which, such as the intranasal route, directly place the antigens in contact with the mucous membranes of the upper respiratory tract. Alternatively, more conventional routes of administration may be used, such as the intramuscular route of administration.
Therefore, the combined immunogenic composition is considered herein for use in medicine, and in particular for preventing or treating in a human subject an infection with RSV and B. pertussis, or a disease associated therewith. In some embodiments containing antigens from other pathogens, said prevention or said treatment will extend to said other pathogens.
In a particular embodiment of these methods and uses, the subject is a human subject. Said human subject may be chosen from the group comprising; a newborn ; A baby ; a kid ; a teenager; an adult ; and an elderly person. The subject may be a pregnant woman carrying a pregnant baby. Alternatively, the subject may not be a pregnant woman. When the subject is a neonate, administration of the combined immunogenic composition may be 1 day, 1 week, or 1 month after birth.
In a preferred embodiment, the subject (preferably, human) receives the combined immunogenic composition in a single dosage form, i.e. in the form of an independent dose that is not part of a predetermined series of doses. The dose may be administered at the same time as other vaccines, for example as part of an immunization schedule such as a pediatric immunization schedule. Although in this single-dose embodiment, the subject may receive more than one dose of the composition during his lifetime of subject, each of these doses is independent and "unique" in the sense that it is administered in the absence of any other planned dose deemed necessary to achieve the desired level of protection. In one embodiment, the combined immunogenic composition is administered to a subject in a one-dose pattern only once in a period of 10, advantageously 5 years. In one embodiment, the subject is a 10 to 18 year old adolescent and the combined immunogenic composition is administered to him only once, i.e. in a single dose pattern. In another embodiment, the subject is a pregnant woman and the combined immunogenic composition is administered to her only once per pregnancy, ie the pregnant woman receives only a single dose of the composition during pregnancy. .
MATERNAL IMMUNIZATION
A particular challenge in developing a safe and effective vaccine that protects infants from RSV and B. pertussis disease is that the highest incidence and morbidity and mortality is very young infant. Young infants, especially premature infants, may have an immature immune system. Protecting young infants from RSV and B. pertussis (pertussis) disease is therefore important. There is also a risk of interference between antibodies transferred via the placenta to the baby ("maternal antibodies") and infant vaccination, so that vaccination in very early childhood may not be sufficiently effective, eg, to elicit a fully protective neutralizing antibody response.
In one aspect, the present invention relates to vaccine schemes, methods and uses of immunogenic compositions and kits suitable for protecting young infants from RSV and B. pertussis-caused disease by active immunization of pregnant women with or effective immunogenic compositions comprising an RSV F protein analog and an acellular type B. pertussis antigen (s) or whole cells. The F protein analog advantageously elicits the production of antibodies (e.g., neutralizing antibodies) by stimulating or increasing the magnitude of the humoral response previously initiated by natural exposure to RSV (or previous vaccination against it). Similarly, B. pertussis antigen elicits antibody production by stimulating or increasing the magnitude of the humoral response previously initiated by natural exposure to B. pertussis, or previous vaccination against it. Antibodies produced in response to the F-protein analogue and B. pertussis antigen are transmitted to the pregnant baby via the placenta, resulting in the passive immunological protection of the infant after birth and during pregnancy. critical period for infection and severe disease caused by RSV and B. pertussis (eg, before infant vaccination is fully protective). Typically, the passive immunological protection conferred by this method lasts from birth to at least two months, for example up to about 6 months or more.
All of these compositions are designed to induce a strong antibody response (e.g., neutralizing antibodies). As pregnant mothers have typically been exposed to RSV one or more times in their lifetime, they have an existing primary RSV response. The proportion of the population exposed to RSV infection before adulthood is essentially 100%. Pediatric immunization programs designed to protect and prevent whooping cough are common. However, despite widespread immunization, natural infection with B. pertussis is also common. Thus, B. pertussis sensitization is also widespread. Protection against RSV and B. pertussis for the infant immediately after birth and for the next few crucial months can therefore be achieved by stimulating these primary responses as effectively as possible to increase serum antibody responses (levels). against RSV and B. pertussis in the mother, and advantageously by respecting the subclasses (subtypes) of particular antibodies such as IgG1 that can cross the placenta and provide protection to the baby. In one embodiment, the immunogenic compositions usable herein do not comprise an adjuvant, or include an adjuvant that promotes a strong IgGi response such as an inorganic salt such as an aluminum salt, particularly a hydroxylated hydroxide. aluminum, an aluminum phosphate, or calcium phosphate. Thus, in a particular embodiment, an immunogenic composition useful for maternal immunization is advantageously formulated with an inorganic salt, advantageously alum. In other embodiments, the adjuvant that promotes a strong IgG1 response is an oil-in-water emulsion, or a saponin, such as QS21 (or a detoxified form thereof).
A pregnant female may be a woman, and therefore the pregnant infant or baby may be human. For a pregnant woman, the gestational age of the fetus under development is measured from the first day of the last menstrual period. The number of weeks of pregnancy is measured as of 14 days after the first day of the last period. Therefore, when a pregnant woman is at 24 weeks of gestation, this will be 26 weeks after the first day of her last menstrual period, or 26 weeks of pregnancy. When a pregnancy has been achieved by a medically assisted procreation technique, the gestational age of the developing fetus is calculated as of two weeks from the date of conception.
The term "pregnant baby" as used herein refers to the developing fetus or fetus of a pregnant woman. The term "gestational age" is used to designate the number of weeks of gestation, i.e '. the number of weeks since the first day of the last period. Pregnancy in women is typically about 40 weeks from the first day of the last menstrual period, and can conveniently be divided into quarters, the first trimester extending from the first day of the last menstrual period to the 13th week of gestation; the second from the 14th to the 27th week of gestation, and the third starting at the 28th week and going until birth. The third trimester starts at the 26th week of pregnancy and continues until the baby is born.
The term "infant" as used herein ranges from 0 to 2 years. It will be understood that the protection afforded by the methods and uses described above can protect the young person as a child, between 2 and 11 years old, or even early in life, for example between 2 and 5 years old, or even in his adolescence, between 12 and 12 years of age. and 18 years old. However, it is during childhood, especially from birth to about 6 months, that an individual is most vulnerable to severe RSV infection and pertussis complications.
An infant may be immunologically immature during the first months of life, especially if born prematurely, eg, before 35 weeks of gestation, when the immune system may not be well developed enough to mount an immune response capable of prevent infection or disease caused by a pathogen the way an immune system developed in response to the same pathogen. An immunologically immature infant is more likely to succumb to infection and illness than an infant with a more developed or mature immune system. Infants may also be more vulnerable to IVRI (including pneumonia) during the first months of life for physiological and developmental reasons, for example, the airways are smaller and less developed than in children and adults. For these reasons, any reference in this application to the first six months of infancy may be extended to premature infants and preterm infants based on the amount of time lost in gestational age below 40 weeks or below 38 weeks or under 35 weeks.
In another embodiment, the pregnant woman and her infant or the full female and her cub are of any kind among those. described above under "subjects". For a full animal, such as a female guinea pig or a full cow, the "gestation" time is the time since mating. In women and in some animals, for example, the guinea pig, antibodies pass from the mother to the fetus via the placenta. Some isotypes of antibodies may preferentially be transferred across the placenta, for example, in women, with IgG1 antibodies being the most efficiently transferred isotype across the placenta. Although subclasses exist in laboratory animals, such as guinea pigs and mice, the various subclasses do not necessarily perform the same function, and a direct correlation between subclasses in women and the animal can not be easily established.
Advantageously, the protection of the infant by inhibition of infection and reduction of the incidence or severity of the disease caused by RSV and B. pertussis covers at least the neonatal period and very early childhood, by example at least the first weeks of life after birth, such as the first month after birth, or the first two months, or the first three months, or the first four months, or the first five months, or the first six months after birth, or more, eg, when the infant is a full-term infant at about 40 weeks of gestation or more. After the first few months, when the infant is less vulnerable to the effects of severe RSV infection and whooping cough, protection against RSV and B. pertussis infection may decline. Thus, vital protection is provided during the period when it is most needed. In the case of a premature infant, advantageously protection is provided over a longer period of time after birth, for example, an additional period of time equivalent to at least the period of time between birth and what would have been a 35-week gestation (ie, about 5 additional weeks), or a 38-week gestation (about 2 additional weeks), or longer depending on the gestational age of the baby at the time of birth.
It will be apparent that protecting the infant does not necessarily mean 100% protection against RSV or B. pertussis infection. As long as there is a reduction in the incidence or severity of the infection or disease, it will be assumed that protection is provided. Advantageously, infant protection includes its protection against serious illness and hospitalization caused by RSV and B. pertussis. As such, the compositions and methods described herein reduce the incidence or severity of RSV-related disease, such as lower respiratory tract infection (IVRI), pneumonia or other symptoms or illness, and by B. pertussis. For example, with respect to RSV, the administration of an immunogenic composition as described herein may reduce the incidence (in a cohort of infants whose mothers have been vaccinated) of IVRI of at least about 50%, or at least about 60%, or 60 to 70%, or at least about 70%, or at least about 80%, or at least about 90%, compared to infants whose mothers have not been vaccinated. Advantageously, this administration reduces the severity of the IVRI by at least about 50%, or at least about 60%, or 60 to 70%, or at least about 70%, or at least about 80%, or at least about 90%, compared to infected infants whose mothers have not been vaccinated. Advantageously, this administration reduces the need for hospitalization due to severe RSV-induced disease in this at least about cohort. 50%, or at least about 60%, or 60 to 70%, or at least about 70%, or at least about 80%, or at least about 90%, compared to infants infected women whose mothers have not been vaccinated. Whether hospitalization for severe IVRI is deemed necessary, or that a particular case of IVRI being hospitalized may vary from country to country, and therefore IVRI considered serious according to well-known definite clinical symptoms in the technique seems to be a better measure than the need for hospitalization. With respect to B. pertussis, administration of an immunogenic composition containing cell-free pertussis antigen or whole cells as described herein may reduce incidence (in a cohort of infants whose mothers were vaccinated ) serious diseases (eg, pneumonia and / or distress and respiratory failure) of at least about 50%, or at least about 60%, or 60 to 70%, or at least about 70%, or at least about 80%, or at least about 90%, compared to infants whose mothers have not been vaccinated. Advantageously, this administration reduces the severity of pneumonia by at least about 50%, or at least about 60%, or 60 to 70%, or at least about 70%, or at least about 80%, or at least about 90%, compared to infected infants whose mothers were not vaccinated. Advantageously, this administration reduces the need for hospitalization, because of serious complications of pertussis in this cohort of at least about 50%, or at least about 60%, or 60 to 70%, or at least about 70%, or at least about 80%, or at least about 90%, compared to infected infants whose mothers have not been vaccinated.
Typically, according to the vaccine schemes, the described methods, uses and kits, the protein F analogue and the B. pertussis antigen are administered to the pregnant woman during the third trimester of pregnancy (gestation), although that a beneficial effect (especially for pregnancies at increased risk of preterm birth) can be obtained before the beginning of the third trimester. The timing of maternal immunization is determined to allow the generation of maternal antibodies and their transfer to the fetus. Therefore, advantageously sufficient time elapses between immunization and birth to allow optimal transfer of maternal antibodies across the placenta. In women, antibody transfer usually starts at about 25 weeks of gestation, increasing to 28 weeks and becoming and remaining optimal from about 30 weeks of gestation. It is believed that a minimum of about two to four weeks is required between maternal immunization as described herein and at birth to allow effective transfer of maternal antibodies to RSV F protein and B antigens. pertussis (eg, comprising one or more antigens among pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin (PRN), type 2 fimbriae (FIM2), type 3 fimbriae (FIM3) and BrkA, or a pertussis antigen of whole cell type) to the fetus. Therefore, maternal immunization can be performed at any time after 25 weeks of gestation (measured from the first day of the last menstrual period), for example at or after 25, 26, 27, 28, 29, 30, 31, 32 , 33 or 34 weeks of gestation (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 weeks of pregnancy), or at or before 38, 37, 36, 35, 34, 33, 32, 31 or 30 weeks of pregnancy (36, 35, 34, 33, 32, 31, 29 or 28 weeks of pregnancy). Favorably, maternal immunization is carried out between 26 and 28 weeks, for example between 26 and 38 weeks, as between 28 and 34 weeks of gestation.
Advantageously, maternal immunization is performed at least two or three or at least four or at least five or at least six weeks before the expected date of delivery. The timing of administration may need to be adjusted in the case of a pregnant woman at risk of premature delivery, in order to have sufficient time for antibody generation and transfer to the fetus.
Advantageously, a single dose (or single doses) of the RSV F protein analogue and the antigen (s) or formulation thereof is administered to the pregnant woman during the period described. The above maternal immunization against RSV and B. pertussis may be considered as a "stimulation" of existing maternal immunity against RSV and B. pertussis which. increases the immune response against RSV and B. pertussis that has previously been primo-inoculated, e.g., by natural exposure or vaccination. Thus, a single dose should be required. Therefore, in a preferred embodiment of the schemes, methods and uses described herein, especially when the antigenic component of RSV (eg, recombinant protein, such as an F-protein analogue) and the antigenic component of B. pertussis. are co-formulated in a single immunogenic composition (ie combined), the RSV F-protein analogue and B. pertussis antigen are administered in a single-dose (or single-dose) regimen, respectively. In other words, during a pregnancy (pregnancy), the pregnant woman receives the F protein analogue and the B. pertussis antigens only once, which means that when they are co-formulated in a combined immunogenic composition said composition is administered only once during pregnancy. If a second dose is administered, it is also advantageously in the same period of time as the administration of the first, advantageously at a time interval between the first and the second dose of one to eight weeks. or two to six weeks, for example, two weeks or four weeks or six weeks. The administration of an F protein analogue and a B. pertussis antigen to a pregnant woman has the effect of stimulating maternal antibody titers, for example, to increase serum antibody titers (eg neutralizers), preferably from the IgG1 subclass. Increased maternal antibody titer causes passive transfer of RSV-specific and B. pertussis-specific antibodies with neutralizing effector function to gestating baby across the placenta by an Fc-receptor mediated transport mechanism , eg, in the syncytiotrophoblast of chorionic villi. Placental transport of RSV-specific IgGi and B. pertussis specific antibodies resulting from the immunization methods described herein should be effective and result in titers which, in near-term infants, are close to, or exceed the titles in the maternal circulation. For example, RSV-specific antibody titers are advantageously at levels of at least 30 μg / ml at birth. Typically, titers may be equal to or greater than, for example, 40 μg / mL, 50 μg / mL, 60 μg / mL or greater, such as 75 μg / mL, 80 μg / mL, 90 μg / mL, 100 μg / mL, or up to 120 pg / mL or more in healthy infants born at the end of pregnancy. These values may be on an individual basis or on a median population basis. Advantageously, the level of antibody observed at birth is above the indicated thresholds and persists for several months after birth.
Anti-pertussis antibody titers (eg, PT-) are typically measured by ELISA in terms of ELISA units / ml (US), as described, eg, in Meade et al., "Description and evaluation of serology assays used in multicenter trial of acellular pertussis vaccines, Pediatrics (1995) 96: 570-5, incorporated herein by reference. Briefly, for example, microtiter plates (e.g., Immulon 2, VWR International, West Chester, PA, USA) are coated with standard amounts of PT, FHA, FIM or PRN. Successive serum dilutions are incubated for about 2 hours at 28 ° C and an appropriate dilution of alkaline phosphatase-conjugated goat anti-human IgG is added. The reaction develops and the plate is read at 405 nm. The low detection limit of each specific antibody is determined by multiple measurements of a reference substance diluted sequentially for each antigen and is fixed at 1 ELISA unit (EU) for PT, FHA and PRN, and at 2 'EU for FIM. . Advantageously, after the administration of an immunogenic composition comprising a pertussis antigen according to the vaccine scheme, the method, the use or as contained in the kits described above, the anti-pertussis antibody titers are levels of at least 10 EU at birth. Typically, the titers may be equal to or greater than, for example, 20 EU, 30 EU, 40 EU, 50 EU, 60 EU, 70 EU, 80 EU, 90 EU or above 100 EU. These values may be on an individual basis or on a median population basis. Advantageously, the level of antibody observed at birth is above the indicated thresholds and persists for several months after birth.
The effector function, e.g., neutralizing capacity (neutralizing titer) of the transferred RSV antibodies can also be evaluated, and gives a measure of the functional attribute correlated to the protection. For example, in the case of RSV, a specific amount of a RSV virus capable of replication and a definite serum dilution are mixed and incubated. The virus-serum reaction mixture is then transferred to host cells (e.g., HEp-2 cells) permissive for viral replication and incubated under conditions and for a period of time sufficient for cell growth and viral replication. The unneutralized virus is capable of infection and replication in host cells. This leads to the formation of a given number of plaque forming units (PFU) on the cell monolayer that can be detected with a fluorochrome-labeled anti-RSV antibody. The neutralizing titer is determined by calculating the serum dilution that induces a specific level of inhibition (e.g., 50% inhibition or 60% inhibition) of the PFUs compared to a cell monolayer infected with the virus alone, without serum. For example, the Palivizumab antibody has been shown to have a neutralization titer (median effective concentration [EC50]) expressed as the antibody concentration required to reduce detection of RSV antigen by 50% compared to infected cells. by untreated virus - 0.65 μg per mL (mean 0.75 ± 0.53 μg per mL, n = 69, range 0.07-2.89 μg per mL) and 0.28 μg per mL (mean 0.35 ± 0.23 μg per mL, n = 35, range 0.03-0.88 μg / mL) against clinical RSV A and RSV isolates, respectively. Therefore, in some embodiments, the neutralizing titer of antibodies transferred via the placenta to the infant may be measured in the infant after birth and has (on a median population basis) an EC50 value of at least about 0.50 μg / mL (e.g., at least about 0.65 μg / mL), or higher for RSV strain A and EC50 value of at least about 0.3 μg / mL (e.g. at least about 0.35 μg / mL), or more for RSV strain B. Advantageously, the neutralizing antibody titer remains above the indicated threshold for several weeks to months after birth.
The toxin neutralizing effector function of pertussis anti-toxoid antibodies can also be measured, if desired, eg, in a Chinese hamster ovary (CHO) cell neutralization assay, for example as described in Gillenius et al., "The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells". J. Biol. Stand. (1985) 13: 61-66, incorporated herein by reference. However, the neutralizing activity in this assay is less well correlated with protection.
Optionally, according to vaccine schedules, methods, uses and kits described, to prolong protection against RSV and B. pertussis beyond the first months of life when passively transferred maternal antibodies provide protection, the infant may be actively immunized to elicit an adaptive immune response specific for RSV and / or B. pertussis. This active immunization of the infant may be practiced by administering one or more of a composition that contains RSV antigen and / or B. pertussis antigen. For example, the one or more compositions may comprise an F protein analog, optionally formulated with an adjuvant to enhance the immune response elicited by the antigen. For administration to an infant who has not previously been exposed to RSV, the protein F analog may be formulated with an adjuvant that elicits an immune response that is characterized by the production of T cells that exhibit a cytokine profile. Thl (or which is characterized by an equilibrium of T cells that exhibit Th1 and Th2 cytokine profiles). Similarly, the infant may be actively immunized with a pertussis vaccine (B. pertussis), which may optionally be administered as a combination vaccine which also provides protection against other pathogens.
Alternatively, rather than administering an RSV F protein analog or other protein subunit vaccine to the infant, the composition that elicits an adaptive immune response to protect against RSV may comprise a vaccine derived from a live attenuated virus. , or a nucleic acid that encodes one or more RSV antigens (such as a F protein antigen, a G antigen, an N antigen, or an M2 antigen, or fragments thereof). For example, the nucleic acid may be in a vector, such as a recombinant viral vector, for example, an adenoviral vector, an adeno-associated viral vector, an MVA vector, a mumps vector, or the like. Exemplary viral vectors are described in WO2012 / 089231, which is hereby incorporated by reference for its description of immunogenic compositions which contain a viral vector which encodes one or more RSV antigens. Alternatively, the nucleic acid may be a self-replicating nucleic acid, such as a self-replicating RNA, eg, in the form of a viral replicon, such as an alpha-viral replicon (eg, in the form of a viral replicon particle encapsulated with viral structural proteins). Examples of such self-replicating RNA replicons are described in WO2012 / 103361, which is incorporated herein for its description of RNA replicons that encode RSV proteins and their formulation as immunogenic compositions.
In addition or alternatively, one or more compositions containing a B. pertussis antigen may be administered to the infant. For example, the composition may comprise an acellular pertussis antigen selected from the group consisting of pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin (PRN), type 2 fimbriae (FIM2), fimbriae type 3 (FIM3) and BrkA, or a combination thereof (eg, PT and FHA; PT, FHA and PRN; or PT, FHA, PRN and FIM2 or FIM3, or both), eg where PT is chemically or genetically detoxified as described herein. Alternatively, the composition may comprise a whole cell pertussis antigen as described herein.
In the context of the vaccine schemes, methods and uses described herein, the antigenic component of RSV (eg, recombinant protein, such as an F-protein analogue) and the antigenic component of B. pertussis may be co- formulated in a single immunogenic (ie combined) composition, as described herein. Alternatively, the RSV antigenic component and the B. pertussis antigenic component are formulated in two or more different immunogenic compositions, which may be administered at the same time, or at different times, eg, according to the various schedules of Pediatric immunization approved and recommended, and may be presented in kits (as described herein).
When a composition that elicits an RSV responsive immune response and / or an adaptive immune response to B. pertussis is administered to an infant born to a mother who has been immunized against RSV and B. pertussis during pregnancy, as described in present, the composition can be administered one or more times. The first administration may occur on the day of birth, or soon after (e.g., the day or the day after birth), or in the week or approximately two weeks thereafter. Alternatively, the first administration may take place about 4 weeks, about six weeks, about 2 months, about 3 months, about 4 months after birth, or later, such as about 6 months, about 9 months, or about 12 months. after birth. For example, in the case of a composition containing a B. pertussis antigen (eg, Pa or Pw), it is common to administer the vaccine at approximately 2, 4 and 6 months after birth (followed by 12 -18 months and possibly between 4 and 7 years). Thus, in one embodiment, this disclosure relates to methods for protecting an infant from RSV and B. pertussis-mediated disease by administering one or more compositions that elicit a specific RSV immune response and / or B. pertussis in an infant born to a mother to whom one or more immunogenic compositions comprising an F protein analog and a B. pertussis antigen have been administered during pregnancy. Advantageously, the maternal anti-RSV and anti-B antibodies. pertussis do not mediate the inhibition or "blunting" of the infant immune response to these respective antigens in the infant-administered compositions.
As mentioned above, the immunogenic compositions for use in the vaccine schemes, the methods and uses described can be VRS-B compositions. combined pertussis (co-formulated) as described herein, or may be different compositions which separately provide an F protein analog and a B. pertussis antigen. These "separate" compositions can be provided in kits. They can be administered on the same day (co-administered) or on different days.
In the immunization schedules, methods and uses described, the infant may be immunologically immature. It may be less than six months, for example less than two months, for example less than one month, for example, being a newborn.
Said at least one immunogenic composition administered to the pregnant woman as part of the vaccine schemes, methods and uses described may, in one embodiment, be administered at 26 weeks of gestation or later, for example between 26 and 38 weeks of gestation, for example, between 28 and 34 weeks of gestation.
In one embodiment of the vaccine schemes, methods and uses described, said at least one subset of RSV-specific antibodies is detectable at a level of 30 μg / mL or more in infant serum at birth and / or at least a subset of anti-pertussis antibodies is detectable at a level of 10 ELISA units / ml (EU) or more in the infant serum at birth.
In some embodiments, such vaccine regimens, methods and uses further include administering to the infant at least one composition that initiates or induces an active immune response against RSV and / or B. pertussis. When an active immune response is initiated or induced against both RSV and B. pertussis, said at least one composition that initiates or induces an active immune response against RSV and said at least one composition that initiates or induces an active immune response against B The pertussis may be the same composition or alternatively they may be different. In the latter case, the different compositions can be administered on the same day or on different days. Advantageously, the active immune response initiated or induced in the infant by said at least one immunogenic composition is not quantitatively different, in the clinical sense of the term, from the active immune response generated in response to said one or more compositions in infants. born to mothers who had not been immunized during pregnancy according to the vaccination schedules, methods and uses described.
In embodiments of the vaccine schemes, methods and uses wherein at least one composition that initiates or induces an active immune response against RSV and / or B. pertussis in the infant is administered to the infant, said at least one administered composition the infant may comprise a nucleic acid, a recombinant viral vector or a viral replicon particle, said nucleic acid, recombinant viral vector or viral replicon particle encoding at least one RSV protein antigen or antigenic analogue. Said at least one composition may comprise a RSV antigen comprising an F protein analogue.
Kits comprising a plurality of immunogenic compositions formulated for administration to a pregnant woman are described, said kits comprising: (a) a first immunogenic composition comprising an F protein analog capable of inducing, stimulating or stimulating a humoral immune response specific for RSV; and (b) a second immunogenic composition comprising at least one B. pertussis antigen capable of inducing, eliciting or stimulating a specific humoral immune response of B. pertussis, the first and second immunogenic composition inducing, eliciting or stimulating after administering to a pregnant woman at least a subset of RSV-specific antibodies and at least a subset of antibodies specific for B. pertussis, said antibodies being transferred via the placenta to the pregnant baby of said pregnant woman, for protect it against infection or disease caused by RSV and B. pertussis. Preferably, the respective compositions of the kit are administered to the pregnant woman only once per pregnancy. In other words, during a pregnancy, the pregnant woman preferably receives a single dose of each of the compositions of the kit.
In this kit, the F protein analog of the first composition and / or said at least B. pertussis antigen of the second immunogenic composition may be as described herein, including in disclosures made in the context of the description of the disclosed combined immunogenic compositions. In one embodiment, the first immunogenic composition and / or the second immunogenic composition are in a pre-filled syringe. This syringe can be a syringe with two compartments.
The following examples are provided to illustrate particular features and / or embodiments. These examples are not to be construed as limiting the invention to the particular features or embodiments described.
EXAMPLES
In all the examples, the RSV (Pre-F) vaccine used comprises a modified glycosylation-type Pre-F antigen of the type corresponding to SEQ ID NO: 22, ie containing the modification L112Q and a modification of the amino acids corresponding to positions 500- 502 of SEQ ID NO: 2 selected from: NGS; NKS; NGT; and NKT.
Example 1 - Principle validation of maternal immunization against RSV in the guinea pig model
The guinea pig model was chosen because its placenta structure and IgG transfer is closer to human than typical rodent models (reviewed in Pentsuk and van der Laan (2009)). ) Birth Defects Research (part B) 86: 328-344). The relatively long gestation period of guinea pigs (68 days) allows immunization and the development of an immune response during pregnancy. In order to reproduce the RSV immunity status of pregnant women who have been exposed to RSV throughout their lifetime and have a pre-existing RSV immune response, female guinea pigs have been primo-inoculated either 6 weeks, 10 weeks before vaccination (FIG 2).
Female guinea pigs (N = 5 / group) were intranasally primo-inoculated with live RSV (2.5 x 105 pfu), 6 or 10 weeks with vaccination (approximately at the time of mating or 4 weeks before). Two groups were not first-inoculated. Solid females were immunized approximately 6 weeks after the onset of pregnancy with 10% PreF antigen combined with aluminum hydroxide. A group of non-inoculated females received an injection of PBS. Serum samples were collected during the primary inoculation and gestation period to monitor levels of binding and neutralizing anti-RSV antibodies.
The offspring (7-16 days old) was challenged intranasally with RSV at 1 x 107 pfu. Four days after the virulent challenge, the lungs were removed and separated into 7 lobes. The virus was titrated in 6 of 7 lobes and total viral particles per gram of lung were calculated.
The results are shown on the graph of FIGs. 3 and 4.
Similar antibody levels were observed on the day of vaccination (D70-75 - before vaccination) - that the guinea pigs were first inoculated 6 or 10 weeks earlier. Plateau titers were reached 14 days after the primary inoculation. Neutralizing antibody titres do not decline after reaching a plateau for at least about 60 days. Therefore, primoinoculation at these two time points was equivalent in this model and suitable for reproducing maternal infection in women.
The results obtained for viral load in the lungs in guinea pigs (FIG 3) indicate that offspring born from first-inoculated and vaccinated mothers were protected against RSV viral challenge, compared to offspring born non-inoculated / unvaccinated mothers. On the other hand, offspring born to non-inoculated / vaccinated mothers were not protected against RSV viral challenge. Steff et al (Proof of the concept of a maternal RSV, recombinant F protein, vaccine for protection of offspring in the guinea pig model - poster 114, RSV Vaccines for the World Conference, Porto, Portugal, 14-16 October 2013) , provide further evidence of the effectiveness of the PreF antigen in inducing protective antibody levels in guinea pigs after maternal immunization.
Example 2 - Combination vaccine protects against RSV challenge
This example demonstrates protection against RSV caused by a combined vaccine containing RSV (Pre-F) and B. pertussis (PT, FHA and PRN) antigens. Immogenicity (neutralizing antibody titres). both doses of the combined Pa-VRS vaccine were evaluated in the Balb / c mouse model, followed by an intranasal RSV challenge to measure the efficacy of the combination vaccine.
Groups of BALB / c mice (n = 14 / group) were immunized intramuscularly at 3 week intervals with the formulations shown in Table 1.
Table 1: Vaccine formulations administered before
provocation by the VRS
Serums from all mice were collected individually on Day 0 (before the first immunization), Day 21 (before the second immunization) and Day 35 (2 weeks after the second immunization) and tested for the presence of antibodies. anti-RSV neutralizers using a plaque reduction assay. Briefly, serial dilutions of each serum were incubated with Long RSV (targeting 100 pfu / well) for 20 min at 33 ° C. After incubation, the virus-serum mixture was transferred to plates previously inoculated with Vero cells and emptied of their growth medium. On each plate, the cells of one column were incubated with the virus alone (100% infectivity) and 2 wells received neither virus nor serum (cell controls). Plates were incubated for 2 h at 33 ° C, media was removed and RSV medium containing 0.5% CMC (low viscosity carboxymethylcellulose) was added to all wells. Plates were incubated for 3 days at 33 ° C before immunofluorescence staining.
For staining, the cell monolayers were washed with PBS and fixed with 1% paraformaldehyde. RSV-positive cells were detected with commercial goat anti-RSV antiserum, followed by FITC-conjugated rabbit anti-goat IgG. The number of stained plaques per well was counted using an automated imaging system. The neutralizing antibody titers of each serum was determined to be the reciprocal of the serum dilution causing a 60% reduction in the number of plaques, compared to the serum-free control (E 600). The results are shown in FIG. 5A.
The adjuvanted PreF vaccine with А1 (ОН) з protects mice against viral intranasal challenge with RSV and this animal model is therefore useful for studying the ability of RSV vaccines to mediate viral clearance in the lungs. The combination of B. pertussis (PT, FHA and PRN) and RSV (PreF) antigens in a single vaccine was then tested for protective efficacy in the mouse model of RSV intranasal viral challenge. Two weeks after the second vaccination dose, the mice were subjected to a virulent challenge by instillation of 50 μl (25 μl per nostril) with a VRS A Long strain (approximately 1.45 × 10 6 pfu / 50 μl). The lungs were removed four days after the viral challenge to assess the pulmonary viral load. Four days after the virulent challenge, the mice were euthanized, the lungs were removed under aseptic conditions and individually weighed and homogenized. Serial dilutions (8 replicates of each) of each pulmonary homogenate were incubated with Vero cells and the wells containing plates were identified by immunofluorescence, 6 days after seeding. The viral titer was determined by the Spearman-Kârber method for the calculation of TCID50 and was expressed per gram of lung. The statistical method used is an analysis of variance (ANOVA 1) on log10 values.
The results are illustrated in FIG. 5B. As expected, 2 μg of PreF combined with Δ1 (ОН) з effectively promoted virus clearance in the lungs, compared to Pa-vaccinated mice alone (control group where no protection against RSV challenge is expected). . Only two out of 14 animals in the PreF group had detectable levels of RSV in the lungs, with no detectable RSV in the other 12 animals. The Pa-VRS combination vaccine was also able to protect mice against viral challenge by RSV as evidenced by only one of 14 animals with detectable levels of RSV in the lungs, the RSV being undetectable in all 13 other animals. Overall, animals vaccinated with PreF + A1 (NO) vaccine or with Pa + PreF + Al (NO) antigens, had significantly lower pulmonary viral titers than control animals vaccinated with Pa alone ( P <0.001). In the group vaccinated with Pa + PreF antigens in the absence of adjuvant, there was no significant reduction (P <0.001) in viral titers, however no animals in this group appeared to be fully protected against viral challenge by RSV because the virus was quantifiable in the lungs of all animals. Using a viral challenge animal model, we observed that the combined Pa-VRS vaccine elicited a protective immune response against RSV comparable to that of the RSV vaccine. This immune response has been associated with the production of neutralizing anti-RSV antibodies.
Example 3 - Combination vaccine protects against virulent challenge by B. pertussis
This example demonstrates protection against Bordatella pertussis caused by a combination vaccine containing RSV and B. pertussis antigens (PT, FHA and PRN). The immunogenicity (neutralizing antibody titers) of two doses of the combination vaccine Pa-VRS was evaluated in the Balb / c model, followed by intranasal challenge with an infectious B. pertussis strain to measure the efficacy of the combined vaccine. .
Groups of BALB / c mice (n = 20 / group) were immunized subcutaneously twice to three weeks apart with the formulation shown in Table 2.
Table 2: Vaccine formulation administered prior to virulence challenge by B. pertussis
The sera from all the mice were collected individually seven days after the second immunization (d28 - eve of the virulent challenge) and tested for the presence of anti-PT, anti-FHA and anti-PRN IgG antibodies. Briefly, 96-well plates were coated with FHA (2 μg / ml), PT (2 μg / ml) or PRN (6 μg / ml) in carbonate-bicarbonate buffer (50 mM) and incubated overnight. at 4 ° C. After the saturation step with the 1% PBS-BSA buffer, the murine sera were diluted to 1/100 in 0.2% PBS-BSA 0.05% Tween and serially diluted in the wells of the plates ( 12 dilutions, step 4). An anti-mouse IgG coupled to peroxidase was added (1/5000 dilution). The colorimetric reaction was observed after the addition of the peroxidase substrate (OPDA), and stopped with 1 M HCl before reading by spectrophotometry (wavelengths: 490-620 nm). For each serum tested and reference added on each plate, a 4 parameter logistic curve was smoothed according to the relationship between OD and dilution (Softmaxpro). This allowed the calculation of the title of each sample expressed in STD securities. Serological antibody responses specific to vaccine-induced Pa (PT, FHA and PRN) antigens are considered indicative (but not critical) of the ability of vaccines to elicit antibody responses against individual antigens present in the Pa vaccine. FIG. 6A shows that DTPa, Pa alone and the Pa-VRS combination favored specific IgG responses of PT, FHA and PRN after two immunizations. No antigen specific antibodies were detected in sera from unvaccinated or RSV vaccinated mice (data not shown). Statistical analyzes demonstrated the equivalence between the anti-PT and anti-FHA antibody responses induced by DTPa (Infanrix ™) and the Pa-VRS combination. The amounts of anti-PRN antibodies induced by the Pa vaccine alone and Pa-VRS combination vaccine was also statistically equivalent, demonstrating that the presence of RSV antigen did not interfere with the production of anti-pertussis antibody responses.
To demonstrate the protection, one week after the stimulation, the mice were subjected to a virulent challenge by instillation of 50 μl of bacterial suspension (approximately 5 × 10 CFU / 50 μl) into the left nostril. Five mice from each group were euthanized 2 hours, 2 days, 5 days and 8 days after the virulent bacterial challenge. The lungs were removed under aseptic conditions and individually homogenized. Bacterial clearance of the lungs was measured by counting colony growth on Bordet-Gengou agar plates. Data were plotted against the average number of colony forming units (CFU - log10) per lung in each treatment group at. every moment of collection. The statistical method used is an analysis of variance (ANOVA) on 2-factor log10 values (treatment and day) using a heterogeneous variance model.
In this model, the acellular B. pertussis (Pa) vaccine protects mice against intranasal challenge with the bacterium. This animal model is therefore useful for studying the ability of a B. pertussis vaccine to mediate bacterial clearance in the lungs. The combination of B. pertussis (PT, FHA and PRN) and RSV (Pre-F) antigens in a single vaccine was then tested for protective efficacy in the mouse model of the intranasal viral challenge. Representative results are illustrated in FIG. 6B. As expected, the adjusted human dose (a quarter dose of the commercial DTPa Infanrix ™ vaccine) effectively promoted bacterial clearance compared to unvaccinated mice. Both the Pa alone vaccine and the Pa-VRS combination vaccine have been able to elicit a protective immune response leading to the elimination of the bacterium. As expected, the VRS PreF vaccine alone was unable to protect against B. pertussis in this animal model.
These results demonstrate in an animal model that the combined Pa-VRS vaccine elicited a protective immune response against B. pertussis as well as against RSV as demonstrated in Example 2 above. This immune response has been associated with the production of specific antibodies against the three subunit antigens present in the acellular Pa vaccine (PT, FHA and PRN).
Example 4 - Administration of Pa-VRS combination vaccine to full mothers does not interfere with protection of pups after challenge with RSV in the guinea pig model
Female guinea pigs (N = 5 / group) were intranasally primo-inoculated with live RSV (800 pfu). One of the groups was not first-inoculated. Mating started the day after primoinoculation. Full females were immunized 4 and. 7 weeks after the first inoculation (two-dose regimen) or 7 weeks after the primary inoculation (single-dose regimen) with one of the following vaccines: 10 μg PreF antigen combined with aluminum hydroxide (130 μg ), 10 μg PreF + antigen DTaP antigens (5 μl diphtheria toxoid, 2 μl tetanus toxoid, 5 μg FHA, 5 μg inactivated pertussis toxoid, 1.6 μg PRN) combined with aluminum hydroxide (130 μg) or only with DTaP antigens (same amounts as above) combined with aluminum hydroxide (100 μg). Serum samples were collected 14 days after the first or second immunization (day 63 after priming) for the once-or-once-immunized females, respectively. The neutralizing anti-RSV antibody levels were determined at this time point ( 6 weeks before the birth of the young).
Serum samples were taken from the offspring within 24 to 72 hours after birth. Babies between 5 and 18 days were challenged intranasally with RSV at 2 x 106 pfu. Four days after the virulent challenge, the lungs were removed and homogenized. The virus was titrated in lung homogenates and total virus particles per gram of lung were calculated.
The results are shown in the graphs of FIGs. 7 and 8.
RSV neutralizing antibody titers in mothers vaccinated once or twice with DTaP antigens alone (groups 3 and 6 in FIG 7A) were 316 and 272, respectively. This represents the titers induced by RSV primo-inoculation since there was virtually no RSV-neutralizing response in non-primocinoculated mothers vaccinated with DTaP antigens (Group 7 in Figure 7A). Babies born to RSV-primed mothers and vaccinated once or twice with DTaP only had only RSV neutralization titres of 425 and 563 (groups 3 and 6 in Fig. 7B), respectively, representing Neutralizing antibody levels transferred to offspring due to primo-inoculation with live RSV. These neutralizing antibody titers were sufficient to induce complete protection against RSV challenge in the offspring (FIG 8).
Comparing the levels of neutralizing antibodies induced in the mothers after primary inoculation with live RSV and either a single dose of PreF vaccine alone (group 1 in FIG 7A), or a combined dose of PreF antigens and DTaP (group 2 in FIG 7B), no significant differences in neutralizing antibody titers were observed, indicating a lack of DTaP vaccine interference on the anti-RSV neutralizing antibody response. A similar observation can be made for the neutralizing antibody titers of the small ones (compare groups 1 and 2 in FIG 7B). However, when first-inoculated mothers received two doses of combined PreF and DTaP antigens, the anti-RSV neutralizing titres in the mothers were lower than those obtained after PreF vaccination only, although the difference did not reach any significance. statistic (titres of 832 vs. 1590 after combination vaccine PreF-DTaP versus vaccine PreF only, respectively, groups 4 and 5, FIG 7A). Neutralizing antibody levels transferred to pups when mothers were vaccinated with two doses of the PreF-DTaP combination vaccine were significantly lower than those observed when mothers were vaccinated twice with the PreF-only vaccine (titres of 519 vs. 2439 after combined vaccine PreF-DTaP vs PreF only, respectively, groups 4 and 5, FIG 7C The results indicate that maternal vaccination with a single dose of combined DTaP-RSV vaccine does not interfere with levels of anti-neutralizing antibodies. RSV transferred to pups, while some degree of interference was apparent in the anti-RSV neutralizing antibody levels observed in the small 24 and 72 hours after birth after maternal vaccination with two doses with DTaP-RSV combined.
The results obtained for pulmonary viral load in guinea pig offspring (FIG 8) indicate that offspring born from first-inoculated and vaccinated mothers were completely protected against viral challenge by RSV, regardless of the vaccine regimen used. in mothers. The fact that animals primo-inoculated and vaccinated with DTaP antigens only (without RSV antigen) are fully protected against RSV viral challenge, whereas non-primo-inoculated animals vaccinated with DTaP antigens alone are not protected. protected suggests that primo-inoculation with live RSV was sufficient to induce protective levels of antibodies that were transferred to the offspring, regardless of the vaccine regimen used after the primary inoculation. Apparent interference with observed levels of neutralizing antibodies elicited after two doses of combined PreF and DTaP antigens (FIG 7) had no detectable interference on pup protection against RSV challenge. SEQUENCE LISTING SEQ ID NO: l sequence of nucleotides encoding the reference fusion protein of RSV strain A2 No. GenBank accession: U50362 atggagttgctaatcctcaaagcaaatgcaattaccacaatcctcactgcagtcacatttgttttgcttctggtcaaaacatcactgaaga attttatcaatcaacatgcagtgcagtagcaaaggctatcttagtgctctgagaactggttggtataccagtgttataactatagattaagt aatatcaaggaaaataagtgtaatggaacagatgctaaggtaaaattgataaacaagaattagataaatataaaaatgctgtaacagaa ttgcagttgctcatgcaaagcacccagcaacaaacaatcgagccagaagagaactaccaaggtttatgaattatacactcaaaatgcc aaaaaaaccaatgtaacattaagcaagaaaaggaaaagaagatttcttggtttttgttaggtgttggatctgcaatcgccagtggcgttg ctgtatctaaggtcctgcacctgaaggggaagtgaacaagatcaaaagtgctctactatccacaaacaaggctgtagtcagttatcaa atggagttagtgtcttaaccagcaaagtgttagacctcaaaaactatatagaaaacaattgttacctattgtgaacaagcaaagctgcag catatcaaatatagcaactgtatagagttccaacaaaagaacaacagactactagagattaccagggaatttagtgttaagcaggtgta actacacctgtaagcacttacatgttaactaatagtgaattattgtcattatcaatgatatgcctataacaaatgatcagaaaaagttaatgt ccaacaatgttcaaatgttagaca gcaaagttactctatcatgtccataataaaagaggaagtcttagcatatgtgtacaattaccactat atggtgttatagatacaccctgttggaaactacacacatccccctatgtacaaccaacacaaaagaagggtccaacatctgtttaacaa gaactgacagaggtggtactgtgacaatgcaggatcagtatctttcttcccacaagctgaaacatgtaaagtcaatcaaatcgagtattt tgtgacacaatgaacagtttaacattaccaagtgaagtaaactctgcaatgttgacatattcaaccccaaatatgattgtaaaattatgact tcaaaaacgatgtaagcagctccgttatcacatctctaggagccattgtgtcatgctatggcaaaacaaatgtacagcatccaataaaa atcgtggaatcataaagacattttctaacgggtgcgatatgtatcaaataaaggggtggacactgtgtctgtaggtaacacattatattat gtaaaaagcaagaaggtaaaagtctctatgtaaaaggtgaaccaataataaatttctatgacccttagtattcccctctgatgaatttgat gcatcaatatctcaagtcaacgagaagattaacagagcctagcatttattcgtaaatccgatgaattattacataatgtaaatgctggtaat ccaccataaatatcatgataactactataattatagtgattatagtaatattgttatcttaattgctgttggactgctcttatactgtaaggcca gaagcacaccagtcacactaagaaagatcaactgagtggtataaataatattgcatttagtaactaa SEQ ID NO: 2 Amino acid sequence of F protein precursor reference RSV strain A2 Fo No. GenBank accession: AAB86664
Mellilkanaittiltavtfcfasgqniteefyqstcsavskgylsalrtgwytsvitielsnikenkcngtdakvklikqeldkykna vtelqllmqstpatnnrarrelprfmnytlnnakktnvtlskkrkrrflgfllgvgsaiasgvavskvlhlegevnkiksallstnkav vslsngvsvltskvldlknyidkqllpivnkqscsisniatviefqqknnrlleitrefsvnagvttpvstymltnsellslindmpitn dqkklmsnnvqivrqqsysimsiikeevlaywqlplygvidtpcwklhtsplcttntkegsnicltrtdrgwycdnagsvsffp qaetckvqsnrvfcdtmnsltlpsevnlcnvdifnpkydckimtsktdvsssvitslgaivscygktkctasnknrgiiktfsngcd yvsnkgvdtvsvgntlyyvnkqegkslyvkgepiinfydplvfpsdefdasisqvnekinqslaflrksdellhnvnagkstini mittiiiviivillsliavglllyckarstpvtlskdqlsginniafsn SEQ ID No: 3 nucleotide sequence encoding the reference protein G of RSV strain Long
Atgtccaaaaacaaggaccaacgcaccgctaagacactagaaaagacctgggacactctcaatcatttattattcatatcatcgggct tatataagttaaatcttaaatctatagcacaaatcacattatccattctggcaatgataatctcaacttcacttataattacagccatcatattc atagcctcggcaaaccacaaagtcacactaacaactgcaatcatacaagatgcaacaagccagatcaagaacacaaccccaacata cctcactcaggatcctcagcttggaatcagcttctccaatctgtctgaaattacatcacaaaccaccaccatactagcttcaacaacacc aggagtcaagtcaaacctgcaacccacaacagtcaagactaaaaacacaacaacaacccaaacacaacccagcaagcccactac aaaacaacgccaaaacaaaccaccaaacaaacccaataatgattttcacttcgaagtgtttaactttgtaccctgcagcatatgcagca acaatccaacctgctgggctatctgcaaaagaataccaaacaaaaaaccaggaaagaaaaccaccaccaagcctacaaaaaaacc aaccttcaagacaaccaaaaaagatctcaaacctcaaaccactaaaccaaaggaagtacccaccaccaagcccacagaagagcca accatcaacaccaccaaaacaaacatcacaactacactgctcaccaacaacaccacaggaaatccaaaactcacaagtcaaatgga aaccttccactcaacctcctccgaaggcaatctaagcccttctcaagtctccacaacatccgagcacccatcacaaccctcatctccac ccaacacaacacgccagtag SEQ ID NO: 4
Amino acid sequence of the YRS reference protein G
MSKNKDQRTAKTLEKTWDTLNHLLFISSGLYKLNLKSIAQITLSILAMIISTSLIITAIIF
IASANHKVTLTTAIIQDATSQIKNTTPTYLTQDPQLGISFSNLSEITSQTTTILASTTPG
VKSNLQPTTVKTKNTTTTQTQPSKPTTKQRQNKPPNKPNNDFHFEVFNFVPCSICSN
NPTCWAICKRIPNKKPGKKTTTKPTKKPTFKTTKKDLKPQTTKPKEVPTTKPTEEPTI
NTTKTNITTTLLTNNTTGNPKLTSQMETFHSTSSEGNLSPSQVSTTSEHPSQPSSPPNT
TRQ SEQ ID No: 5
Nucleotide sequence of the analog optimized for CHO Pref aagcttgccaccatggagctgctgatcctgaaaaccaacgccatcaccgccatcctggccgccgtgaccctgtgcttcgcctcctcc cagaacatcaccgaggagttctaccagtccacctgctccgccgtgtccaagggctacctgtccgccctgcggaccggctggtacac ctccgtgatcaccatcgagctgtccaacatcaaggaaaacaagtgcaacggcaccgacgccaaggtgaagctgatcaagcaggag ctggacaagtacaagagcgccgtgaccgaactccagctgctgatgcagtccacccctgccaccaacaacaagtttctgggcttcctg ctgggcgtgggctccgccatcgcctccggcatcgccgtgagcaaggtgctgcacctggagggcgaggtgaacaagatcaagagc gccctgctgtccaccaacaaggccgtggtgtccctgtccaacggcgtgtccgtgctgacctccaaggtgctggatctgaagaactac atcgacaagcagctgctgcctatcgtgaacaagcagtcctgctccatctccaacatcgagaccgtgatcgagttccagcagaagaac aaccggctgctggagatcacccgcgagttctccgtgaacgccggcgtgaccacccctgtgtccacctacatgctgaccaactccga gctgctgtccctgatcaacgacatgcctatcaccaacgaccagaaaaaactgatgtccaacaacgtgcagatcgtgcggcagcagtc ctacagcatcatgagcatcatcaaggaagaggtgctggcctacgtggtgcagctgcctctgtacggcgtgatcgacaccccttgctg gaagctgcacacctcccccctgtgcaccaccaacaccaaggagggctccaacatctgcctg acccggaccgaccggggctggta ctgcgacaacgccggctccgtgtccttcttccctctggccgagacctgcaaggtgcagtccaaccgggtgttctgcgacaccatgaa. ctccctgaccctgccttccgaggtgaacctgtgcaacatcgacatcttcaaccccaagtacgactgcaagatcatgaccagcaagac cgacgtgtcctccagcgtgatcacctccctgggcgccatcgtgtcctgctacggcaagaccaagtgcaccgcctccaacaagaacc ggggaatcatcaagaccttctccaacggctgcgactacgtgtccaataagggcgtggacaccgtgtccgtgggcaacacactgtact acgtgaataagcaggagggcaagagcctgtacgtgaagggcgagcctatcatcaacttctacgaccctctggtgttcccttccgacg agttcgacgcctccatcagccaggtgaacgagaagatcaaccagtccctggccttcatccggaagtccgacgagaagctgcataac gtggaggacaagatcgaggagatcctgtccaaaatctaccacatcgagaacgagatcgcccggatcaagaagctgatcggcgagg cctgataatctaga SEQ ID N0: 6
Amino Acid Sequence of Analog PreF
MELLILKTNAITAILAAVTLCFASSQNITEEFYQSTCSAYSKGYLSALRTGWYTSVITI
ELSNIKENKCNGTDAKVKLIKQELDKYKSAVTELQLLMQSTPATNNKFLGFLLGVG
SAIASGIAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ
LLPIVNKQSCSISNIETVIEFQQICNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLIN
DMPITNDQKKLMSNNV QIVRQQS Y SIMSIIKEEVL A YVV QLPL Y GVIDTPC WKLHTS
PLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPLAETCKVQSNRVFCDTMNSLTL
PSEVNLCNIDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKT
FSNGCD YV SNKGVDTV SV GNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDA
SISQVNEKINQSLAFIRKSDEKLHNVEDKIEEILSKIYHIENEIARIKKLIGEA SEQ ID No: 7
Nucleotide sequence encoding optimized for CHO PreFG_Vl aagcttgccaccatggagctgctgatcctcaagaccaacgccatcaccgccatcctggccgccgtgaccctgtgcttcgcctcctcc cagaacatcaccgaagagttctaccagtccacctgctccgccgtgtccaagggctacctgtccgccctgcggaccggctggtacac ctccgtgatcaccatcgagctgtccaacatcaaagaaaacaagtgcaacggcaccgacgccaaggtcaagctgatcaagcaggaa ctggacaagtacaagagcgccgtgaccgaactccagctgctgatgcagtccacccctgccaccaacaacaagaagtttctgggctt cctgctgggcgtgggctccgccatcgcctccggcatcgccgtgagcaaggtgctgcacctggagggcgaggtgaacaagatcaa gagcgccctgctgtccaccaacaaggccgtggtgtccctgtccaacggcgtgtccgtgctgacctccaaggtgctggatctgaaga actacatcgacaagcagctgctgcctatcgtgaacaagcagtcctgctccatctccaacatcgagaccgtgatcgagttccagcaga agaacaaccggctgctggagatcacccgcgagttctccgtgaacgccggcgtgaccacccctgtgtccacctacatgctgacaaac tccgagctgctctccctgatcaacgacatgcctatcaccaacgaccaaaaaaagctgatgtccaacaacgtgcagatcgtgcggcag cagtcctacagcatcatgagcatcatcaaggaagaagtcctggcctacgtcgtgcagctgcctctgtacggcgtgatcgacacccctt gctggaagctgcacacctcccccctgtgcaccaccaacaccaaagagggctccaacatctg cctgacccggaccgaccggggct ggtactgcgacaacgccggctccgtgtccttcttccctctggccgagacctgcaaggtgcagtccaaccgggtgttctgcgacacca tgaactccctgaccctgccttccgaggtgaacctgtgcaacatcgacatcttcaaccccaagtacgactgcaagatcatgaccagcaa gaccgacgtgtcctccagcgtgatcacctccctgggcgccatcgtgtcctgctacggcaagaccaagtgcaccgcctccaacaaga accggggaatcatcaagaccttctccaacggctgcgactacgtgtccaataagggcgtggacaccgtgtccgtgggcaacacactg tactacgtgaataagcaggaaggcaagagcctgtacgtgaagggcgagcctatcatcaacttctacgaccctctggtgttcccttccg acgagttcgacgcctccatcagccaggtcaacgagaagatcaaccagtccctggccttcatccggaagtccgacgagaagctgcat aacgtggaggacaagatcgaagagatcctgtccaaaatctaccacatcgagaacgagatcgcccggatcaagaagctgatcggcg aggctggcggctctggcggcagcggcggctccaagcagcggcagaacaagcctcctaacaagcccaacaacgacttccacttcg aggtgttcaacttcgtgccttgctccatctgctccaacaaccctacctgctgggccatctgcaagagaatccccaacaagaagcctgg caagaaaaccaccaccaagcctaccaagaagcctaccttcaagaccaccaagaaggaccacaagcctcagaccacaaagcctaa ggaagtgccaaccaccaagcaccaccaccatcaccactgataatcta SEQ ID N0: 8
Peptide PreFG Vl for CHO
MELLILKTNAITAILAAVTLCFASSQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITI
ELSNIKENKCNGTDAKVKLIKQELDKYKSAVTELQLLMQSTPATNNKKFLGFLLGV
GSAIASGIAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK
QLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLI
YSIMSIIKEEVL YV V QLPL Y GVIDTPC WKLHT NDHQWLRQ
SPLCTTNTKEGSNICLTRTDRG WY CDNAGS SFFPL AET CKV QSNRVF CDTMNSLT
LPSEVNLCNIDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIK
TFSNGCD YV SNKGVDTV SV GNTL YYVNKQEGKSLYVKGEPIINF YDPLVFPSDEFD
ASISQVNEKINQSLAFIRKSDEKLHNVEDKIEEILSKIYHIENEIARIKKLIGEAGGSGG
SGGSKQRQNKPPNKPNNDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKKTTTK
PTKKPTFKTTKKDHKPQTTKPKEVPTTK SEQ ID No: 9
Nucleotide sequence encoding PreFG_V2 CHO aagcttgccaccatggagctgctgatcctcaagaccaacgccatcaccgccatcctggccgccgtgaccctgtgcttcgcctcctcc cagaacatcaccgaagagttctaccagtccacctgctccgccgtgtccaagggctacctgtccgccctgcggaccggctggtacac ctccgtgatcaccatcgagctgtccaacatcaaagaaaacaagtgcaacggcaccgacgccaaggtcaagctgatcaagcaggaa ctggacaagtacaagagcgccgtgaccgaactccagctgctgatgcagtccacccctgccaccaacaacaagaagtttctgggctt cctgctgggcgtgggctccgccatcgcctccggcatcgccgtgagcaaggtgctgcacctggagggcgaggtgaacaagatcaa gagcgccctgctgtccaccaacaaggccgtggtgtccctgtccaacggcgtgtccgtgctgacctccaaggtgctggatctgaaga actacatcgacaagcagctgctgcctatcgtgaacaagcagtcctgctccatctccaacatcgagaccgtgatcgagttccagcaga agaacaaccggctgctggagatcacccgcgagttctccgtgaacgccggcgtgaccacccctgtgtccacctacatgctgacaaac tccgagctgctctccctgatcaacgacatgcctatcaccaacgaccaaaaaaagctgatgtccaacaacgtgcagatcgtgcggcag cagtcctacagcatcatgagcatcatcaaggaagaagtcctggcctacgtcgtgcagctgcctctgtacggcgtgatcgacacccctt gctggaagctgcacacctcccccctgtgcaccaccaacaccaaagagggctccaacatctgcctgacccgga ccgaccggggct ggtactgcgacaacgccggctccgtgtccttcttccctctggccgagacctgcaaggtgcagtccaaccgggtgttctgcgacacca tgaactccctgaccctgccttccgaggtgaacctgtgcaacatcgacatcttcaaccccaagtacgactgcaagatcatgaccagcaa gaccgacgtgtcctccagcgtgatcacctccctgggcgccatcgtgtcctgctacggcaagaccaagtgcaccgcctccaacaaga accggggaatcatcaagaccttctccaacggctgcgactacgtgtccaataagggcgtggacaccgtgtccgtgggcaacacactg tactacgtgaataagcaggaaggcaagagcctgtacgtgaagggcgagcctatcatcaacttctacgaccctctggtgttcccttccg acgagttcgacgcctccatcagccaggtcaacgagaagatcaaccagtccctggccttcatccggaagtccgacgagaagctgcat aacgtggaggacaagatcgaagagatcctgtccaaaatctaccacatcgagaacgagatcgcccggatcaagaagctgatcggcg aggctggcggcaagcagcggcagaacaagcctcctaacaagcccaacaacgacttccacttcgaggtgttcaacttcgtgccttgct ccatctgctccaacaaccctacctgctgggccatctgcaagagaatccccaacaagaagcctggcaagaaaaccaccaccaagcct accaagaagcctaccttcaagaccaccaagaaggaccacaagcctcagaccacaaagcctaaggaagtgccaaccaccaagcac caccaccatcaccactgataatcta SEQ ID No: 10
Peptide PreFG_V2 for CHO
MELLILKTN HAS AIL A A VTLCF AS SQNITEEF YQSTCS AV SKGYLS ALRT G WYTS VITI
ELSNIKENKCNGTDAKYKLIKQELDKYKSAVTELQLLMQSTPATNNKKFLGFLLGV
GSAIASGIAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK
QLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLI
YSIMSIIKEEVL A YVV QLPL Y GVIDTPC WKLHT NDHQDQKKLMSNNV
SPLCTTNTKEGSNICLTRTDRG WY CDN AGS V SFFPL AET CKVQSNRVF CDTMN SLT
LPSEVNLCNIDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIK
TFSNGCDYYSNKGVDTVSYGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFD
ASISQVNEKINQSLAFIRKSDEKLHNVEDKIEEILSKIYHIENEIARIKKLIGEAGGKQR
QNKPPNKPNNDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKKTTTKPTKKPTF
KTTKKDHKPQTTKPKEVPTTK SEQ ID No: 11
Exemplary bispirale (isoleucine slide)
EDKIEEILSKIYHIENEIARIKKLIGEA SEQ ID No: 12
CH02 polynucleotide encoding the antigen Pref atggagctgcccatcctgaagaccaacgccatcaccaccatcctcgccgccgtgaccctgtgcttcgccagcagccagaacatcac ggaggagttctaccagagcacgtgcagcgccgtgagcaagggctacctgagcgcgctgcgcacgggctggtacacgagcgtgat cacgatcgagctgagcaacatcaaggagaacaagtgcaacggcacggacgcgaaggtgaagctgatcaagcaggagctggaca agtacaagagcgcggtgacggagctgcagctgctgatgcagagcacgccggcgacgaacaacaagttcctcggcttcctgctggg cgtgggcagcgcgatcgcgagcggcatcgccgtgagcaaggtgctgcacctggagggcgaggtgaacaagatcaagtccgcgc tgctgagcacgaacaaggcggtcgtgagcctgagcaacggcgtgagcgtgctgacgagcaaggtgctcgacctgaagaactacat cgacaagcagctgctgccgatcgtgaacaagcagagctgcagcatcagcaacatcgagaccgtgatcgagttccagcagaagaac aaccgcctgctggagatcacgcgggagttctccgtgaacgcaggcgtgacgacgcccgtgtctacgtacatgctgacgaacagcg agctgctcagcctgatcaacgacatgccgatcacgaacgaccagaagaagctgatgagcaacaacgtgcagatcgtgcgccagca gagctacagcatcatgagcatcatcaaggaggaggtgctggcatacgtggtgcagctgccgctgtacggcgtcatcgacacgccct gctggaagctgcacacgagcccgctgtgcacgaccaacacgaaggagggcagcaacatctgcctgacgcggacggaccgggg ctggtactg cgacaacgcgggcagcgtgagcttcttcccgctcgcggagacgtgcaaggtgcagagcaaccgcgtcttctgcgac acgatgaacagcctgacgctgccgagcgaggtgaacctgtgcaacatcgacatcttcaacccgaagtacgactgcaagatcatgac gagcaagaccgatgtcagcagcagcgtgatcacgagcctcggcgcgatcgtgagctgctacggcaagacgaagtgcacggcga gcaacaagaaccgcggcatcatcaagacgttcagcaacggctgcgactatgtgagcaacaagggcgtggacactgtgagcgtcg gcaacacgctgtactacgtgaacaagcaggagggcaagagcctgtacgtgaagggcgagccgatcatcaacttctacgacccgct cgtgttcccgagcgacgagttcgacgcgagcatcagccaagtgaacgagaagatcaaccagagcctggcgttcatccgcaagagc gacgagaagctgcacaacgtggaggacaagatcgaggagatcctgagcaagatctaccacatcgagaacgagatcgcgcgcatc aagaagctgatcggcgaggcgcatcatcaccatcaccattga SEQ ID No: 13
Polynucleotide with intron encoding the antigen Pref atggagctgctgatcctgaaaaccaacgccatcaccgccatcctggccgccgtgaccctgtgcttcgcctcctcccagaacatcacc gaggagttctaccagtccacctgctccgccgtgtccaagggctacctgtccgccctgcggaccggctggtacacctccgtgatcacc atcgagctgtccaacatcaaggaaaacaagtgcaacggcaccgacgccaaggtgaagctgatcaagcaggagctggacaagtac aagagcgccgtgaccgaactccagctgctgatgcagtccacccctgccaccaacaacaagtttctgggcttcctgctgggcgtggg ctccgccatcgcctccggcatcgccgtgagcaaggtacgtgtcgggacttgtgttcccctttttttaataaaaagttatatctttaatgttat atacatatttcctgtatgtgatccatgtgcttatgactttgtttatcatgtgtttaggtgctgcacctggagggcgaggtgaacaagatcaa gagcgccctgctgtccaccaacaaggccgtggtgtccctgtccaacggcgtgtccgtgctgacctccaaggtgctggatctgaaga actacatcgacaagcagctgctgcctatcgtgaacaagcagtcctgctccatctccaacatcgagaccgtgatcgagttccagcaga agaacaaccggctgctggagatcacccgcgagttctccgtgaacgccggcgtgaccacccctgtgtccacctacatgctgaccaac tccgagctgctgtccctgatcaacgacatgcctatcaccaacgaccagaaaaaactgatgtccaacaacgtgcagatcgtgcggcag cagtcctacagcatcatgagcatcatcaaggaagaggtgctggcctacgtggtgcag ctgcctctgtacggcgtgatcgacacccct tgctggaagctgcacacctcccccctgtgcaccaccaacaccaaggagggctccaacatctgcctgacccggaccgaccggggct ggtactgcgacaacgccggctccgtgtccttcttccctctggccgagacctgcaaggtgcagtccaaccgggtgttctgcgacacca tgaactccctgaccctgccttccgaggtgaacctgtgcaacatcgacatcttcaaccccaagtacgactgcaagatcatgaccagcaa gaccgacgtgtcctccagcgtgatcacctccctgggcgccatcgtgtcctgctacggcaagaccaagtgcaccgcctccaacaaga accggggaatcatcaagaccttctccaacggctgcgactacgtgtccaataagggcgtggacaccgtgtccgtgggcaacacactg tactacgtgaataagcaggagggcaagagcctgtacgtgaagggcgagcctatcatcaacttctacgaccctctggtgttcccttccg acgagttcgacgcctccatcagccaggtgaacgagaagatcaaccagtccctggccttcatccggaagtccgacgagaagctgcat aacgtggaggacaagatcgaggagatcctgtccaaaatctaccacatcgagaacgagatcgcccggatcaagaagctgatcggcg aggccggaggtcaccaccaccatcaccactga SEQ ID NO: 14 Synthetic linker sequence
GGSGGSGGS SEQ ID No: 15
Fur site cleavage
RARR SEQ ID No: 16
Fur site cleavage
RKRR SEQ ID No: 17
Nucleotide sequence encoding PreF_NGTL atggagctgctgatcctgaaaaccaacgccatcaccgccatcctggccgccgtgaccctgtgcttcgcctcctcccagaacatcacc gaggagttctaccagtccacctgctccgccgtgtccaagggctacctgtccgccctgcggaccggctggtacacctccgtgatcacc atcgagctgtccaacatcaaggaaaacaagtgcaacggcaccgacgccaaggtgaagctgatcaagcaggagctggacaagtac aagagcgccgtgaccgaactccagctgctgatgcagtccacccctgccaccaacaacaagtttctgggcttcctgctgggcgtggg ctccgccatcgcctccggcatcgccgtgagcaaggtgctgcacctggagggcgaggtgaacaagatcaagagcgccctgctgtcc accaacaaggccgtggtgtccctgtccaacggcgtgtccgtgctgacctccaaggtgctggatctgaagaactacatcgacaagca gctgctgcctatcgtgaacaagcagtcctgctccatctccaacatcgagaccgtgatcgagttccagcagaagaacaaccggctgct ggagatcacccgcgagttctccgtgaacgccggcgtgaccacccctgtgtccacctacatgctgaccaactccgagctgctgtccct gatcaacgacatgcctatcaccaacgaccagaaaaaactgatgtccaacaacgtgcagatcgtgcggcagcagtcctacagcatca tgagcatcatcaaggaagaggtgctggcctacgtggtgcagctgcctctgtacggcgtgatcgacaccccttgctggaagctgcaca cctcccccctgtgcaccaccaacaccaaggagggctccaacatctgcctgacccggaccgaccggggctggtactgcgac AACG ccggctccgtgtccttcttccctctggccgagacctgcaaggtgcagtccaaccgggtgttctgcgacaccatgaactccctgaccct gccttccgaggtgaacctgtgcaacatcgacatcttcaaccccaagtacgactgcaagatcatgaccagcaagaccgacgtgtcctc cagcgtgatcacctccctgggcgccatcgtgtcctgctacggcaagaccaagtgcaccgcctccaacaagaaccggggaatcatca agaccttctccaacggctgcgactacgtgtccaataagggcgtggacaccgtgtccgtgggcaacacactgtactacgtgaataagc aggagggeaagagectgtaegtgaagggegagcetatcatcaaettctacgaccctctggtgttcccttccgacgagttcgacgcct ccatcagccaggtgaacgagaagatcaacgggaccctggccttcatccggaagtccgacgagaagctgcataacgtggaggaca agatcgaggagatcctgtccaaaatctaccacatcgagaacgagatcgcccggatcaagaagctgatcggcgaggcc SEQ ID No: 18
Amino acid sequence of PreF_NGTL
MELLILKTN WAS AIL AVTLCF AS SQNITEEF YQSTCS SKG AV YLS ALRT GWYTS VITI
ELSNIKENKCNGTDAKYKLIKQELDKYKSAVTELQLLMQSTPATNNKFLGFLLGVG
SAIASGIAVSKYLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ
LLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLIN
DMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTS
PLCTTNTKEGSNICLTRTDRGWY CDNAGS V SFFPLAETCKVQSNRVFCDTMNSLTL
PSEVNLCNIDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKT
FSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDA
SISQVNEKINGTLAFIRKSDEKLHNVEDKIEEILSKIYHIENEIARIKKLIGEA SEQ ID No: 19
Nucleotide sequence encoding PreF_Ll 12Q atggagctgctgatcctgaaaaccaacgccatcaccgccatcctggccgccgtgaccctgtgcttcgcctcctcccagaacatcacc gaggagttctaccagtccacctgctccgccgtgtccaagggctacctgtccgccctgcggaccggctggtacacctccgtgatcacc atcgagctgtccaacatcaaggaaaacaagtgcaacggcaccgacgccaaggtgaagctgatcaagcaggagctggacaagtac aagagcgccgtgaccgaactccagctgctgatgcagtccacccctgccaccaacaacaagtttctgggcttcctgcagggcgtggg ctccgccatcgcctccggcatcgccgtgagcaaggtgctgcacctggagggcgaggtgaacaagatcaagagcgccctgctgtcc accaacaaggccgtggtgtccctgtccaacggcgtgtccgtgctgacctccaaggtgctggatctgaagaactacatcgacaagca gctgctgcctatcgtgaacaagcagtcctgctccatctccaacatcgagaccgtgatcgagttccagcagaagaacaaccggctgct ggagatcacccgcgagttctccgtgaacgccggcgtgaccacccctgtgtccacctacatgctgaccaactccgagctgctgtccct gatcaacgacatgcctatcaccaacgaccagaaaaaactgatgtccaacaacgtgcagatcgtgcggcagcagtcctacagcatca tgagcatcatcaaggaagaggtgctggcctacgtggtgcagctgcctctgtacggcgtgatcgacaccccttgctggaagctgcaca cctcccccctgtgcaccaccaacaccaaggagggctccaacatctgcctgacccggaccgaccggggctggtactgcg acaacg ccggctccgtgtccttcttccctctggccgagacctgcaaggtgcagtccaaccgggtgttctgcgacaccatgaactccctgaccct gccttccgaggtgaacctgtgcaacatcgacatcttcaaccccaagtacgactgcaagatcatgaccagcaagaccgacgtgtcctc cagcgtgatcacctccctgggcgccatcgtgtcctgctacggcaagaccaagtgcaccgcctccaacaagaaccggggaatcatca agaccttctccaacggctgcgactacgtgtccaataagggcgtggacaccgtgtccgtgggcaacacactgtactacgtgaataagc aggagggcaagagcctgtacgtgaagggcgagcctatcatcaacttctacgaccctctggtgttcccttccgacgagttcgacgcct ccatcagccaggtgaacgagaagatcaaccagtccctggccttcatccggaagtccgacgagaagctgcataacgtggaggacaa gatcgaggagatcctgtccaaaatctaccacatcgagaacgagatcgcccggatcaagaagctgatcggcgaggcc SEQ ID No: 20
Amino acid sequence of PreF_Ll 12Q
MELLILKTNAITAILAAVTLCFASSQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITI ELSNIKENKCNGTDAKVKLIKQELDKYKSAVTELQLLMQSTPATNNKFLGFLQGVG SAIASGIAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ LLPIYNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLIN DMPITNDQKKLMSNNY QIVRQQS YSIMSIIKEEVLA YVV QLPLY GVIDTPC WKLHTS PLCTTNTKEGSNICLTRTDRG WY CDN AGS V SFFPL AET CKVQSNRVF CDTMNSLTL PES VNLCNIDIFNPKYDCKIMTSKTD VS S S VITSLGAIVSC YGKTKCTASNKNRGIIKT FSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDA SISQVNEKINQSLAFIRKSDEKLHNVEDKIEEILSKIYHIENEIARIKKLIGEA SEQ ID No: 21
Nucleotide sequence encoding PreF_NGTL_Ll 12Q atggagctgctgatcctgaaaaccaacgccatcaccgccatcctggccgccgtgaccctgtgcttcgcctcctcccagaacatcacc gaggagttctaccagtccacctgctccgccgtgtccaagggctacctgtccgccctgcggaccggctggtacacctccgtgatcacc atcgagctgtccaacatcaaggaaaacaagtgcaacggcaccgacgccaaggtgaagctgatcaagcaggagctggacaagtac aagagcgccgtgaccgaactccagctgctgatgcagtccacccctgccaccaacaacaagtttctgggcttcctgcagggcgtggg ctccgccatcgcctccggcatcgccgtgagcaaggtgctgcacctggagggcgaggtgaacaagatcaagagcgccctgctgtcc accaacaaggccgtggtgtccctgtccaacggcgtgtccgtgctgacctccaaggtgctggatctgaagaactacatcgacaagca gctgctgcctatcgtgaacaagcagtcctgctccatctccaacatcgagaccgtgatcgagttccagcagaagaacaaccggctgct ggagatcacccgcgagttctccgtgaacgccggcgtgaccacccctgtgtccacctacatgctgaccaactccgagctgctgtccct gatcaacgacatgcctatcaccaacgaccagaaaaaactgatgtccaacaacgtgcagatcgtgcggcagcagtcctacagcatca tgagcatcatcaaggaagaggtgctggcctacgtggtgcagctgcctctgtacggcgtgatcgacaccccttgctggaagctgcaca cctcccccctgtgcaccaccaacaccaaggagggctccaacatctgcctgacccggaccgaccggggctggta ctgcgacaacg ccggctccgtgtccttcttccctctggccgagacctgcaaggtgcagtccaaccgggtgttctgcgacaccatgaactccctgaccct gccttccgaggtgaacctgtgcaacatcgacatcttcaaccccaagtacgactgcaagatcatgaccagcaagaccgacgtgtcctc cagcgtgatcacctccctgggcgccatcgtgtcctgctacggcaagaccaagtgcaccgcctccaacaagaaccggggaatcatca agaccttctccaacggctgcgactacgtgtccaataagggcgtggacaccgtgtccgtgggcaacacactgtactacgtgaataagc aggagggcaagagcctgtacgtgaagggcgagcctatcatcaacttctacgaccctctggtgttcccttccgacgagttcgacgcct ccatcagccaggtgaacgagaagatcaacgggaccctggccttcatccggaagtccgacgagaagctgcataacgtggaggaca agatcgaggagatcctgtccaaaatctaccacatcgagaacgagatcgcccggatcaagaagctgatcggcgaggcc SEQ ID No: 22
Amino acid sequence of PreF_NGTL_Ll 12Q
MELLILKTNAITAILAAVTLCFASSQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITI
ELSNIKENKCNGTDAKVKLIKQELDKYKSAVTELQLLMQSTPATNNKFLGFLQGVG
SAIASGIAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ
LLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLIN
DMPITNDQKKLMSNNV QIVRQQS YSIMSIIKEEVLA YVV QLPLY GVIDTPC WKLFTTS
PLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPLAETCKVQSNRVFCDTMNSLTL
PSEVNLCNIDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKT
FSNGCD YV SNKGVDTV SV GNTL YYVNKQEGKSLYVKGEPIINF YDPLVFPSDEFDA
SISQVNEKINGTLAFIRKSDEKLHNVEDKIEEILSKIYHIENEIARIKKLIGEA

权利要求:
Claims (113)
[1]
A combined immunogenic composition comprising at least one respiratory syncytial virus (RSV) antigen and at least one Bordetella pertussis antigen, wherein the at least one RSV antigen is a recombinant soluble analog of the F protein and the at least one antigen of B. pertussis comprises at least one acellular pertussis antigen (Pa) or comprises a whole cell antigen (Pw).
[2]
The combined immunogenic composition of claim 1, wherein said F protein analog is a PreF antigen which comprises at least one modification that stabilizes the pre-fusion conformation of the F protein.
[3]
A combined immunogenic composition according to claim 1 or 2, wherein the F protein analogue comprises in the N-terminus to C-terminus direction: a F2 domain and a F domain of a F protein polypeptide of VRS, and a heterologous trimerization domain, with no furine cleavage site between domain F2 and domain Fi.
[4]
The combined immunogenic composition according to any one of claims 1 to 3, wherein the F protein analog comprises at least one modification selected from: (i) a modification that alters glycosylation; (ii) a modification that removes at least one non-furine cleavage site; (iii) a modification that deletes one or more amino acids from the pep27 domain; and (iv) a hydrophilic amino acid substitution or substitution modification in a hydrophobic domain of the extracellular domain of the F protein.
[5]
A combined immunogenic composition according to claim 3 or 4, wherein the F2 domain comprises a RSV F protein polypeptide corresponding to amino acids 26-105 and / or the FI domain comprises a RSV F protein polypeptide corresponding to amino acids 137-516 of the precursor polypeptide of the reference protein F (Fo) of SEQ ID NO: 2.
[6]
The combined immunogenic composition of claim 1, wherein the F protein analog is selected from the group consisting of: i. a polypeptide comprising a polypeptide selected from the group of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22; ii. a polypeptide encoded by a polynucleotide selected from the group of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 17, SEQ ID NO: 19 and SEQ ID NO: 21, or by a polynucleotide sequence that hybridizes under substantially stringent stringent conditions to a polynucleotide selected from the group of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 17, SEQ ID NO : 19 and SEQ ID NO: 21, said polypeptide comprising an amino acid sequence corresponding at least in part to a natural strain of RSV; iii. a polypeptide having a sequence identity of at least 95% with a polypeptide selected from the group of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22, said polypeptide comprising an amino acid sequence that does not correspond to a natural strain of RSV.
[7]
The combined immunogenic composition according to claim 1, wherein said F protein analog comprises a F2 domain and a Fi domain of a RSV F protein polypeptide, the F protein polypeptide comprising at least one alteration that alters the glycosylation.
[8]
The combined immunogenic composition of claim 7, wherein said F protein analog comprises at least one modification selected from: (i) adding an amino acid sequence comprising a heterologous trimerization domain; (ii) a deletion of at least one furin cleavage site; (iii) a deletion of at least one non-furine cleavage site; (iv) a deletion of one or more amino acids of the pep27 domain; and (v) at least one hydrophilic amino acid substitution or addition in a hydrophobic domain of the extracellular domain of the F protein.
[9]
A combined immunogenic composition according to claim 7 or 8, wherein said at least one altering glycosylation modification comprises a substitution of one or more amino acids comprising and / or adjacent to the amino acid corresponding to the position 500 of SEQ ID NO: 2.
[10]
The combined immunogenic composition according to any one of claims 7-9, wherein the amino acids corresponding to positions 500-502 of SEQ ID NO: 2 are selected from: NGS; NKS; NGT; NKT.
[11]
The combined immunogenic composition of any one of claims 7-10, wherein the alteration that alters glycosylation comprises a glutamine substitution at the amino acid corresponding to the 500 position of SEQ ID NO: 2.
[12]
The combined immunogenic composition of any of claims 7-11, wherein the F protein analog comprises an intact fusion peptide between the F2 domain and the F1 domain.
[13]
The combined immunogenic composition of any one of claims 7-12, wherein said at least one modification comprises the addition of an amino acid sequence comprising a heterologous trimerization domain.
[14]
The combined immunogenic composition of claim 12, wherein the heterologous trimerization domain is positioned at the C-terminus with respect to the F1 domain.
[15]
A combined immunogenic composition according to any one of claims 7-14 comprising a F2 domain and a Fi domain without an intermediate furine cleavage site.
[16]
The combined immunogenic composition of any one of claims 7-15, wherein the protein F analog assembles to form a multimer, such as a trimer.
[17]
A combined immunogenic composition according to any one of claims 7-16, wherein the F2 domain comprises at least a portion of a RSV F protein polypeptide corresponding to amino acids 26-105 of the reference F protein precursor polypeptide (Fo) of SEQ ID NO: 2.
[18]
A combined immunogenic composition according to any one of claims 7-17, wherein the Fi domain comprises at least a portion of a RSV F protein polypeptide corresponding to amino acids 137-516 of the reference protein F precursor polypeptide (Fo) of SEQ ID NO: 2.
[19]
A combined immunogenic composition according to any one of claims 7-18, wherein the F2 domain comprises a RSV F protein polypeptide corresponding to amino acids 26-105 and / or wherein the Fi domain comprises an F protein polypeptide RSV corresponding to amino acids 137-516 of the standard F protein precursor polypeptide (Fo) of SEQ ID NO: 2.
[20]
The combined immunogenic composition of any of claims 7-19, wherein the F protein analog is selected from the group consisting of: i. a polypeptide comprising SEQ ID NO: 22; ii. a polypeptide encoded by SEQ ID NO: 21 or a polynucleotide sequence that hybridizes under stringent conditions substantially its entire length to SEQ ID NO: 21; iii. a polypeptide having a sequence identity of at least 95% with SEQ ID NO: 22.
[21]
21. The combined immunogenic composition according to any one of claims 7-20, wherein the F2 domain comprises amino acids 1-105 of the RSV F protein polypeptide.
[22]
A combined immunogenic composition according to any of claims 7-21, wherein the F2 domain and the F1 domain are positioned with an intact fusion peptide and without an intermediate pep27 domain.
[23]
23. A combined immunogenic composition according to any one of claims 8-22, wherein the heterologous trimerization domain comprises a superhelical domain or comprises an isoleucine barrier.
[24]
The combined immunogenic composition of claim 23, wherein the isoleucine zipper-like domain comprises the amino acid sequence of SEQ ID NO: 11.
[25]
A combined immunogenic composition according to any one of claims 7-24, wherein the F protein analog comprises at least one hydrophilic amino acid substitution or addition in a hydrophobic domain of the extracellular domain of the F protein.
[26]
The combined immunogenic composition of claim 25, wherein the hydrophobic domain is the HRB superhelical domain of the extracellular domain of the F protein.
[27]
27. Combined immunogenic composition according to claim 26, wherein the HRB superhelical domain comprises the substitution of a neutral residue with a charged residue at the position corresponding to amino acid 512 of the precursor of the reference protein F ( Fo) of SEQ ID NO: 2.
[28]
The combined immunogenic composition according to claim 27, wherein the HRB superhelical domain comprises the substitution of leucine by a lysine or glutamine at the position corresponding to amino acid 512 of the precursor protein F reference (Fo ) of SEQ ID NO: 2.
[29]
The combined immunogenic composition of claim 25, wherein the hydrophobic domain is the HRA domain of the extracellular domain of the F protein.
[30]
30. Combined immunogenic composition according to claim 29, wherein the HRA domain comprises the addition of a charged residue following the position corresponding to amino acid 105 of the precursor of the reference F protein (Fo) of SEQ ID N0: 2.
[31]
The combined immunogenic composition according to claim 30, wherein the HRA domain comprises the addition of a lysine following the position corresponding to amino acid 105 of the precursor of the reference F protein (Fo) of SEQ ID N0: 2.
[32]
A combined immunogenic composition according to any of claims 25-31, wherein the F protein analog comprises at least one first hydrophilic amino acid substitution or addition in the HRA domain and at least one second substitution or addition. hydrophilic amino acid type in the HRB domain of the extracellular domain of the F protein.
[33]
A combined immunogenic composition according to any of claims 7-32, wherein the F protein analog comprises at least one amino acid addition, deletion or substitution which eliminates a furin cleavage site present in a precursor of natural F protein (Fo).
[34]
The combined immunogenic composition of claim 33, wherein the F protein analog comprises an amino acid addition, deletion or substitution which removes a furin cleavage site at a position corresponding to amino acids 105-109, at a position corresponding to amino acids 133-136, or at two positions corresponding to amino acids 105-109 and 133-136 of the precursor of the reference protein F (Fo) of SEQ ID NO: 2.
[35]
The combined immunogenic composition according to any of claims 7-34, wherein the F1 and F2 polypeptide domains correspond in sequence to the long strain of RSV A.
[36]
36. A combined immunogenic composition according to any of claims 7-35, wherein the at least one RSV antigen comprises a multimer, such as a trimer, of polypeptides.
[37]
37. A combined immunogenic composition according to any one of claims 1-36, wherein said at least one antigen Pa is selected from the group consisting of: pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin ( PRN), type 2 fimbriae (FIM2), type 3 fimbriae (FIM3) and BrkA.
[38]
38. A combined immunogenic composition according to claim 37, wherein the PT is chemically detoxified, or is genetically detoxified for example by one or both mutations: R9K and E129G.
[39]
39. Combined immunogenic composition according to claim 37 or 38, wherein said at least one antigen Pa comprises: PT and FHA; PT, FHA and PRN; or PT, FHA, PRN and either FIM2 or FIM3, or both.
[40]
40. A combined immunogenic composition according to any one of claims 37 to 39, comprising: i. 10-30 μg, for example exactly or approximately 25 μg of PT; ii. 10-30 μg, for example exactly or approximately 25 μg of FHA.
[41]
41. The combined immunogenic composition of claim 40, further comprising: 2-10 μg, for example exactly or approximately 8 μg of PRN.
[42]
42. A combined immunogenic composition according to any one of claims 37 to 39, comprising: i. 10-30 μg, for example exactly or approximately 20 μg PT; ii. 10-30 μg, for example exactly or approximately 20 μg of FHA; iii. 2-10 μg, for example exactly or approximately 3 μg of PRN; and iv. 1-10 pg, for example exactly or approximately 5 pg in total of FIM2 and FIM3.
[43]
43. Combined immunogenic composition according to any one of claims 37 to 39, comprising: i. 2-10 μg, for example exactly or approximately 8 μg PT; ii. 2-10 μg, for example exactly or approximately 8 μg of FHA; and iii. 0.5-4 μg, for example exactly or approximately 2.5 μg of PRN.
[44]
44. The combined immunogenic composition according to any one of claims 37 to 39, comprising: i. 2-10 μg, for example exactly or approximately 2.5 μg PT; ii. 2-10 μg, for example exactly or approximately 5 μg of FHA; iii. 0.5-4 μg, for example exactly or approximately 3 μg of PRN; and iv. 1-10 μg, for example exactly or approximately 5 μg in total of FIM2 and FIM3.
[45]
45. Combined immunogenic composition according to any one of claims 37 to 39, comprising: i. 2-5 μg, for example exactly or approximately 3.2 μg PT; ii. 25-40 μg, for example exactly or approximately 34.4 μg of FHA; iii. 0.5-3 μg, for example exactly or approximately 1.6 μg of PRN; and iv. 0.5-1 μg, for example exactly or approximately 0.8 μg of FIM2.
[46]
46. Combined immunogenic composition according to any one of claims 37 to 39, comprising: i. 2-10 μg, for example exactly or approximately 8 μg PT; ii. 1-4 μg, for example exactly or approximately 2.5 μg of FHA; and iii. 1-4 μg, for example exactly or approximately 2.5 μg of PRN.
[47]
47. A combined immunogenic composition according to any one of claims 1 to 36, wherein said at least one B. pertussis antigen comprises a Pw antigen.
[48]
48. The combined immunogenic composition of claim 47, wherein said Pw antigen has a reduced endotoxin content.
[49]
49. The combined immunogenic composition according to claim 48, wherein said reduced endotoxin content is obtained by chemical extraction of a lipo-oligosaccharide (LOS), or by genetic manipulation of an endotoxin production, for example to induce overexpression. or the heterologous expression of a 3-O-deacylase.
[50]
50. A combined immunogenic composition according to any one of claims 47 to 49, wherein said Pw antigen comprises B. pertussis cells comprising at least one partially 3-O-deacylated LOS.
[51]
51. The combined immunogenic composition according to any one of claims 1 to 50, further comprising a pharmaceutically acceptable carrier or excipient.
[52]
52. The combined immunogenic composition of claim 51, wherein the vehicle or excipient comprises a buffer.
[53]
53. Combined immunogenic composition according to any one of claims 1 to 52, further comprising at least one adjuvant.
[54]
54. The combined immunogenic composition of claim 53, wherein the at least one adjuvant comprises at least one adjuvant selected from the group consisting of: an aluminum salt such as aluminum hydroxide or aluminum phosphate; calcium phosphate; 3D-MPL; QS21; an oligodeoxynucleotide adjuvant containing CpG; and an oil emulsion in water.
[55]
55. The combined immunogenic composition of claim 53 or 54, wherein the at least one adjuvant comprises aluminum hydroxide.
[56]
56. Combined immunogenic composition according to any one of claims 53 or 54, wherein the at least one adjuvant comprises an oil-in-water emulsion.
[57]
57. The combined immunogenic composition according to claim 56, wherein the oil-in-water emulsion comprises less than 5 mg of squalene per human dose.
[58]
58. The combined immunogenic composition of claim 56 or 57, wherein the oil-in-water emulsion comprises a tocol.
[59]
59. The combined immunogenic composition of claim 53 wherein said adjuvant is suitable for administration to a neonate or pregnant woman.
[60]
60. Combined immunogenic composition according to any one of claims 1 to 52, wherein the immunogenic composition does not comprise adjuvant.
[61]
61. A combined immunogenic composition according to any one of claims 1 to 60, further comprising at least one antigen from a pathogenic organism other than RSV and B. pertussis.
[62]
62. The combined immunogenic composition of claim 61 comprising one or more antigens selected from the group consisting of: diphtheria toxoid (D); tetanus toxoid (T); hepatitis B surface antigen (HBsAg); inactivated polio virus (IPV); capsular saccharide of H. influenzae type b (Hib) conjugated to a carrier protein; capsular saccharide of N. meningitidis type C conjugated to a carrier protein; capsular saccharide of N. meningitidis type Y conjugated to a carrier protein; capsular saccharide of N. meningitidis type A conjugated to a carrier protein; capsular saccharide of N. meningitidis type W conjugated to a carrier protein; and an antigen from N. meningitidis type B.
[63]
63. The combined immunogenic composition of claim 62 comprising: D and T; D, T and IPV; D, T and HBsAg; D, T and Hib; D, T, IPV and HBsAg; D, T, IPV and Hib; D, T, HBsAg and Hib; or D, T, IPV, HBsAg and Hib.
[64]
64. The combined immunogenic composition of claim 62 or 63 comprising, in addition to said at least one RSV antigen: i. 20-30 μg, for example exactly or approximately 25 μg PT; ii. 20-30 μg, for example exactly or approximately 25 μg of FHA; iii. 1-10 μg, for example exactly or approximately 3 or 8 μg of PRN; iv. 10-30 Lf, for example exactly or approximately 15 or 25 Lf of D; and V. 1-15 Lf, for example exactly or approximately 5 or 10 Lf of T.
[65]
65. A combined immunogenic composition according to claim 62 or 63 comprising, in addition to said at least one RSV antigen: i. 2-10 μg, for example exactly or approximately 2.5 or 8 μg PT; ii. 2-10 μg, for example exactly or approximately 5 or 8 μg of FHA; iii. 0.5-4 μg, or for example 2-3 μg as exactly or approximately 2.5 or 3 μg of PRN; iv. 1-10 Lf, for example exactly or approximately 2 or 2.5 or 9 Lf of D; and V. 1-15 Lf, for example exactly or approximately 5 or 10 Lf of T.
[66]
66. The combined immunogenic composition according to claims 40 to 46, 62 or 65, wherein the at least one RSV antigen comprises a PreF antigen which comprises at least one modification which stabilizes the F protein pre-fusion conformation.
[67]
67. The combined immunogenic composition according to claim 66, further comprising no adjuvant, or comprising an adjuvant of inorganic salt type.
[68]
68. A method for eliciting an immune response against RSV and B. pertussis, comprising administering to a subject the combined immunogenic composition of any one of claims 1 to 67.
[69]
69. The method according to claim 68, wherein administration of said composition elicits a specific RSV immune response without aggravating the viral disease after contact with RSV.
[70]
The method of claims 68 or 69, wherein said immune response is a stimulation response.
[71]
The method according to any one of claims 69 to 70, wherein the immune response against RSV and B. pertussis comprises a protective immune response that reduces or prevents the incidence, or reduces the severity of RSV infection. and B. pertussis and / or reduces or prevents the incidence, or reduces the severity of a pathological response after infection with RSV and B. pertussis.
[72]
72. Combined immunogenic composition according to any one of claims 1 to 67 for use in medicine.
[73]
73. Combined immunogenic composition according to any one of claims 1 to 67 for preventing or treating in a subject infection with RSV and B. pertussis, or a disease associated therewith.
[74]
The method of any of claims 68-71 or the combined immunogenic composition of claims 72 or 73, wherein the combined immunogenic composition is administered, or is intended to be administered, to a subject in a single dose pattern.
[75]
The method of any of claims 68-71 or the combined immunogenic composition of claims 72 or 73, wherein the subject is a mammal, such as a human, selected from the group consisting of: a newborn; A baby ; a kid ; a teenager ; an adult ; and an elderly person.
[76]
76. The combined immunogenic method or composition according to claim 75, wherein the subject is a 10 to 18 year old adolescent and wherein said combined immunogenic composition is administered, or is to be administered, once.
[77]
77. A method according to any one of claims 68-71 or a combined immunogenic composition according to claims 72 or 73, wherein the subject is not a full female.
[78]
78. A method according to any one of claims 68-71 or a combined immunogenic composition according to claims 72 or 73, wherein the subject is optionally a pregnant woman carrying a pregnant child.
[79]
79. A combined immunogenic method or composition according to claim 78, wherein said combined immunogenic composition is administered, or is intended to be administered, to said pregnant woman once per pregnancy.
[80]
80. Vaccination schedule for protecting an infant against infection or disease caused by RSV and B. pertussis, the vaccination schedule comprising: administering to a pregnant woman carrying a pregnant child of at least one immunogenic composition capable of stimulating a humoral immune response specific to both RSV and B. pertussis, said at least one immunogenic composition comprising a recombinant RSV antigen comprising an F protein analog and at least one B. pertussis antigen, wherein at least one subset of RSV-specific antibodies and at least one subset of B. pertussis-specific antibodies elicited or amplified in the pregnant woman by said at least one immunogenic composition are transferred via the placenta to the pregnant child to protect it against infection or disease caused by RSV and B. pertussis.
[81]
81. A method of protecting an infant against infection or disease caused by RSV and B. pertussis, the method comprising: administering to a pregnant woman carrying a pregnant child at least one immunogenic composition capable of stimulating a humoral immune response specific for both RSV and B. pertussis, said at least one immunogenic composition comprising a recombinant RSV antigen comprising an F protein analog and at least one B. pertussis antigen, wherein at least one -A set of RSV-specific antibodies and at least a subset of B. pertussis-specific antibodies raised or amplified in the pregnant woman by said at least one immunogenic composition are transferred via the placenta to the pregnant child, for the thus protect against infection or disease caused by RSV and B. pertussis.
[82]
82. An immunogenic composition or plurality of immunogenic compositions comprising a RSV recombinant antigen comprising an F protein analog and at least one B. pertussis antigen that can be used to protect an infant from infection or disease caused by RSV and B wherein the immunogenic composition (s) is / are formulated for administration to a pregnant woman and wherein the immunogenic composition (s) is / are capable (s) of stimulating a specific humoral immune response to both RSV and B. pertussis, and in which at least a subset of RSV-specific antibodies and at least a subset of B. pertussis-specific antibodies whose production has been stimulated in pregnant women by the immunogenic composition (s) is transferred via the placenta to the pregnant child, thereby protecting it against infection or disease. by the VRS and B. pertussis.
[83]
83. The vaccination scheme, method or use according to any of claims 8 to 82, wherein the recombinant RSV antigen comprising an F protein analogue and at least one B. pertussis antigen are co-formulated in the same immunogenic composition, said composition being a combined immunogenic composition as defined in any one of claims 1 to 67.
[84]
84. The vaccination scheme, method or use according to any one of claims 80 to 83, wherein said immunogenic composition is administered, or is intended to be administered to said pregnant woman only once per pregnancy.
[85]
85. The vaccination scheme, method or use according to any one of claims 80 to 82, wherein the recombinant RSV antigen comprising an F protein analogue and at least one B. pertussis antigen are formulated in immunogenic compositions. different.
[86]
86. The vaccination scheme, method or use according to claim 85, wherein the two different immunogenic compositions are administered on the same day (coadministered).
[87]
87. The vaccination scheme, method or use of claim 85, wherein the two different immunogenic compositions are administered on different days.
[88]
88. Vaccination scheme, method or use according to any one of claims 85 to 87, wherein the F protein analogue is as defined in any one of claims 1 to 36 and the at least one B antigen pertussis is as defined in any one of claims 37 to 50.
[89]
89. The vaccination scheme, method or use according to any one of claims 80 to 88, wherein said solid female is a human being.
[90]
90. A vaccination scheme, method or use according to any one of claims 80 to 89, wherein the infant is immunologically immature.
[91]
91. The vaccination scheme, method or use according to any one of claims 80 to 90, wherein the infant is less than six months old.
[92]
92. Vaccination scheme, method or use according to any one of claims 80 to 91, wherein the infant is less than two months, for example less than one month, for example is a newborn.
[93]
93. The vaccination scheme, method or use according to any one of claims 80 to 92, wherein the at least subset of RSV-specific antibodies and / or pertussis-specific antibodies transferred via the placenta comprises antibodies. IgG, preferably IgG1 antibodies.
[94]
94. The vaccination scheme, method or use according to any one of claims 80 to 93, wherein the at least subset of RSV-specific antibodies transferred via the placenta is neutralizing antibodies.
[95]
The vaccination scheme, method or use according to any one of claims 80 to 94, wherein the at least one subset of RSV-specific antibodies is detectable at a level of 30 μg / mL or more in the serum of the infant at birth.
[96]
96. The vaccination scheme, method or use according to any one of claims 81 to 95, wherein the at least subset of pertussis-specific antibodies is detectable at a level of 10 ELISA units / ml (EU) or more. in the serum of the infant.
[97]
The vaccination scheme, method or use of any one of claims 80 to 96, further comprising administering to an infant at least one composition that initiates or induces an active immune response against RSV in the infant.
[98]
98. The vaccination scheme, method or use according to any one of claims 80 to 97, further comprising administering to the infant at least one composition which initiates or induces an active immune response against B. pertussis in the infant.
[99]
99. Immunization scheme, method or use according to claim 97 or 98, comprising the administration to the infant of at least one composition which initiates or induces an active immune response against RSV and at least one composition which initiates or induces an active immune response against B. pertussis.
[100]
The vaccination scheme, method or use according to claim 99, wherein the at least one composition that initiates or induces an active immune response against RSV and the at least one composition that initiates or induces an active immune response against B. pertussis is same composition.
[101]
101. The vaccination scheme, method or use according to claim 99, wherein the at least one composition that initiates or induces an active immune response against RSV and the at least one composition that initiates or induces an active immune response against B. pertussis are different compositions.
[102]
102. The vaccination scheme, method or use of claim 101, wherein the different compositions are administered on the same day or on different days.
[103]
The vaccination scheme, method or use of any one of claims 97 to 101, wherein the at least one infant-administered composition comprises a RSV antigen comprising an F-protein analog.
[104]
104. Vaccination scheme, method or use according to any one of claims 97 to 102, wherein the at least one composition administered to the infant comprises a nucleic acid, a recombinant viral vector or a viral replicon particle, said nucleic acid, vector recombinant viral or viral replicon particle encoding at least one RSV protein antigen or antigenic analogue.
[105]
The vaccination scheme, method or use according to any one of claims 80 to 104, wherein the at least one immunogenic composition is administered to a pregnant woman at 26 weeks of gestation or later.
[106]
106. The vaccination scheme, method or use according to any one of claims 80 to 105, wherein the pregnant woman is between 26 and 38 weeks of gestation, for example between 28 and 34 weeks of gestation.
[107]
A kit comprising a plurality of immunogenic compositions formulated for administration to a pregnant woman, wherein the kit comprises: (a) a first immunogenic composition comprising an F protein analog capable of inducing, stimulating or stimulating a humoral immune response specific for RSV; and (b) a second immunogenic composition comprising at least one B. pertussis antigen capable of inducing, eliciting or stimulating a specific humoral immune response of B. pertussis, the first and second immunogenic composition inducing, eliciting or stimulating after administering to a pregnant woman at least a subset of RSV-specific antibodies and at least a subset of antibodies specific for B. pertussis, said antibodies being transferred via the placenta to the pregnant baby of the pregnant woman, for protect it against infection or disease caused by RSV and B. pertussis.
[108]
The kit of claim 107, wherein the F protein analog of the first immunogenic composition is as defined in any one of claims 1 to 36.
[109]
The kit of claim 107 or 108, wherein the at least one antigen of B. pertussis of the second immunogenic composition is as defined in any one of claims 37 to 50.
[110]
110. Kit according to claims 107 to 109, wherein the relevant features of the kit are as defined for the vaccine scheme, method or use according to any one of claims 83 to 101.
[111]
The kit according to any one of claims 107 to 110, wherein the first immunogenic composition and / or the second immunogenic composition are in at least one pre-filled syringe.
[112]
112. Kit according to claim 111, wherein the pre-filled syringe is a syringe with two compartments.
[113]
113. Kit according to any one of claims 107 to 112, wherein the respective compositions are for administration to said pregnant woman only once per pregnancy.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6664338B2|2020-03-13|Immunogenic combination

---

JP2019163284A|2019-09-26|Combination immunogenic compositions

---

JP2018172417A|2018-11-08|Methods for eliciting immune response to rsv and bordetella pertussis in infants

---

KR20140033171A|2014-03-17|Inactivated dengue virus vaccine

---

JP5809560B2|2015-11-11|Vaccine composition for use against influenza

---

JP2011528222A|2011-11-17|Chimeric respiratory syncytial virus polypeptide antigen

---

JP2016516755A|2016-06-09|Vaccine composition and method of use thereof

---

JP2015525794A|2015-09-07|Method for eliciting an immune response against RSV and Bordetella pertussis in infants

---

BE1022174B1|2016-02-24|VACCINE

---

CA2828068C|2019-03-19|Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines

---

Iyer et al.2017|An indian perspective of some recent developments in polio, dpt, zika and rotavirus vaccines

---

Guillén et al.2011|Desarrollo de plataforma de adyuvación para vacunas preventivas y terapeúticas basada en partículas semejantes a virus: demostración de efecto en modelos animales y humanos

同族专利:

---

公开号 | 公开日

---

IL243778D0|2016-04-21|

---

BR112016002354A2|2017-09-12|

---

JP2019163284A|2019-09-26|

---

JP6564367B2|2019-08-21|

---

JP2016527294A|2016-09-08|

---

EP3492097A1|2019-06-05|

---

SG11201600709TA|2016-02-26|

---

MX2016001695A|2016-05-02|

---

EA201690115A1|2016-07-29|

---

KR20160040290A|2016-04-12|

---

AU2014304545A1|2016-02-25|

---

CN105555304A|2016-05-04|

---

EP3030260A1|2016-06-15|

---

WO2015018806A1|2015-02-12|

---

CA2919773A1|2015-02-12|

---

US20160193322A1|2016-07-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO2005032584A2|2003-10-02|2005-04-14|Glaxosmithkline Biologicals S.A.|Pertussis antigens and use thereof in vaccination|

---

WO2007068907A2|2005-12-13|2007-06-21|Glaxosmithkline Biologicals Sa|Vaccine compositions comprising a saponin adjuvant|

---

WO2010046935A1|2008-10-24|2010-04-29|Panacea Biotec Ltd.|Combination vaccine with acellular pertussis|

---

WO2010149745A1|2009-06-24|2010-12-29|Glaxosmithkline Biologicals S.A.|Recombinant rsv antigens|

---

WO2014024026A1|2012-08-06|2014-02-13|Glaxosmithkline Biologicals S.A.|Method for eliciting in infants an immune response against rsv and b. pertussis|

---

US4372945A|1979-11-13|1983-02-08|Likhite Vilas V|Antigen compounds|

---

US4235877A|1979-06-27|1980-11-25|Merck & Co., Inc.|Liposome particle containing viral or bacterial antigenic subunit|

---

US4270537A|1979-11-19|1981-06-02|Romaine Richard A|Automatic hypodermic syringe|

---

IL61904A|1981-01-13|1985-07-31|Yeda Res & Dev|Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same|

---

US4866034A|1982-05-26|1989-09-12|Ribi Immunochem Research Inc.|Refined detoxified endotoxin|

---

US4436727A|1982-05-26|1984-03-13|Ribi Immunochem Research, Inc.|Refined detoxified endotoxin product|

---

SE8205892D0|1982-10-18|1982-10-18|Bror Morein|IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF|

---

US4596556A|1985-03-25|1986-06-24|Bioject, Inc.|Hypodermic injection apparatus|

---

US4707543A|1985-09-17|1987-11-17|The United States Of America As Represented By The Secretary Of The Army|Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines|

---

US4877611A|1986-04-15|1989-10-31|Ribi Immunochem Research Inc.|Vaccine containing tumor antigens and adjuvants|

---

CA1283827C|1986-12-18|1991-05-07|Giorgio Cirelli|Appliance for injection of liquid formulations|

---

AT80179T|1986-12-23|1992-09-15|Univ Leland Stanford Junior|MODIFIED PERTUSSISTOXIN.|

---

GB8704027D0|1987-02-20|1987-03-25|Owen Mumford Ltd|Syringe needle combination|

---

CA1331443C|1987-05-29|1994-08-16|Charlotte A. Kensil|Saponin adjuvant|

---

US5057540A|1987-05-29|1991-10-15|Cambridge Biotech Corporation|Saponin adjuvant|

---

US4940460A|1987-06-19|1990-07-10|Bioject, Inc.|Patient-fillable and non-invasive hypodermic injection device assembly|

---

US4941880A|1987-06-19|1990-07-17|Bioject, Inc.|Pre-filled ampule and non-invasive hypodermic injection device assembly|

---

US4790824A|1987-06-19|1988-12-13|Bioject, Inc.|Non-invasive hypodermic injection device|

---

US5726292A|1987-06-23|1998-03-10|Lowell; George H.|Immuno-potentiating systems for preparation of immunogenic materials|

---

JP2918895B2|1987-09-04|1999-07-12|アムジエン・インコーポレーテツド|Bordetella toxin subunit analogs derived from recombinant DNA|

---

IT1223334B|1987-11-02|1990-09-19|Sclavo Spa|IMMUNOLOGICALLY ACTIVE POLYPEPTIDES WITH AN ALTERED TOXICITY USEFUL FOR THE PREPARATION OF AN ANTIPERTOX VACCINE|

---

GB8727489D0|1987-11-24|1987-12-23|Connaught Lab|Detoxification of pertussis toxin|

---

US5339163A|1988-03-16|1994-08-16|Canon Kabushiki Kaisha|Automatic exposure control device using plural image plane detection areas|

---

US5278302A|1988-05-26|1994-01-11|University Patents, Inc.|Polynucleotide phosphorodithioates|

---

US4912094B1|1988-06-29|1994-02-15|Ribi Immunochem Research Inc.|Modified lipopolysaccharides and process of preparation|

---

FR2638359A1|1988-11-03|1990-05-04|Tino Dalto|SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN|

---

DK0396964T3|1989-04-28|1995-10-30|Sclavo Spa|Pertussis toxin mutants, Bordetella strains capable of producing such mutants, and their use in the development of antipertussis vaccines|

---

US5312335A|1989-11-09|1994-05-17|Bioject Inc.|Needleless hypodermic injection device|

---

US5064413A|1989-11-09|1991-11-12|Bioject, Inc.|Needleless hypodermic injection device|

---

WO1991012020A1|1990-02-12|1991-08-22|Smithkline Beecham Biologicals |Novel vaccine and method therefor|

---

US5190521A|1990-08-22|1993-03-02|Tecnol Medical Products, Inc.|Apparatus and method for raising a skin wheal and anesthetizing skin|

---

US5527288A|1990-12-13|1996-06-18|Elan Medical Technologies Limited|Intradermal drug delivery device and method for intradermal delivery of drugs|

---

GB9118204D0|1991-08-23|1991-10-09|Weston Terence E|Needle-less injector|

---

SE9102652D0|1991-09-13|1991-09-13|Kabi Pharmacia Ab|INJECTION NEEDLE ARRANGEMENT|

---

US5328483A|1992-02-27|1994-07-12|Jacoby Richard M|Intradermal injection device with medication and needle guard|

---

KR100287083B1|1992-05-23|2001-04-16|장 스테판느|Combination vaccine comprising hepatitis B surface antigen and other antigens|

---

US5383851A|1992-07-24|1995-01-24|Bioject Inc.|Needleless hypodermic injection device|

---

US5569189A|1992-09-28|1996-10-29|Equidyne Systems, Inc.|hypodermic jet injector|

---

US5334144A|1992-10-30|1994-08-02|Becton, Dickinson And Company|Single use disposable needleless injector|

---

EP0812593B8|1993-03-23|2010-11-10|SmithKline Beecham Biologicals S.A.|Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a|

---

US5961970A|1993-10-29|1999-10-05|Pharmos Corporation|Submicron emulsions as vaccine adjuvants|

---

CA2175375C|1993-11-17|2010-01-05|John Gwynfor Davies|Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use|

---

WO1995024176A1|1994-03-07|1995-09-14|Bioject, Inc.|Ampule filling device|

---

US5466220A|1994-03-08|1995-11-14|Bioject, Inc.|Drug vial mixing and transfer device|

---

WO1995026204A1|1994-03-25|1995-10-05|Isis Pharmaceuticals, Inc.|Immune stimulation by phosphorothioate oligonucleotide analogs|

---

DK0772619T4|1994-07-15|2011-02-21|Univ Iowa Res Found|Immunomodulatory oligonucleotides|

---

AUPM873294A0|1994-10-12|1994-11-03|Csl Limited|Saponin preparations and use thereof in iscoms|

---

US5599302A|1995-01-09|1997-02-04|Medi-Ject Corporation|Medical injection system and method, gas spring thereof and launching device using gas spring|

---

DE69637254T2|1995-04-25|2008-06-19|Glaxosmithkline Biologicals S.A.|Vaccines containing a saponin and a sterol|

---

EP1082965B1|1995-06-23|2009-06-10|GlaxoSmithKline Biologicals S.A.|A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate|

---

US5666153A|1995-10-03|1997-09-09|Virtual Shopping, Inc.|Retractable teleconferencing apparatus|

---

US5730723A|1995-10-10|1998-03-24|Visionary Medical Products Corporation, Inc.|Gas pressured needle-less injection device and method|

---

US5893397A|1996-01-12|1999-04-13|Bioject Inc.|Medication vial/syringe liquid-transfer apparatus|

---

GB9607549D0|1996-04-11|1996-06-12|Weston Medical Ltd|Spring-powered dispensing device|

---

US5856462A|1996-09-10|1999-01-05|Hybridon Incorporated|Oligonucleotides having modified CpG dinucleosides|

---

GB9623233D0|1996-11-07|1997-01-08|Smithkline Beecham Biolog|Vaccine composition|

---

US6303347B1|1997-05-08|2001-10-16|Corixa Corporation|Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors|

---

US6113918A|1997-05-08|2000-09-05|Ribi Immunochem Research, Inc.|Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors|

---

US6764840B2|1997-05-08|2004-07-20|Corixa Corporation|Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors|

---

US5993412A|1997-05-19|1999-11-30|Bioject, Inc.|Injection apparatus|

---

GB9727262D0|1997-12-24|1998-02-25|Smithkline Beecham Biolog|Vaccine|

---

IT1298087B1|1998-01-08|1999-12-20|Fiderm S R L|DEVICE TO CONTROL THE NEEDLE PENETRATION DEPTH, IN PARTICULAR APPLICABLE TO AN INJECTION SYRINGE|

---

HU0102332A3|1998-06-08|2002-11-28|Sca Emballage France|Fast flattening packaging|

---

CZ302062B6|1998-06-30|2010-09-22|Om Pharma|Acyl dipeptide derivative process for its preparation, intermediates for the preparation thereof and pharmaceutical composition in which the derivative is comprised|

---

US6551600B2|1999-02-01|2003-04-22|Eisai Co., Ltd.|Immunological adjuvant compounds compositions and methods of use thereof|

---

US20040006242A1|1999-02-01|2004-01-08|Hawkins Lynn D.|Immunomodulatory compounds and method of use thereof|

---

US6379324B1|1999-06-09|2002-04-30|The Procter & Gamble Company|Intracutaneous microneedle array apparatus|

---

US6256533B1|1999-06-09|2001-07-03|The Procter & Gamble Company|Apparatus and method for using an intracutaneous microneedle array|

---

US6494865B1|1999-10-14|2002-12-17|Becton Dickinson And Company|Intradermal delivery device including a needle assembly|

---

WO2001046127A1|1999-12-22|2001-06-28|Om Pharma|Acyl pseudopeptides bearing a functionalised auxiliary spacer|

---

NZ523319A|2000-06-29|2006-01-27|Glaxosmithkline Biolog Sa|Vaccine compositions comprising Pw, TT, DT and H. influenzae type B with a lower dose of Hib compared with the standard does |

---

US7524509B2|2001-03-09|2009-04-28|Id Biomedical Corporation Of Quebec|Proteosome-liposaccharide vaccine adjuvant|

---

AT404561T|2001-04-17|2008-08-15|Dainippon Sumitomo Pharma Co|NEW ADENINE DERIVATIVES|

---

DE60230340D1|2001-11-16|2009-01-22|3M Innovative Properties Co|N-Ä4- -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use|

---

US20040087992A1|2002-08-09|2004-05-06|Vladimir Gartstein|Microstructures for delivering a composition cutaneously to skin using rotatable structures|

---

EP1592302A4|2003-02-13|2007-04-25|3M Innovative Properties Co|Methods and compositions related to irm compounds and toll-like receptor 8|

---

US7368537B2|2003-07-15|2008-05-06|Id Biomedical Corporation Of Quebec|Subunit vaccine against respiratory syncytial virus infection|

---

BRPI0402630B8|2004-07-05|2021-05-25|Fund Butantan|process of obtaining a less reactogenic cellular pertussis vaccine|

---

CA2588080C|2004-11-18|2013-01-08|3M Innovative Properties Company|Masking method for coating a microneedle array|

---

JP5015787B2|2004-11-18|2012-08-29|スリーエムイノベイティブプロパティズカンパニー|Contact coating method of microneedle array|

---

EP1828378B1|2004-12-17|2014-06-11|De Staat der Nederlanden, vert. door de minister Van VWS, Ministerie van Volksgezondheid, Welzijn en Sport|Deacylation of lps in gram negative bacteria|

---

EP2181121A4|2007-03-21|2012-07-11|Id Biomedical Corp Quebec|Chimeric antigens|

---

US8911749B2|2007-04-16|2014-12-16|Corium International, Inc.|Vaccine delivery via microneedle arrays|

---

ES2817249T3|2007-04-16|2021-04-06|Corium Inc|Microneedle matrices obtained by dissolution and casting containing an active principle|

---

CA2759850C|2009-04-24|2019-10-22|Corium International, Inc.|Methods for manufacturing microprojection arrays|

---

JP5796011B2|2009-06-24|2015-10-21|グラクソスミスクライン バイオロジカルズ ソシエテ アノニム|vaccine|

---

BR112012001666A2|2009-07-15|2019-09-24|Novartis Ag|rsv f protein compositions and methods for making the same|

---

WO2012089231A1|2010-12-30|2012-07-05|Okairòs Ag|Paramyxovirus vaccines|

---

WO2012103361A1|2011-01-26|2012-08-02|Novartis Ag|Rsv immunization regimen|GB0822633D0|2008-12-11|2009-01-21|Novartis Ag|Formulation|

---

CN108290928A|2015-09-01|2018-07-17|安可Qr Ml有限公司|Coiled coil connector|

---

US10837934B2|2018-03-28|2020-11-17|Samsung Electronics Co., Ltd.|Water detection circuit, electronic device including the same, and water detection method|

---

WO2021183533A1|2020-03-09|2021-09-16|Dynavax Technologies Corporation|Active booster immunization against tetanus, diphtheria and pertussis|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB13139902|2013-08-05|

---

GBGB1313990.2A|GB201313990D0|2013-08-05|2013-08-05|Combination immunogenic compositions|

---

GB201401883A|GB201401883D0|2014-02-04|2014-02-04|Combination immunogenic compositions|

---